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NOX = NADPH oxidases 
ONOO- = peroxynitrite 
PAGE = polyacrylamide gel electrophoresis 
pAkt = phosphorylated protein kinase B 
PE = phenlyephrine 
pEC50 = -log10 concentration causing 50% response 
PKC = protein kinase C 
PPP = pentose phosphate pathway 
RAGE = receptors for AGE 
RNS = reactive nitrogen species 
ROS = reactive oxygen species 
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Rmax = maximum response 
SD = standard diet 
SDS = sodium dodecyl sulfate 
SEM = standard error of the mean 
Ser473 = serine 473 
Ser1177 = serine 1177 
Ser1179 = serine 1179 
sGC = soluble guanylate cyclase 
SKCa = small calcium activated potassium channel 
SNP = sodium nitroprusside 
SOD= superoxide dismutase 
STZ = streptozotocin 
T3 = tocotrienol 
Thr 495 = threonine 495 
TBST = tris buffered saline with tween-20  
TC = tocopherol 
TCA = tricarboxylic acid cycle 
VSMC = vascular smooth muscle cell 
WAT = white adipose tissue 
WD = western diet
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Abstract 
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Diabetes and obesity are non-communicable metabolic disorders that are reaching pandemic 
proportions across the world. Both diabetic and obese patients are at an increased risk of 
developing cardiovascular complications that are preceded by endothelial dysfunction. 
Vascular endothelium releases many chemicals such as the vasoconstrictor endothelin-1 and 
vasodilators such as prostacyclin and nitric oxide (NO). NO is synthesized by the enzyme 
endothelial derived nitric oxide synthase (eNOS). The bioavailability of NO has been 
demonstrated to be significantly reduced during diabetes and obesity due to increased oxidative 
stress in the vasculature that results from an increased production of reactive oxygen species 
(ROS) such as superoxide (O2
- 
). Antioxidants have the potential to reduce oxidative stress in 
the vasculature. Vitamin E is a family of compounds, consisting of tocopherols and tocotrienols. 
Vitamin E, mainly as α-tocopherol, has been reported to have beneficial effects on vascular 
function through its antioxidant activity however large-scale clinical trials (mainly using α-
tocopherol) have produced disappointing results.  
 
There has been emerging literature indicating that tocotrienols, the less extensively studied 
members of the vitamin E family that share structural similarities with tocopherols possess 
comparatively superior antioxidant activity in comparison to tocopherols. Thus it has been 
proposed that tocotrienols may also have therapeutic benefits, including improvement of 
vascular endothelial function particularly in pathologies involving oxidant stress such as 
diabetes and obesity.  
 
Due to the lack of literature that currently exists on the antioxidant effects of tocotrienols in the 
vasculature, the aim of this thesis was to examine the antioxidant activity of tocotrienols. We 
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also wanted to study the effect of a tocotrienol rich fraction of palm oil i.e. tocomin 
(composition: tocotrienols: 40%, α-tocopherol: 11% and palm olein: 38%) on endothelial 
function and O2
-
 production in aortae in the presence of oxidative stress and in animal models 
of diabetes and obesity.  
 
The first study, investigated whether tocotrienols, the less abundant components of vitamin E 
compared to tocopherols, might be more effective at preserving endothelial function. 
Superoxide generated by hypoxanthine/xanthine oxidase or rat aorta was measured using 
lucigenin-enhanced chemi-luminescence. The effect of 𝛼-tocopherol, 𝛼-, 𝛿-, and 𝛾-tocotrienols 
and a tocotrienol rich palm oil extract (tocomin) on levels of O2
-
 was assessed.   Endothelial 
function in rat aorta was assessed in the presence of the auto-oxidant pyrogallol. Whilst all of 
the compounds displayed antioxidant activity, the tocotrienols were more effective when O2
-
 
was produced by hypoxanthine/xanthine oxidase whereas tocomin and 𝛼-tocopherol were more 
effective in the isolated aorta. Tocomin and 𝛼-tocopherol restored endothelial function in the 
presence of oxidant stress but 𝛼-, 𝛿-, and 𝛾-tocotrienols were ineffective. The protective effect 
of tocomin was replicated when the tocotrienols were present with, but not without, 𝛼-
tocopherol. Tocotrienol rich tocomin was more effective than 𝛼-tocopherol at reducing 
oxidative stress and restoring endothelium-dependent relaxation in rat aortae and although 𝛼-, 
𝛿-, and 𝛾-tocotrienols effectively scavenged O2
-
, they did not improve endothelial function.  
 
Having observed the antioxidant activity of tocomin and its ability to improve endothelial 
function in a pyrogallol-induced model of oxidative stress, the second study examined whether 
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the antioxidant effect of tocomin could be replicated in animal models of diabetes and obesity 
and the possible mechanisms of endothelial dysfunction in aortae from diabetic and obese rats. 
Diabetes was induced in Wistar rats by a single tail vein injection of streptozotocin (50 mg/kg). 
Rats remained diabetic for 10 weeks. Obesity was induced by feeding Wistar Hooded-rats a 
high-fat western diet (WD; 21% fat) for 12 weeks. Aortae from both diabetic and obese rats 
had increased oxidative stress that was seen as an increase in O2
- production. Acute treatment 
of the aortae with tocomin was able to attenuate O2
- 
production in both diabetic and WD (obese) 
rat aortae. This study also demonstrated that both diabetes and a high-fat western diet cause 
endothelial dysfunction in the diabetic and WD aortae. Diabetes reduced sensitivity to 
acetylcholine (ACh) and reduced the maximum response in the aorta, whereas in comparison a 
WD only reduced sensitivity to ACh while maximum relaxation was preserved. Endothelial 
dysfunction was attenuated acutely in the diabetic and WD rat aortae by the addition of α-
tocopherol and tocomin, where tocomin was up to 100 times more potent than α-tocopherol as 
demonstrated in the previous study. We also demonstrated that there was a decrease in NO 
bioavailability in WD rat aortae in comparison to the standard diet (SD) aortae that correlates 
with endothelial dysfunction in the WD rat aorta.  
 
The study also contrasted the different mechanisms of endothelial dysfunction in the diabetic 
and WD rat aortae in comparison to the sham and SD aortae respectively. Increased O2
- 
production in the diabetic and WD aortae was attributed to an increase in the expression of the 
O2
-
 producing enzyme Nox2. Both diabetic and WD aortae also had decreased eNOS 
expression. However during diabetes a decrease in eNOS expression was not associated with 
a decrease in the ratio of phosphorylated Akt to Akt (pAkt/Akt), calmodulin (CaM) or caveolin-
1 (cav-1) expression suggesting that in advanced diabetes (10-weeks) pAkt/Akt, cav-1 or CaM 
do not provide any compensatory mechanism to improve endothelium-dependent relaxation 
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and perhaps the up-regulation of other O2
- producing pathways e.g. polyol pathway and 
mitochondrial activity may cause uncoupling of eNOS thus further exacerbating endothelial 
dysfunction by impairing eNOS function. In contrast in the obese aorta in the presence of 
oxidative stress, decreased eNOS expression was coupled with a decrease in the ratio of 
pAkt/Akt and of CaM expression. There was also an increase in cav-1 expression indicating 
that a decrease in the expression of positive eNOS regulatory proteins (pAkt/Akt and CaM) 
and an increase in the expression of the negative eNOS regulatory protein cav-1 in the obese 
rat aortae was associated with endothelial dysfunction during obesity. 
 
Having established that tocomin could acutely improve endothelial function in vitro the next 
aim was to investigate whether the beneficial effects could also be observed after treatment in 
vivo in the diabetic and obese rats. The diabetic and obese animal models previously described 
were used in this study again where diabetic rats were treated with tocomin (40mg/kg/day s.c.) 
6 weeks into the study and the obese rats commenced tocomin treatment (40 mg/kg/day s.c.) 8 
weeks into the study. Both groups were treated for a period of 4 weeks. Tocomin did not affect 
the diet-induced weight loss in the diabetic rats or weight gain or the increase in epididymal fat 
of the obese rats. Also similar to the previous study, both the diabetic and obese rat aortae had 
increased O2
- production that was associated with increased Nox2 expression. Four week 
treatment of both diabetic and obese rats with tocomin decreased vascular O2
- production. The 
decrease in O2
- production was correlated with decreased expression of the vascular NADPH 
oxidase subunit Nox2. The diabetic rat aortae also had an impaired maximum response and the 
obese rat aortae had a decreased sensitivity to ACh at the end of the experimental period. Four 
week treatment of diabetic and obese rats with tocomin significantly improved endothelial 
function which is due to an increase in NO bioavailability. 
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Other beneficial actions of tocomin to reduce vascular oxidative stress that was observed in 
this study included an increase in the expression of eNOS and the eNOS activity promoting 
proteins CaM and pAkt/Akt in the obese rat aortae. Further, there was decreased expression of 
the inhibitory protein caveolin-1 in the obese rat aortae. Neither diabetes nor tocomin had any 
affect on pAkt/Akt, CaM and cav-1 expression. 
 
In conclusion, this thesis provides further insights in the pathological process underlying 
endothelial dysfunction in the macro-vasculature over the duration of diabetes and obesity. 
Tocomin that is a mixture of tocotrienols and α-tocopherol is up to 100 times more effective 
than α-tocopherol or tocotrienol isomers alone where the presence of α-tocopherol is necessary 
for the efficacy of tocomin. The beneficial actions of tocomin in this diet-induced model of 
diabetes and obesity suggest that it may have potential to be used as an adjunct therapeutic with 
other anti-diabetic and anti-obesigenic drugs such as metformin and sibutramine to prevent 
vascular disease in diabetes and obesity. 
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Chapter 1 
 
Introduction.
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Diabetes is a complex and progressive metabolic disease that is classically defined as a 
chronic state of hyperglycaemia and disturbances to carbohydrate, protein and fat 
metabolism due to a marked reduction in the production or efficacy of the hormone insulin 
or both (Alberti and Zimmet, 1998). There are 3 types of diabetes; type 1, gestational and 
type 2. Type 1 diabetes, also known as juvenile diabetes, has an early onset of around 12 
years of age and requires lifelong management with insulin injections due to an 
autoimmune destruction of the β-pancreatic cells that consequently leads to a loss of 
insulin release (Harrison et al., 2008). Gestational diabetes occurs during pregnancy and 
has very similar clinical characteristics to type 2 diabetes. Gestational diabetes usually 
disappears after childbirth however women who have had gestational diabetes have a 
higher risk of developing type 2 diabetes and metabolic syndrome later during their life 
(Singh et al., 2013a). Type 2 diabetes, formerly known as non-insulin dependent diabetes, 
is the most common form of diabetes, accounting for almost 90% of all diabetic patients 
worldwide (Craig et al., 2007).  Type 2 diabetes has a late age of onset, occurring mainly 
in people over the age of 40 years, and is preceded by insulin resistance. Type 2 diabetes 
is strongly correlated with obesity and a sedentary lifestyle (Beck-Nielsen et al., 1995). 
 
Diabetes is reaching epidemic proportions not just in Australia but also worldwide. There 
are currently 346 million people worldwide with diabetes and it is projected by the World 
Health Organisation (WHO) that between 2005 and 2030 diabetes related deaths will 
double (WHO, 2013). Diabetes is a significant health burden in Australia where it has an 
estimated conservative cost of $3.1 billion to the Australian government per year 
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(Colagiuri et al., 2011). Also, due to the increasing incidence of childhood obesity 
worldwide, type 2 diabetes is now starting to occur in children at alarming rates. In 
Australia 11% of all type 2 diabetes cases occur in children between the ages of 10–18 
years (Craig et al., 2007).  
 
Diabetic patients are at higher risk of developing pathologies such as diabetic retinopathy, 
nephropathy, neuropathy and cardiovascular disease (CVD) (Ali and Maron, 2006, 
Pasaoglu et al., 2004). CVD is the leading cause of death of diabetic patients in Australia 
(Ali and Maron, 2006). Diabetic patients have twice the risk of developing CVD compared 
to their healthy counterparts. It is estimated that in Australia more than two-thirds of those 
who die of CVD had diabetes or pre-diabetes five years earlier (Craig et al., 2007). It is 
due to these statistics, and similar statistics worldwide, that diabetes has become a major 
health priority for the Australia and other nations (Buse et al., 2007).  
 
As mentioned previously obesity is a major risk factor for type 2 diabetes. The WHO 
defines obesity as abnormal or excessive fat accumulation in the body that may impair 
health with a body mass index (BMI) greater than 30 kg/m2. A BMI between 25-29 is 
considered overweight. Obesity is more prevalent than diabetes where in 2014 more than 
1.9 billion adults worldwide, 18 years and older, were overweight (WHO, 2015). Of these, 
over 600 million were obese. Obesity is also becoming increasingly prevalent amongst 
children worldwide, where in 2013, 42 million under the age of 5 were obese. (WHO, 
2015). From 2007-2008 it was estimated in the US that 31.6% of children were overweight 
and 16.9% of children were obese (Cote et al., 2013). Statistics for Australia are very 
similar where 63% of Australian adults are overweight or obese and 25% of Australian 
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children are either overweight or obese. Obesity is also the second biggest contributor to 
the burden of disease in Australia (Australian Institute Welfare Health, 2015).  
 
Similarly to diabetic patients, obese patients are also at a very high risk of developing 
cardiovascular related complications such as hypertension, myocardial infarction and 
stroke. There is substantial literature that consistently associates endothelial dysfunction 
arising from oxidative stress, or free radical mediated damage, with diabetes, obesity and 
CVD related pathologies (Stephens et al., 2008). This review will discuss the physiology 
of the vascular endothelium and oxidative stress during diabetes and obesity, proposed 
mechanisms through which oxidative stress is increased during diabetes and obesity and 
how it may cause endothelial dysfunction and initiate cardiovascular related pathology 
and CVD. This review will also consider the possible therapeutic use of antioxidants with 
a major focus on α-tocopherol and to a lesser extent tocotrienols that have not been 
extensively studied. The biological actions of these compounds and their potential use to 
prevent diabetes and obesity-induced CVD are also reviewed.  
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Blood vessels are dynamic structures that possess an endothelium consisting of, a thin 
monolayer layer of cells lining the lumen. Endothelium is the continuum of the 
endocardial layer of the heart and internally lines all blood vessels (Figure 1.1). The 
endothelium is a semi-permeable membrane and has several functions such as controlling 
vascular tone by releasing potent vasodilators and anti-platelet agents, prostacyclin and 
nitric oxide (NO) (Cahill and Redmond, 2016). The endothelium also releases 
vasoconstrictors that oppose the actions of the vasodilators such as NO. Endothelin-1, and 
angiotensin II are known to be released from the endothelium to cause vasoconstriction 
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(Sena et al., 2013, Tirapelli et al., 2009). Vascular endothelium also controls the selective 
adhesion and emigration of leukocytes from the bloodstream and it is also a source of the 
glycoprotein Von Willebrand factor which is important in coagulation (Pearson, 2000). 
This suggests that the endothelium possesses anti-atherosclerotic and antithrombotic 
properties. An important function of the endothelium that is of major interest is the 
regulation of vascular tone (Sydow and Münzel, 2003). This is achieved by the release of 
various endogenous substances which cause vasorelaxation/ constriction e.g. NO, 
prostacylin and an unidentified endothelium-derived hyperpolarising factor (EDHF) 
(Félétou and Vanhoutte, 2004, Furchgott, 1983). Vasoactive substances have been shown 
to act in an endothelium-dependent or independent manner. For example, acetylcholine 
(ACh) and bradykinin, amongst other endogenous vasodilators act on the endothelium to 
release factors causing vascular smooth muscle cell relaxation. By contrast NO donors 
such as sodium nitroprusside (SNP) or arachadonic acid act directly on vascular smooth 
cells to cause relaxation i.e. in an endothelium-independent manner. 
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Figure 1.1 The structure and function of the endothelium: The endothelium is the innermost lining 
on the lumen of an artery that is the continuum of the endocardial layer of the heart. Endothelium 
allows for gas exchange and produces the potent vasodilator NO amongst other vasodilators such 
as prostacyclin and endothelium-derived hyperpolarising factor (EDHF). Image adapted from 
(HeartSense, 2015).
 

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Endothelium-dependent relaxation in the vasculature is dependent on the 
bioavailability of endothelium derived relaxing factors (EDRF), the most important of 
which is NO (Moncada et al., 1991). NO is a gaseous free radical with a physiological 
half life of 4-6 seconds (Moncada et al., 1991). In 1980 it was demonstrated by 
Furchgott and Zawadzki (Furchgott and Zawadzki, 1980) that an unknown EDRF is 
released from the vascular endothelium in response to muscarinic agonists. By 1989 it 
was demonstrated by Ignarro et al. (1987) and Moncada et al. (1988) individually that 
the potent endothelium-derived vasorelaxant is in fact NO with cardiovascular 
signalling properties (Yetik-Anacak and Catravas, 2006). NO also possesses several 
other functions including; at physiological concentrations (100 pM- 5 nM) it has 
neurotransmitter and immunological functions (Hall and Garthwaite, 2009). NO can 
also be cytotoxic and induce DNA damage and lipid peroxidation (Wink and Mitchell, 
1998, Moncada et al., 1991) when reacting with superoxide (O2
-
) to form peroxynitrite 
(ONOO
- 
) (Burney et al., 1999). Also since the discovery of NO, other EDRF’s and 
potential endothelium-derived hyperpolarising factors (EDHF) have been identified 
e.g. potassium (K+), hydrogen sulfide (H2S) and prostacylin (PGI2) (Félétou et al., 2011, 
Triggle and Ding, 2010, Wang, 2009).   
 
NO is synthesized from a group of enzymes known as nitric oxide synthase (NOS) 
(Rafikov et al., 2011). There are three known isoforms of NOS; type I neuronal NOS 
(nNOS; synthesize NO as a neurotransmitter from neurons), type II inducible NOS 
(iNOS; synthesize NO from macrophages and cytokines) and type III endothelial 
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derived nitric oxide synthase (eNOS; synthesize NO from vascular endothelial cells) 
(Treuer and Gonzalez, 2015). eNOS derived NO synthesis is stimulated in the body in 
response to various stimuli such as ACh, bradykinin, serotonin and shear stress (Arnal 
et al., 1999).  
 
Figure 1.2 Endothelium-dependent relaxation: Agonists bind to their respective receptors on 
endothelial cells to stimulate NO synthesis (A) eg: ACh/bradykinin stimulate NO synthesis 
from the conversion of L-arginine to L-citrulline that is catalysed by eNOS. NO then diffuses 
through the vascular smooth muscle cell and activates soluble guanylate cyclase (sGC) which 
catalyses the conversion of GTP into cGMP. This causes vasorelaxation by calcium re-entering 
the sacrcoplasmic reticulum. (B) H2S is produced in endothelial cells from the enzyme 
cystathionine γ-lyase (CSE) and activates ATP sensitive potassium channels (KATP) and causes 
vasorelaxation. (C) Cyclooxygenase-1 (COX-1) catalyse the conversion of arachadonic acid 
(AA) into PGI2 to diffuse into the vascular smooth muscle to activate cAMP to cause 
vasorelaxation. Adapted from Wang (2009).  
These stimuli cause an increase in the endothelial free intracellular calcium (Ca2+)
concentration which subsequently causes the binding of eNOS to calmodulin (CaM), 
 

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the regulatory protein of eNOS (Mariotto et al., 2004, Arnal et al., 1999). eNOS 
catalyses the conversion of the amino acid L-arginine to L-citrulline via a series of 
complex chemical reactions to produce NO (Alkaitis and Crabtree, 2012). NO then 
reaches the vascular smooth muscle cells via diffusion and activates the enzyme soluble 
guanylate cyclase (sGC) (Figure 1.2). sGC catalyses the conversion of GTP to cGMP 
which then causes endothelium-dependent relaxation via Ca2+ reuptake into the 
sarcoplasmic reticulum (Katsuki et al., 1977). Other endogenous substances that are 
capable of mediating endothelium-dependent relaxation include prostacyclin and 
endothelium derived hyperpolarising (EDH)-type relaxation. The mechanism through 
which NO and other EDRF’s cause endothelium-dependent vasorelaxation is illustrated 
in Figure 1.2. 
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NO is a free radical possessing antioxidant properties that can be highly toxic at high 
concentrations. It has a very short half-life of 4-6 seconds and has a high affinity to 
react with O2
-
 to form ONOO
-
 (Moncada et al., 1991). As mentioned previously nitric 
oxide synthases (NOSs) are a group of enzymes responsible for the production of NO 
and eNOS is responsible for the production of NO in the vasculature. All NOS isoforms 
are dimerized proteins with an oxygenase and reductase domain separated by a 
calmodulin (CaM) binding domain (Figure 1.3) (Braam and Verhaar, 2007, Mariotto et 
al., 2004). This review will focus on type III NOS i.e. eNOS. 
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Figure 1.3 Simplified eNOS structure: eNOS is a dimeric protein consisting of two domains 
with binding sites for L- arginine, NADPH, FAD, FMN, iron and BH4. NO production is 
stimulated when the regulatory protein calmodulin (CaM) binds to eNOS. Adapted from 
Alderton et al. 2001.  
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As mentioned previously, eNOS is a dimeric enzyme that has a mass of approximately 
260kDa and consists of approximately 1203 amino acids and. eNOS has binding sites 
for several molecules which allow it to synthesize NO effectively. eNOS has a 
reductase domain containing binding sites for the cofactors NADPH, flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN) and the oxygenase domain 
contains binding sites for heme, tetrahydrobiopterin (BH4), and L-arginine (Figure 1.3). 
 

16 
 
Figure 1.4: Schematic eNOS/Akt interaction: During resting conditions eNOS is in an inactive 
state bound to the cav-1 protein. An increase in intracellular Ca2+ concentration causes cav-1 to 
dissociate from the eNOS enzyme subsequently allowing CaM to bind to eNOS. This is 
followed by hsp90 binding to eNOS that activates Akt to phosphorylate eNOS at the s1177 site. 
The calcineurin (calci) protein dephosphorylate eNOS at the Thr495 site which is the inhibitory 
protein of eNOS.  This   Taken from Baligand et al. (2009) .  
 
 
In its resting state, eNOS is bound to caveolin-1 (cav-1). Intracellular Ca2+ 
concentrations can increase in response to various agonists such as ACh and bradykinin 
or shear stress. This causes the dissociation of cav-1 from eNOS allowing CaM and 
heat shock protein 90 (hsp90) to bind to eNOS (Figure 1.4) in response to the elevated 
intracellular Ca2+ concentrations (Dudzinski and Michel, 2007). This complex causes 
protein kinase B (Akt) to phosphorylate eNOS at the serine 1177 site in humans 
(Ser1177) or Ser1179 in animals (Zhao et al., 2015) and dephosphorylate eNOS at the 
inhibitory site of threonine 495 (Thr495) (Balligand et al., 2009). Once eNOS is 
phosphorylated by Akt at Ser1177/1179 (Figure 1.4), NO synthesis commences 
through a five-electron oxidation of amino acid L-arginine producing NO and L-
citrulline (Figure 1.5) (Alkaitis and Crabtree, 2012). Because an increase in intracellular 
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Ca2+ is crucial for eNOS activation, this process is called Ca2+-dependent eNOS 
phosphorylation. eNOS can also synthesize NO in the absence of Ca2+-CaM activation 
from dynamic shear stress and hormones (Zhao et al., 2015).  This process is called 
Ca2+-independent eNOS activation (Flemming et al., 1998). 
ADMA: asymetrical dimethylarginine LNMMA: NG-monomethyl-L-arginine      
BH2:   dihydrobiopterin    DHFR:   dihydrofolate reductase 
Figure 1.5: eNOS derived NO production and the effect of uncoupled eNOS on NO production:
(A) eNOS is stimulated when intracellular calcium binds to CaM that stimulates the conversion 
of L-arginine to L-citrulline producing NO as a by-product. (B) Increased oxidative stress and 
eNOS inhibitors such as ADMA and L-NMMA which are arginine analogues decrease the 
bioavailability of eNOS cofactors such BH4 and NADPH that leads to uncoupling of the eNOS 
dimer and the production of O2- instead of NO. Taken from Alkaitis and Crabtree (2012) . 
The bioavailability of eNOS cofactors is crucial to the proper functioning of eNOS. In 
disease conditions such as diabetes there is decreased bioavailability of cofactors such 
as BH4 and NADPH (Chen et al., 2008). This can lead to uncoupling of the homodimer 
into eNOS monomers. In this state eNOS may start producing O2
-
 rather than NO 
(Figure 1.5) (Satoh et al., 2005). This has been demonstrated to occur in disease states 
such as diabetes (Joshi and Woodman, 2012, Leo et al., 2011a). An excess of reactive 
 
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oxygen species (ROS) causes oxidative stress that is a very important component in the 
pathophysiology of endothelial dysfunction. Endothelial dysfunction eventually can 
become a major cause of cardiovascular related complications in diabetes and obesity 
(Della Rocca and Pepine, 2010). 
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Oxidative stress is classically defined as “a disturbance in the prooxidant-antioxidant 
balance in favour of the former(Sies, 1985). Oxidative stress in a cell can be due to 
either; a) an increase in the number of ROS and reactive nitrogen species (RNS) mainly 
consisting of free radicals which leads to an overload of the antioxidant defense system, 
b) a decrease in the number of antioxidant molecules either endogenous (catalase 
(CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) or exogenous 
(vitamins C and E) leading to an imbalance of the redox system of a cell or c) a 
combination of both (Marks et al., 1996). Antioxidants are molecules that at low 
concentrations can prevent oxidation of various cell components by donating an 
electron to free radicals and that can initiate or take part in increasing the oxidative 
capacity of a cell (Nwose et al., 2007). However, after donating its electron, the 
antioxidant itself becomes a free radical (Nwose et al., 2007). This radical antioxidant 
may potentially oxidise cell components if it cannot be paired with another free radical, 
or find another molecule to donate its electron to, however due to their high chemical 
stability and low reactivity, antioxidant radicals are not chemically damaging and are 
recycled for reuse eg: vitamin C is involved in the recycling of vitamin E (Nwose et al., 
2007, Maxwell and Lip, 1997).  
 
 

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ROS and RNS are highly reactive oxygen and nitrogen containing molecules that often 
have an unpaired electron in their atomic structure e.g. O2
-
, the hydroxyl radical (OH
-
), 
and peroxynitrite (ONOO
-
) (Figure 1.6) (Stephens et al., 2008). ROS and RNS can 
cause tissue damage through oxidation of various cellular components including DNA, 
membrane protein and lipids (Brownlee, 2005).  
 
Endogenous antioxidant enzymes that are involved in ROS metabolism include CAT 
and GPx that converts H2O2 into H2O and O2. GPx and CAT share common cofactors 
with eNOS e.g. NADPH is reduced to NADP+ by GPx to convert H2O2 into H2O (Figure 
1.7). During diseases where oxidative stress is high e.g. diabetes and obesity, the 
bioavailability of cofactors such as NADPH can be reduced due to NADPH being 
diverted to other chemical pathways e.g. the polyol pathway during diabetes. This 
reduced bioavailability of cofactors can compromise GPx and CAT activity and can 
further exacerbate oxidative stress (Nwose et al., 2007, Dincer et al., 2002). This can 
also compromise NO production due to the decreased bioavailability of NADPH. 
 
Increased O2
-
 production has been implicated in the pathophysiology of endothelial 
dysfunction which is a precursor to diabetes and obesity related cardiovascular 
complications (Rains and Jain, 2011). O2
-
 in high concentrations can stimulate other 
cellular reactions for example, O2
-
 reacting with other molecules such as NO to form 
ONOO
-
, a highly toxic RNS (Figure 1.6) thus decreasing NO bioavailability. ONOO
-
 
can react with BH4 to form dihydrobiopterin (BH2) leading to the depletion of BH4    
(Alp and Channon, 2004) which is an important cofactor for eNOS to produce NO.  
This will consequently decrease the bioavailability of NO resulting in impairment of 
endothelium-dependent relaxation due to a decreased activation of sGC. eNOS activity 
 
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may subsequently decrease. BH4 depletion is also known to cause uncoupling of eNOS 
from a dimeric structure into a monomeric structure (Chen et al., 2008) and as 
previously mentioned eNOS in its uncoupled structure produces O2
-  (Figure 1.4) (Satoh 
et al., 2005) that further impairs endothelium-dependent relaxation due to the lack of 
NO, thus making O2
- 
production a self perpetuating process. 
 
 
H2O2 + O2-  → OH- + O2 + OH-                                                                                    Hydroxyl Radical  
 
NADPH + 2O2- → NADP + H+ + 2O2                                             Superoxide Radical 
                    
Mn-SOD + O2- → H2O2                                                                                                     Hydrogen Peroxide 
 
O2-  + NO  → ONOO- →   Nitroarginine and Nitrotyrosine.                  Peroxynitrite  
 
      
 
        Lipid Peroxidation  
                                         DNA Damage 
                                         Protein Damage                                                                
  
Figure 1.6 Potential sources of oxidative stress and its consequences: There are several 
physiological reactions that constantly occur to generate ROS and RNS such as oxidative 
phosphorylation and the pentose phosphate pathway (PPP). If ROS and RNS cannot be 
converted by antioxidants it can lead to oxidative damage in the form of membrane and DNA 
damage. Adapted from Shah et al. (2007).  
 
 
Although ROS are produced in all cells as a by-product of a variety of physiological 
reactions, it is ultimately the lack of a cells capacity to convert ROS into a more stable 
molecule that increases the level of oxidative stress. Thus antioxidants provide cells 
with stability and membrane integrity through an antioxidant sink consisting of several 
endogenous enzymatic antioxidants e.g. SOD, CAT and GPx and exogenous non-
enzymatic molecules e.g. vitamins C and E.  
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Figure 1.7 Sources of O2
- and their metabolism: O2- can be produced from eNOS, Nox, COX 
and XO. O2- is converted into cytotoxic H2O2 by SOD. H2O2 is then converted into H2O and O2
by CAT and GPx. If GPx and CAT enzyme systems are saturated then ROS levels may increase.
O2
- also has a high affinity for NO and if enzymes such as SOD are compromised O2
- can form 
ONOO
-
 upon reacting with NO that can damage DNA. Adapted from Frazziano et al. (2012) . 
519$%)" ".(*$) %$
During diabetes, as a result of hyperglycaemia, and in obesity, due to an increased 
energy influx, there is a significant increase in O2
-
 production due to mechanisms that 
will be discussed later (Antoniades et al., 2009). This increase in oxidative stress can 
subsequently lead to impaired endothelium-dependent relaxation resulting from 
decreased NO bioavailability or a lack of NO production resulting from uncoupling of
the eNOS enzyme (Marinou et al., 2009).  
 
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During diabetes O2
-
 production becomes a vicious process that can cause damage to 
DNA and proteins, subsequently causing activation of inflammatory processes and 
monocyte recruitment in the arterial wall, which play an important role in the 
pathogenesis of atherosclerosis (Schaffer et al., 2012). Decreased NO bioavailability 
during diabetes causes endothelial dysfunction that promotes increased expression of 
cell adhesion molecules, increases platelet activation, impairs vascular relaxation and 
stimulates monocyte and macrophage migration (Penckofer et al., 2002). These 
processes play a major role in the pathogenesis of CVD (Schaffer et al., 2012). Hence, 
endothelial dysfunction is a central mechanism in the development of CVD related 
pathology during diabetes. Therefore it has been proposed that during diabetes 
oxidative stress may be alleviated with the use of appropriate therapy i.e. antioxidants, 
endothelium function can be improved, consequently delaying the onset of diabetes 
related CVD. 
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Obesity is a disease that is usually defined as a body mass index (BMI) greater than 30 
kg/m2. It is diagnosed by an accumulation of excess visceral body fat mostly in the 
abdominal area, and generally occurs as a result of the consumption of excess kilojoules 
(kJ) leaving the body with a positive energy balance i.e. energy consumption exceeding 
energy metabolized  (Figure 1.8) (Hawkesworth, 2013). 
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Figure 1.8 Obesity: Obesity occurs due to energy consumption exceeding energy expenditure 
which results in a positive energy balance and the accumulation of fat in adipocytes especially 
in the abdominal area. A healthy lifestyle incorporating exercise can maintain energy balance 
or have a negative energy balance that can lead to weight loss. 
Energy in the body is derived from carbohydrate, protein or fat. Of these fat is the most 
energy dense (37 kJ/g) whereas carbohydrate and protein are the least energy dense (17 
kJ/g). Carbohydrate, protein and fat are converted into glucose that is metabolised 
through the Krebs (tricarboxylic acid) cycle and electron transport chain. The product 
of glucose metabolism is adenosine triphosphate (ATP) which is the form in which 
energy is metabolised by the body during physiological reactions to convert stored 
energy into heat and kinetic energy (muscle contraction). When the total energy 
consumed in a day is not “burnt” (metabolised i.e. converted into kinetic energy through 
exercise or heat through bodily physiological reactions) it is converted into fat and 
stored in white adipose tissue (Matsuda and Shimomura, 2013). It is important to note 
 
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that although the cumulative effect of a positive energy balance is the most common 
cause of obesity, there are pathologies that may cause energy imbalances. These can 
include genetic and physiological diseases (i.e. Hashimoto disease/hypothyroidism), 
psychological factors (i.e. binge eating disorders, comfort eating), socioeconomic 
factors (limited nutritional information, limited finances to access healthy food), 
iatrogenic causes (antipsychotic medications e.g. clozapine) and physical factors 
(osteoarthritis or having restricted mobility) and rare genetic defects. Thus indicating 
obesity is a direct result from the interaction between the external and physiological 
milieu (Sansbury and Hill, 2014).  
There are two types of adipose tissue in the body i.e. brown adipose tissue (BAT) and 
white adipose tissue (WAT). Brown adipose tissue is more abundant in newborns and 
its primary function is to protect newborns from heat loss by insulating the body. WAT 
is loose connective tissue that mainly consists of adipocytes (Figure 1.9). Adipocytes 
are composed of cholesterol esters and triglycerides. The primary function of WAT is 
to serve as a reservoir of energy that can be metabolised when required. It is mainly 
found around visceral organs where its main function is insulation and to cushion 
important organs from external shock. WAT is also an important endocrine organ 
producing oestrogen, leptin (satiety hormone) and in excess of 260 peptides which will 
not be covered in this thesis (Mutt et al., 2014). Adipocytes also express receptors for 
insulin, growth hormone and the stress hormone cortisol (Schaffler et al., 2006). 
Adipocytes of WAT have the capacity to expand up to 1000 times their original size 
and are significantly increased in mass during obesity (Jo et al., 2012). WAT mass is 
what is attempted to be “lost” during any weight loss regime.  
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Figure 1.9 White and brown adipose tissue: Brown adipose tissue (A; BAT) has a high 
oxidative capacity due to possessing a large number of mitochondria and its main function is 
to insulate. White adipose tissue (B; WAT) volume is occupied by fat and its function is to 
store energy in the form of fat. WAT has very small oxidative capacity due to the low number 
of mitochondria in contrast to BAT. During obesity (C) WAT becomes infiltrated with 
macrophages and lymphocytes due to increased fat volume. This places WAT in a state of 
inflammation that leads to adipocyte apoptosis and the initiation of atherosclerotic processes in 
the vasculature. Adapted from Owens (2014).  
During obesity, due to a significant positive energy balance and the accumulation of 
fats, there is an increase in free fatty acids (FFA) circulating in the blood. These FFA’s 
undergo β-oxidation that, during metabolism in the mitochondria, produce O2- at very 
high rates. This causes excessive stress on the endogenous antioxidant GPx and CAT 
enzyme systems that contributes to the increased oxidative status in the vasculature. 
FFA’s also stimulate protein kinase C (PKC) that stimulates NADPH oxidase-2 (Nox2) 
to further produce O2
-
 (Inoguchi et al., 2000). Similarly in diabetes, this chain of O2-
producing reactions can lead to changes in the vasculature, e.g. uncoupling of eNOS, 
that can lead to the development of cardiovascular complications such as impaired 
vascular relaxation. 
Chronic expansion of adipocytes occurring during obesity can lead to hypoxia and 
inflammation of WAT (Després and Lemieux, 2006). As a result of this WAT 
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inflammation causes the release of several cytokines such as (TNF-α), interleukin (IL)-
6, IL-1β, monocyte chemoattractant protein-1 (MCP-1) and adipokines (i.e. leptin and 
resistin) (Ouchi et al., 2011). This can lead to the onset of insulin resistance and in 
combination with obesity and low grade inflammation can lead to the eventual onset of 
type 2 diabetes (Lopategi et al., 2016). All of these physiological processes, and others 
which will be discussed later in this chapter, place obese patients at an increased risk 
of developing endothelial dysfunction and cardiovascular complications such as stroke 
and coronary artery disease (Caballero, 2005). The connection between diabetes, 
obesity and CVD is illustrated in Figure 1.10. 
 
Figure 1.10 A schematic representation of the connection between obesity, diabetes and CVD: 
Mechanism and consequences of hyperglycaemia-induced oxidative stress: O2
-
 production is 
increased via the up-regulation of several physiological pathways, a consequence the 
bioavailability of NO decreases and O2
-
 production increases leading to the development of 
CVD. 
 
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Evidence of increased oxidative stress during diabetes was reported as early as 1979 by 
Sato et al. (1979) who reported increased levels of lipid peroxides in the plasma of type 
2 diabetic patients. Since then various mechanisms have been proposed through which 
oxidative stress is increased during diabetes. These include mitochondria-induced 
oxidative stress, hyperglycaemia-induced oxidant stress, ROS associated oxidant stress, 
advanced glycation end product (AGE) formation, PKC activation and the hexosamine 
pathway. 
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The mitochondria are the largest producers of O2
-
 in humans under normal homeostatic 
conditions. ATP synthesis is driven by a proton gradient that is generated by protons 
entering the intermembrane space through protein complexes I, III and IV (Figure 1.11) 
(Giacco & Brownlee, 2010). This process is known as the electron transport chain. 
During diabetes, due to increased glucose concentrations, excessive NADH and 
FADH2 enter the electron transport chain (Mehta et al., 2006). This leads to an increase 
in the proton gradient in the inner mitochondrial membrane at the level of complex III, 
which is the rate-limiting enzyme of oxidative phosphorylation.  This causes electrons 
to back up at the level of complex III consequently generating more O2-. The O2-   is 
then converted into cytotoxic H2O2. H2O2 can be converted into H2O and O2 by the 
actions of CAT and GPx (Figure 1.7) (Stephens et al., 2008). However, these enzyme 
systems can also be affected (e.g. decreased GPx activity) during diabetes due to the 
decreased bioavailability of cofactors such as NADPH (Figure 1.12). There is also 
evidence suggesting that mitochondria-induced oxidative stress occurring in diabetes 
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may activate other O2- generating pathways eg: the NADPH oxidases, which further 
exacerbates O2- production and oxidative stress (Giacco & Brownlee, 2010).  
 
Figure 1.11 Glucose metabolism through the Krebs (TCA) cycle and electron transport chain 
(ETC): In the mitochondria during obesity oxidative stress may increase through increased 
FADH2 and NADH influx in the electron transport chain increasing the proton gradient across 
the inner mitochondrial membrane leading to potential saturation of the system leading to 
uncoupling of the electron transport chain and oxidative phosphorylation. Image taken from 
Lodish et al. (2007). 
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One of the main mechanisms through which hyperglycaemia can increase oxidative 
stress and initiate cardiovascular complications in the vasculature is via the polyol 
pathway (Mehta et al., 2006). Aldose reductase is the enzyme responsible for reducing 
toxic aldehydes into inactive alcohols. During hyperglycaemia however, aldose 
reductase can also reduce glucose to sorbitol which is later oxidised to fructose (Figure 
1.12) (Brownlee, 2005). This series of reactions is referred to as the polyol pathway. 
During this reaction, aldose reductase consumes NADPH, which is vital to the 
regeneration of reduced glutathione (GSH) (Figure 1.7). GSH is the molecule which is 
oxidised into oxidised glutathione (GSSG) by the actions of GPx which, as mentioned 
in the previous section, is one of the enzymes responsible for the neutralisation of H2O2 
(Mehta et al., 2006). This depletion of NADPH and decreased bioavailability of GSH 
further exacerbates oxidative stress.  The contribution of the polyol pathway during 
diabetes has been highlighted in many studies, for example Lee and Chung (1999)   who 
demonstrated the role of increased oxidative stress in the development of diabetic 
cataract as a direct outcome of increased activation of the polyol pathway. Polyol 
pathway (Figure 1.12) activation and diabetes/ hyperglycaemia-induced complications 
is very common in organs that do not require insulin for the uptake of glucose such as 
blood vessels, retina and nerves and is a very common cause of endothelial dysfunction 
with diabetes related cardiovascular complications (De Vriese et al., 2000, Fortes et al., 
1983). Oyama and colleagues (2006) demonstrated that in the presence of high glucose, 
endothelial cell damage may occur as a result of increased oxidative stress. They were 
further able to demonstrate that upon blocking the polyol pathway, oxidative stress was 
 
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decreased suggesting that the polyol pathway is a major source of oxidative stress in 
endothelial cells in the presence of high glucose/ diabetes (Oyama et al., 2006). 
 
 
 
Figure 1.12 The polyol pathway: Hyperglycaemia increases influx of glucose into the polyol 
pathway which increases glucose oxidation to fructose. This consumes NADPH in the process 
which is necessary for GSH regeneration. Taken from Brownlee (2005). 
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Another mechanism through which hyperglycaemia can increase oxidative stress 
during diabetes is glucose mediated non-enzymatic glycosylation of proteins. This 
reaction (Maillard reaction) (Figure 1.13) leads to the formation of an unstable Schiff 
base which is characterized by covalent bonds between the amine group of the protein 
and the aldehyde group of the glucose molecule (Stephens et al., 2008). The Schiff base 
then undergoes further rearrangement and oxidation forming Amadori products 
(Maritim et al., 2003). Amadori products have a slow turnover rate (approximately 28 
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days), and undergo several dehydration reactions and rearrangements to form advanced 
glycation end products (AGEs) (Stephens et al., 2008, Maritim et al., 2003).  Once 
formed, AGEs can bind to the AGE receptor; RAGE, the interaction between AGE and 
its receptor increases the production of ONOO
- (Rojas and Morales, 2004). During 
diabetes there is increased production of AGE that can lead to increased vascular 
permeability, cell adhesion molecule expression and cell migration e.g. leukocytes 
(Rojas and Morales, 2004). All of these events are involved in the pathophysiology of 
CVD. Therefore increased AGE formation during diabetes may further compromise the 
ability of the vasculature to deal with oxidant stress and thus accelerate the development 
of CVD. 
 
 
Figure 1.13 The formation of AGEs via the Maillard reaction: GOLD = glyoxal-lysine dimer, 
CML = Nε-(carboxymethyl)lysine, AGEs = advanced glycation end products. Taken from 
Oliveira et al. (2013).   
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Protein kinase C (PKC) is a family of serine/threonine enzymes which participate in a 
diverse range of cellular processes including; receptor desensitization, modulating 
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membrane structure, transcription regulation, mediating immune responses and cell 
growth regulation (Newton, 1995). 
 
During diabetes, increased PKC activation may activate another family of enzymes 
known as Nox (Paravicini and Touyz, 2008). Nox are a family of enzymes that consists 
of seven isoforms however only four of them are expressed on endothelial cells (Nox1, 
2, 4 and 5) (Drummond and Sobey, 2014). Nox (1, 2 and 5) produce O2- by participating 
in a one electron reduction of oxygen using NADPH as the electron source (Figure 
1.14) (Sugamura and Keaney, 2011, Brandes et al., 2014). 
 
 
Studies that have looked at the effect of PKC activation during diabetes include 
Inoguchi et al., (1992) who demonstrated increased PKC activation and diacylglycerol 
(DAG) concentrations in type 1 diabetic rat aorate and heart. Quagilaro et al., (2003) 
also demonstrated that exposure of human endothelial cells to high glucose increased 
PKC-induced activation of Nox leading to an increase in ROS production and cellular 
apoptosis. Nox related oxidative stress can also contribute to CVD related pathologies 
e.g. cardiac remodelling post myocardial infarction, ischaemia-induced angiogenesis 
and atherosclerosis (Judkins et al., 2009, Looi et al., 2008). Nox derived ROS during 
diabetes also activate a series of pathological cellular processes including initiating 
lipid peroxidation, stimulating kinases and stimulation of proinflammatory genes, 
impairment of vasorelaxation and most importantly, inactivation of NO (Paravicini and 
Touyz, 2008). Hence it has been proposed that increased PKC dependent Nox 
activation has severe pathological consequences where ROS production ultimately 
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becomes a self-generating process contributing to endothelial dysfunction and diabetes 
related complications 
 
Figure 1.14: Nox2 structure: The Nox2 enzyme consists of two catalytic subunits; gp91-phox 
(Nox2), and p22-phox domains. Nox2 activation leads to translocation of the gp91 phox and 
Rac subunits that allows superoxide to be produced from oxygen being reduced by using 
NADPH as the source of the electron. Taken from (Panday et al., 2015). 
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During diabetes (types 1 and 2) there is an increased reliance on fatty acid metabolism 
as a source of energy (Giacco and Brownlee, 2010). Energy in the body is derived from 
glycolysis from the conversion of glucose-6-phosphate into pyruvate. Fructose-6-
phosphate is produced during one of the steps of glycolysis. It is also produced in the 
pentose phosphate pathway (PPP), a physiological process that produces NADPH and 
ribose-5-phosphate that is necessary for nucleic acid synthesis (Figure 1.15) 
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 (Wamelink et al., 2008). During diabetes, fructose-6-phosphate is shunted from the 
glycolysis and PPP into the hexosamine pathway via the actions of the enzyme fructose-
6-phosphate amidotransferase (GFAT) where it is then converted into UDP (uridine 
diphosphate)-N-acetylglucosamine (Figure 1.15) (Brownlee, 2001). This molecule is 
utilized by specific O-G1cNAc transferase enzymes for post-translational modification 
of the serine and threonine residues on the cytoplasmic and nuclear proteins (Giacco 
and Brownlee, 2010). This can then lead to activation of important genes such as TGF-
α, TGF-β and plasminogen activator inhibitor (PAI)-1 through mechanisms which are 
unclear. These genes are responsible for vascular smooth muscle proliferation, cell 
differentiation and apoptosis that subsequently can impair vascular function and 
accelerate CVD related processes. Increased expression of these genes has been 
demonstrated during diabetes or in the presence of high glucose (Du et al., 2000, Chen 
et al., 1998). Inhibition of the GFAT enzyme has also been demonstrated to inhibit 
TGF-α transcription occurring as a result of hyperglycaemia (Kolm-Litty et al., 1998) 
indicating that inhibition of the hexosamine pathway can be beneficial to prevent the 
onset of diabetes related CVD complications. The hexosamine pathway will be further 
discussed in section 1.7. 
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Figure 1.15: The hexosamine pathway: Fructose-6-phosphate (F6P) can be formed through 
glycolysis or from the pentose phosphate pathway. During diabetes F6P can be shunted from 
these pathwys into the hexosamine pathway. The hexosamine pathway can lead to activation 
of TGF-β via a series of reactions that can damage DNA. TGF-β is involved in the pathogenesis 
of CVD. Taken from Brownlee (2001). 
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Increased oxidative stress during obesity is one of the major causes of endothelial 
dysfunction that eventually leads to obesity related cardiovascular complications such 
as atherosclerosis. There are several mechanisms and potential sources of ROS (Figure 
1.16) that increase oxidative stress during obesity. These mechanisms include fatty acid 
oxidation, increased mitochondrial oxidative stress, hexosamine pathway and 
decreased vitamin E concentration.  
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Figure 1.16: Potential sources of ROS during obesity: Obesity mostly occurs as a result of 
consuming more kilojoules than is expended. This can cause an increase in O2
-
 production and 
formation of ONOO-, a key mediator of lipid peroxidation from sources such as increased IL-
6-induced xanthine oxidase activation during obesity. NO is produced from the conversion of 
L-Arginine into L-Citrulline and during obesity increased O2
-
 can lead to eNOS uncoupling 
resulting in endothelial dysfunction. The formation of ONOO- decreases NO bioavailability and 
increases lipid peroxidation and foam cell formation in atherosclerotic lesions. Uncoupling of 
eNOS further increases oxidative stress and the formation of other ROS e.g. H2O2 that 
subsequently decrease the activity of GPx and CAT enzymes to further increase oxidative 
injury. Adapted from Avogarro and Vigili de Kretzenberg (2005).  
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Obese people, even in the absence of diabetes, can also have increased oxidative stress 
due to increased FFA oxidation. When energy intake exceeds energy expenditure, there 
is an increase in pyruvate that is the substrate for the TCA cycle (Krebs cycle). Pyruvate 
is produced from glycolysis resulting from the breakdown of monosaccharides, fatty 
acids and amino acids (Figure 1.17). Pyruvate enters the inner mitochondrial membrane 
to enter the Krebs cycle. Pyruvate is converted into a pyruvate dehydrogenase complex 
(acetyl CoA) which undergoes a series of chemical reactions to produce NADH+, 
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FADH2 and ATP (Quijano et al., 2016) which are cofactors for many physiological 
reactions such as the pentose phosphate pathway (PPP) and eNOS derived NO 
production. The Krebs cycle also produces oxaloacetate and isocitrate which are the 
building blocks for many amino acids and other physiological molecules (Umbarger, 
1978). The cofactors which are produced from the TCA cycle are also vital for ATP 
production via the processes of oxidative phosphorylation or the electron transport 
chain that occur in the inner mitochondrial membrane. 
 
During obesity there is excessive energy substrate in the body which then undergoes 
glycolysis for ATP production. This process is anaerobic thus making it extremely 
energy inefficient (4 ATP molecules/ glucose molecule). The pyruvate then produced 
from glycolysis is shuttled into the mitochondria into the Krebs cycle and eventually 
into the inner mitochondria membrane. As mentioned previously in section 1.6.1 
complex III in the inner mitochondrial membrane is the rate-limiting step of ATP 
production in the mitochondria. Therefore, due to excessive substrate availability 
during obesity, similarly to diabetes, there is an increase in the proton gradient in the 
inner mitochondrial membrane that eventually exceeds the capacity of oxidative 
phosphorylation to produce ATP further increasing oxidative stress. This is known as 
uncoupling of the ETC (Martin and McGee, 2014, Forbes and Cooper, 2013). 
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Figure 1.17 The tricarboxylic acid cycle, the ETC and oxidative phosphorylation: During 
obesity and the increased consumption of sugar and fat there is increased substrate entering the 
cell and entering the Krebs cycle. The FADH2 produced enters the ETC and oxidative 
phosphorylation. This causes an increase in O2- from the mitochondria increasing oxidative 
stress. Also complex III is the rate limiting step in the ETC which eventually causes a build up 
of protons in the inner mitochondrial membrane causing the ETC and oxidative 
phosphorylation processes to uncouple subsequently further exaggerating oxidative stress. 
Adapted from Forbes and Cooper (2013).
60<07 #$"'&"!/#"%&%%'!!%'!$%%&!
Under normal physiological conditions, FFAs are an important energy source for most 
body tissues and are the primary oxidative fuel for the liver, resting skeletal muscle, the 
renal cortex and the myocardium. Free fatty acids are a particularly important energy 
source during starvation, exercise and pregnancy, as they allow the preservation of 
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glucose for cerebral requirements (Boden and Shulman, 2002). However, 
overproduction of FFAs, which occurs during obesity, can cause a number of 
pathological processes, one of which is insulin resistance, a hallmark characteristic of 
metabolic syndrome. 
 
         IGT:   Impaired glucose tolerance            CVD:   Cardiovascular disease 
 
Figure 1.18 The relationship between obesity, increased FFA/ free glucose and insulin 
resistance, diabetes and cardiovascular disease: Overnutrition and decreased physical activity 
leads to increased glucose and FFA’s entering adipocytes. Insulin is immediately released to 
allow glucose uptake however the excessive insulin release leads to insulin resistance. Insulin 
resistance coupled with oxidative stress in turn induces endothelial dysfunction. Endothelial 
dysfunction may lead to the development of CVD related pathologies. Taken from Ceriello and 
Motz (2004). 
 

40 
As mentioned in the previous section FFAs are a major source of ROS in obesity. 
Amongst the many molecules secreted by adipose tissue, adiponectin is a cytokine 
highly abundant in plasma and only expressed in adipose tissue (Yadav et al., 2012). 
Adiponectins have an anti-inflammatory effect on endothelial cells to improve vascular 
function (Hotta et al., 2000). Adiponectin concentration is inversely proportional to fat 
content (Lopez-Jaramillo, 2016). Saito et al. (2008) have previously demonstrated 
increased oxidative stress in the plasma and visceral adipose tissue of obese patients. 
These patients also had low levels of adiponectin that was increased by treatment with 
HMGCoA reductase inhibitor pravastatin (cholesterol lowering statin). They also 
demonstrated decreased oxidative stress with pravastatin treatment.  Obesity has been 
demonstrated to decrease adiponectin levels. Conversely, increased adiponectin has 
been demonstrated to decrease circulating FFAs and increase insulin sensitivity (Lihn 
et al., 2005). Insulin resistance is a major predecessor of CVD (Figure 1.18).  
Insulin is the major blood glucose-regulating hormone of the body and functions to 
promote glucose uptake from the blood into body organs. Insulin is produced in the 
islet β-cells of the pancreas and is very sensitive to oxidative stress. This is due to a 
lack of endogenous antioxidants in pancreatic- β cells i.e. SOD, GPx and CAT (Ceriello 
and Motz, 2004, Tiedge et al., 1997).  
Insulin resistance is the inability of the body to respond to endogenous insulin resulting 
in hyperglycaemia and can progress into type 2 diabetes (Arner, 2002). During insulin 
resistance due to decreased insulin-mediated glucose uptake can lead to increased 
oxidative stress (Figure 1.19). There have been studies that have demonstrated 
increased oxidative stress in skeletal muscle leading to decreased glucose uptake by 
skeletal muscle (Roy et al., 1998). Skeletal muscle is the major consumer of insulin-
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mediated glucose uptake. Excessive glucose in skeletal muscle is known to cause
glucose toxicity whereby muscles can decrease glucose uptake by decreasing GLUT4 
expression, which is the protein involved in insulin-mediated glucose uptake (Kim et 
al., 2001). Therefore it can be suggested that oxidative stress leads to decreased glucose 
uptake that can subsequently contribute to hyperglycaemia and insulin resistance 
(Figure 1.17). It may also be suggested that during obesity, as a result of increased 
caloric intake, insulin resistance can be a protective mechanism whereby muscles 
protect themselves from glucose toxicity (Unger, 2003). This was demonstrated by 
Hoehn et al. (2009) that demonstrated that insulin resistance is a defence mechanism in 
adipocytes, myotubes and mice. 
 
IR:   Insulin Resistance NFκB:    
PI3K: PGI2 synthase: 
Figure 1.19 The effect of FFAs and insulin resistance on endothelial oxidative stress eNOS 
activity: An increase in adipose tissue mass and FFA’s in the vasculature leads to increased 
FFA oxidation that subsequently increases ROS production this has a downstream affect on 
AGE and PKC production that reduces eNOS activity and consequently NO production. Taken 
from Giacco and Brownlee (2010).  
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The consumption of excess calories (nutrient excess) has deleterious effects on 
glycolytic pathways of the body. The hexosamine pathway can increase oxidative stress 
in both diabetic and obese subjects. The hexosamine pathway accounts for 
approximately 3% of total glucose utilized by the body (Buse et al., 2007) however 
during obesity its activity can be significantly upregulated. The substrate for the 
hexosamine pathway is fructose-6-phosphate that is a produced in glycolysis and 
pentose phosphate pathway (PPP). The PPP is the physiological pathway that provides 
substrate for the TCA cycle and the electron transport chain/ oxidative phosphorylation. 
The hexosamine pathway is responsible for the synthesis of the glycosyl side chain of 
glycolipids, proteoglycans and glycoproteins (Buse, 2005). 
 
Figure 1.20 The hexosamine pathway: During obesity there is an increased influx of substrate 
(glucose (glucose-6-phosphate; G6P)) entering the glycolysis pathway, however there is also 
an increased influx of substrate entering the hexosamine pathway that concerts glucose into 
glucosamine-6-phosphate. Following several reactions UDP-GlcNAc is produced that is 
necessary for the glycolipid synthesis. Sustained long-term UDP-GlcNAc production that 
occurs during obesity is shown to inhibit eNOS activity and is involved in the pathophysiology 
of insulin resistance.  Taken from Wellen and Thompson (2010). 
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During obesity or nutrient excess, when there are increased glucose and FFAs 
circulating in the blood, there is an increased level of fructose-6-phosphate that is 
shunted from glycolysis and the PPP into the hexosamine pathway. The end-product 
from the hexosamine pathway is uridine diphosphate N-acetylglucosamine (UDP-
GlcNAc) (Figure 1.20) which is necessary for nucleocytoplasmic O-GlcNAc protein 
modification and N-linked glycosylation in the Golgi and endoplasmic reticulum 
(Wellen and Thompson, 2010, Love and Hanover, 2005). O-GlcNAcylation is of 
particular importance, especially to aortic smooth muscle cells, where increased O-
GlcNAcylation has shown to inhibit the Akt activation site of eNOS (Musicki et al., 
2005). This subsequently decreases eNOS activity and impairs vascular relaxation 
contributing to the pathogenesis of obesity- and diabetes -induced cardiovascular 
disease (Giacco and Brownlee, 2010).   
 
One of the major enzymes involved in the hexosamine pathway is glucosamine—
fructose-6-phosphate aminotransferase (GFAT). Over expression of GFAT has been 
demonstrated to be destructive to pancreatic-β cells and increase the oxidative status in 
β-pancreatic cells and eventually lead to diabetes (Robertson, 2004). One study has also 
demonstrated that hyperglycaemia can suppress insulin gene transcription and decrease 
insulin-mediated glucose uptake (Robertson et al., 1992). Therefore suggesting that up 
regulation of the hexosamine pathway occurs during obesity as a mechanism to 
decrease mitochondrial-induced oxidative stress to reduce substrate entering the TCA 
cycle and subsequently the ETC. However, hexosamine up-regulation leads to 
pancreatic-β cell destruction that leads to increased oxidative stress in the pancreas and 
insulin deficiency (Prentki and Nolan, 2006).   
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Vitamin E (Figure 1.20), is a lipid soluble vitamin that acts as a chain breaking 
antioxidant that scavenges peroxyl radicals to prevent lipid peroxidation in plasma 
membranes (Traber and Stevens, 2011). The most widely studied form of vitamin E is 
α-tocopherol.  Vitamin E levels have been reported to be significantly lower in obese 
patients in comparison to healthy people (Traber, 2014). A study conducted by Strauss 
(1999) demonstrated that obese children had significantly lower levels of fat-soluble 
vitamins (α-tocopherol and β-carotene) in comparison to healthy weight children.    
Interestingly, a recent study published by Mah et al. (2015) has also found that despite 
adequate α-tocopherol (vitamin E) intake, obese patients with metabolic syndrome had 
significantly lower levels of plasma α-tocopherol. The study also demonstrated 
decreased absorption of α-tocopherol in obese metabolic syndrome patients in 
comparison to healthy subjects. This was attributed to increased basal inflammation 
and increased oxidative stress that is experienced during metabolic syndrome.

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As discussed in sections 1.6 and 1.7, oxidative stress is a major cause of endothelial 
dysfunction. Vascular endothelium is highly enriched with exogenous (vitamins A&E) 
and endogenous (SOD, GPx and CAT) antioxidant systems that allow it to serve as an 
antioxidant barrier hence protecting the vasculature from oxidative damage (Lazo-de-
la-Vega-Monroy and Fernndez-Mej, 2013). However, during diabetes and obesity, due 
to the increased production of ROS and a significant reduction in the antioxidant 
capacity of endogenous antioxidant systems, antioxidants may serve as a useful therapy 
to alleviate oxidative stress and thus prevent vascular complications such as CVD. 
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There has been a spectrum of antioxidants that have been used to improve endothelium-
dependent relaxation in animal studies. Leo and colleagues (2011) demonstrated that 
3',4'-dihydroxyflavonol was able to improve endothelium-dependent relaxation in 
mesenteric arteries from type 1 diabetic rats after one week of treatment. They also 
demonstrated that the antioxidant was able to reduce oxidant stress and prevent eNOS 
uncoupling indicating that eNOS is an important contributor in the maintenance of 
endothelium-dependent relaxation (Leo et al., 2011a). Other antioxidants that may 
improve endothelial function during diabetes include angiotensin converting enzyme 
(ACE) inhibitors, which have been reported to improve endothelial function in the right 
common femoral artery of type 1 diabetic patients (Arcaro et al., 1999). The SOD 
mimetic tempol has also been demonstrated to improve endothelium-relaxation in the 
STZ rat (Nassara et al., 2002). In addition, polyphenolic tea compounds have been 
demonstrated to reduce oxidative stress in the blood in an animal model of insulin 
resistance (Hininger-Favier et al., 2009). 
 
When translating the animal research outcomes into large scale human clinical trials, 
most antioxidants and their ability to reduce cardiovascular pathologies has produced 
disappointing results (Leopold, 2015). This includes large scale clinical trials using 
antioxidants such as selenium where long term supplementation was not able to reduce 
cardiovascular mortality or reduce the risk of cardiovascular events (Rees et al., 2013). 
Ascorbic acid (vitamin C) and its effect on endothelial function during CVD has also 
been extensively studied with mixed outcomes. For example, a study conducted by 
Antoniades et al. (2004) studied the effect of vitamin C on endothelial function in 
patients with coronary artery disease (CAD) and diabetes. They demonstrated that 4-
week vitamin C supplementation significantly improved forearm vasodilatation in 
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patients with CAD plus diabetes however, they were not able to demonstrate the same 
effect in diabetic patients. Similarly a study conducted by Chen et al. (2006)  was not 
able to demonstrate any significant effect of vitamin C supplementation in type 2 
diabetic patients. Studies that have been able to demonstrate any significant benefit of 
vitamin C supplementation during CVD have usually had patients on extremely high 
concentrations of vitamin C (>500mg/day) (Ashor et al., 2014). Although this may 
improve cardiovascular outcomes, extremely high supplementation of vitamin C has 
shown to increase oxidative damage to peripheral blood lymphocytes in terms of 
modified DNA bases (Podmore et al., 1998).  
 
Therefore, if increased oxidative stress is a major cause of endothelial dysfunction and 
the cardiovascular complications of diabetes and obesity then antioxidant therapy may 
alleviate or delay any subsequent cardiovascular complications. 

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Vitamin E is a family of antioxidant molecules which consist of tocopherols and 
tocotrienols (Atkinson et al., 2008). Both tocopherols and tocotrienols have four 
chemically distinct isomers named alpha (α), beta (β), delta (δ) and gamma (γ) based 
on the positioning of the methyl molecules on the chromanol ring (Figure 1.20). Both 
tocopherols and toctrienols share structural similarities but they differ chemically in 
their chains as tocopherols have a phytyl chain and tocotrienols have an isoprenoid 
chain (Figure 1.21) (Aggarwal et al., 2010). 
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    tocopherol (TC)                                                  tocotrienol  (T3) 
Figure 1.21 Chemical structure of tocopherols and tocotrienols: Tocopherols and tocotrienols 
are members of the vitamin E family that have 4 known isomers each. Both tocopherol and 
tocotrienols have a chromonal ring with and a hydroxyl group attached to the ring. The α TC/T3 
has 3 methyl groups on the chromonal ring, δ -TC/T3 has 1 methyl group and β γ-TC/T3 have 
2 methyl groups. The designation of the individual isomers is based on the number and position 
of the methyl groups on the chromonal ring (red).  
 
Most of the scientific literature on vitamin E and its antioxidant properties has focused 
on tocopherols, especially α-tocopherol. This can be attributed to the relatively greater 
abundance of tocopherols in food sources in comparison to tocotrienols and the ease of 
extraction from natural sources, hence making it an extensively researched molecule.   
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The main function of vitamin E is to act as a chain breaking antioxidant and scavenge 
lipid peroxyls and O2
-  
to prevent oxidative damage to membranes and DNA in 
biological tissues (Yoshida et al., 2003). Once vitamin E (e.g. α-tocopherol) scavenges 
lipid peroxyls or O2
-  it becomes a tocopheroxyl radical (Figure 1.21) (Kamal-Eldin and 
 

48 
Appelqvist, 1996). The tocopheroxyl radical is then recycled back to vitamin E by using 
vitamin C as an electron acceptor. The basic antioxidant action of vitamin E and how 
it is recycled is illustrated in Figure 1.22. 
 
 
Figure 1.22 Vitamin E function: Vitamin E scavenges lipid peroxyls and is recycled back into 
vitamin E by the actions of vitamin C. This antioxidant system also requires GSH and NADPH 
to allow effective recycling of vitamin E. During states of increased oxidative stress may 
decrease the bioavailability of cofactors GSH and NADPH leading to decreased vitamin E 
recycling consequently affecting other enzyme system such as eNOS.  Taken from Packer et 
al., (2001). 
 
Vitamin E is found in the plasma membranes (lipid bilayer) of cells and is part of larger 
antioxidant network system rather than an antioxidant functioning in isolation 
(Atkinson et al., 2008). It is also the most abundant lipid soluble antioxidant found in 
membranes (Rigotti, 2007) that allows it to perform its antioxidant function effectively. 
Although all forms of tocopherols and tocotrienols are found in foods, the body only 
maintains α-tocopherol in the body it is one of the most important dietary antioxidants 
and all dietary guidelines of vitamin E intake are based on the consumption of α-
tocopherol (Packer et al., 2001).   
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Vitamin E is solubilized into micelles by the actions of bile salts and intestinal lipids 
after which they are absorbed into the intestinal epithelium (Figure 1.23) (Traber et al., 
1990). They are then actively transported into the bloodstream through various carriers 
including chylomicrons and mainly high and low density lipoproteins (Anwar et al., 
2006, Perugini et al., 2000). They are then incorporated into membranes by the actions 
of the α-tocopherol transport protein (α-TTP) (Figure 1.22) (Manor and Morley, 2007).  
 
Figure 1.23 Vitamin E absorption and transport: α-TC is absorbed in the small intestine and 
incorporated into chylomicrons. They are then converted into remnant particles. Remnant 
chylomicron associated α-TC is transported to the liver and is selectively incorporated into 
VLDL’s by the α-TTP and is re-secreted into circulation. Endogenous apoB–containing 
VLDL’s and LDL’s can exchange α-TC with HDL’s where LDL and HDL are the main sources 
for the cellular uptake of α-TC in peripheral tissues. HDL’s can also remove excess α-TC from 
cells. Adapted from Mardones and Rigotti (2003) .  
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The plasma concentration of vitamin E (α-tocopherol) in humans is reported to range 
from 15-20 μmol/L (Grzelińska et al., 2009, Schweigert et al., 2003) however this is 
not indicative of the concentration of vitamin E in cell membranes, the term “tocol 
sufficiency” which refers to the amount of vitamin E expressed as a mole percentage 
of the phospholipids, is a better indicator of vitamin E in a cell (Atkinson et al., 2008). 
However there is a lack of literature that measures vitamin E concentration in this 
manner and  is variable from tissue to tissue (McMurchie and McIntosh, 1986). For 
example the concentration of vitamin E in human platelets is 0.1-0.15 mol% (Steiner, 
1978) and 0.05-0.13 mol%  in rat liver mitochondria (Gruger and Tappel, 1971). As 
mentioned previously, despite sharing structural similarity both tocopherols and 
tocotrienols differ functionally that gives each type of vitamin E unique properties 
which will be discussed further.  
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Tocopherols were the first identified components of vitamin E and are the most 
abundant. Sources of tocopherols include; various nuts (including, almonds, hazelnuts 
and pistachios), flaxseed, poppy seed and sunflower seeds (Aggarwal et al., 2010).  
 
There have been numerous animal studies that have looked at the effect of vitamin E 
(α-tocopherol) and its ability to improve endothelial function in diabetic animal models. 
This includes a study by Keegan and colleagues (1995) who demonstrated an 
improvement in endothelium-dependent relaxation in type 1 diabetic rat aorta with a 
1% dietary supplement of α-tocopherol. α-Tocopherol was also able to increase 
superoxide scavenging capacity in this study. This suggests that vitamin E exerts its 
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protective effects through its antioxidant activity. Another study conducted by Wigg 
and colleagues (2004) was able to demonstrate that α-tocopherol supplementation 
(1g/kg/day) improved endothelium-dependent relaxation in type 1 diabetic rat 
mesenteric arteries, which was attributed to an increased NO bioavailability. Also a 
reduction in vessel wall stress was observed as a decrease in the wall thickness of 
messenteric and femoral arteries (Wigg et al., 2004). This was potentially through 
vitamin E decreasing arterial wall thickness by directly affecting re-arrangement of the 
components and/or structure of the arterial walls. Therefore these and other studies 
indicate a potential for α-tocopherol as an effective antioxidant in alleviating vascular 
oxidant stress.  
 
There have been several reports that α-tocopherol improves vascular function or 
reduces oxidant stress during diabetes in animals (Gazis et al., 1999, Karasu et al., 1997, 
Rosen et al., 1985) and small human trials (Skyrme-Jones et al., 2000, Bursell et al., 
1999) large scale clinical trials have also conducted but with very disappointing results. 
This includes the HOPE study that was unable to demonstrate any long term benefit of 
vitamin E supplementation in preventing major cardiovascular events in patients with 
diabetes or vascular disease (Lonn et al., 2005). The HOPE study examined the effect 
of vitamin E (α-tocopherol) supplementation (400 IU/day) in patients with CAD for an 
average period of 4.5 years. Their findings revealed that if anything, vitamin E 
supplementation increased the incidence of heart failure in the supplemented patients. 
Another example was the Framingham study that demonstrated that vitamin E 
supplementation (100-600 IU/day, 67% participants had > 300 IU/day) did not reduce 
CVD related mortality or decrease the risk of CVD in patients with diabetes or pre-
existing vascular disease (Dietrich et al., 2009). The alpha-tocopherol and beta-carotene 
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study (ATBC) (Leppälä et al., 2000) demonstrated no significant benefit of 
supplementation of 50mg/day of α-tocopherol on incident of myocardial infarction or 
fatal CAD. On the contrary, the study demonstrated an increased rate of fatal 
hemorrhagic stroke in the study’s participants. Another large-scale clinical trial 
includes the Physicians Health Study II (PHS-II) (Gaziano et al., 2009). The PHS II 
study also did not demonstrate any long-term benefit of vitamin E or C supplementation 
on reducing the risk of prostrate or any cancer. 
 
There have been many reasons put forward to explain why tocopherol supplementation 
studies (including the ones mentioned previously) have not proven successful in 
humans. Some suggestions include the advanced age of participants, the diabetes and/or 
vascular disease being too far advanced that treatment with antioxidants such as vitamin 
E is not beneficial, and the potential for tocopherols to become a pro-oxidant at high 
concentrations (Paravicini and Touyz, 2008, Bowry et al., 1992). This has led 
investigators to test different antioxidants that may be able to serve as a more useful 
antioxidant in ameliorating diabetes and obesity-induced endothelial dysfunction and 
its subsequent cardiovascular complications. 
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Tocotrienols, are a more recently identified but perhaps a more potent member of the 
vitamin E family (Serbinova et al., 1991). Tocotrienols were first described in 1964 
when they were isolated from the latex of the rubber plant, Havea brasiliensis (Dunphy 
et al., 1965). Since then other richer sources of tocotrienols have been identified 
including palm oil, rice bran, wheat germ and barley (Aggarwal et al., 2010). 
Tocotrienols just like tocopherols have 4 chemical isomers and their nomenclature is 
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based on the position of the methyl molecules on the chromanol ring, identical to the 
nomenclature of tocopherols (Figure. 1.19).  
 
Tocotrienols have a very similar chemical structure to tocopherols but are significantly 
more potent antioxidants than tocopherols. This was demonstrated by a study conducted 
by Serbinova and colleagues in 1991, revealing α-tocotreinol to be up to 50 times more 
potent than α-tocopherol as an antioxidant against (Fe2+ + ascorbate) and (Fe2+ + 
NADPH)-induced lipid peroxidation in rat liver microsomal membranes and 6.5 times 
more effective than α-tocopherol in reducing oxidative. The high potency of 
tocotrienols can potentially be attributed to the presence of double bonds in the phytyl 
chain making them highly lipid soluble and can therefore achieve high intracellular 
concentrations (Aggarwal et al., 2010).   
 
Tocotrienols are also considered to possess other properties that tocopherols do not 
possess including anticholesterol (Pearce et al., 1992) and antithrombotic properties 
(Baliarsingh et al., 2005). Hence it could be hypothesised that tocotrienols may improve 
diabetes and obesity-induced endothelial dysfunction consequently preventing or 
delaying the onset of diabetes and obesity related complications such as CVD. 
 
Studies investigating the effect of tocotrienols on vascular function include by Muharis 
et al. (2010). They demonstrated that acute exposure to tocotrienol rich palm oil 
fractions and α-tocopherol (1/mg/mL) significantly improved endothelium-dependent 
relaxation in type 1 diabetic and spontaneously hypertensive rats. However, whether 
tocotrienol rich palm oil is a more potent antioxidant than α-tocopherol was not studied 
as the study used the same dosage for both tocotrienols and α-tocopherol. The 
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antioxidant properties of tocotrienols was also reflected in their results that studied 
superoxide-scavenging capacity, which showed that α-tocopherol and their tocotrienol 
rich fraction possessed similar superoxide scavenging capacity at the same 
concentrations (0.3mg/mL-1mg/mL). Another study that has demonstrated tocotrienol 
rich fraction reducing vascular oxidant stress during diabetes is by Budin et al. (2009). 
They demonstrated that eight-week supplementation of the diet of type 1 diabetic rats 
with a tocotrienol rich fraction (200mg/kg/day) lowered blood glucose levels, 
decreased oxidant stress and improved the morphology of the aorta which was seen as 
a decrease in vascular smooth muscle cell proliferation, inhibition of dense amorphous 
material formation, more regular elastic lamina and a smooth tunica intima (Budin et 
al., 2009). Both of these studies involved extracts of palm oil that included some 
tocopherol as well as a mixture of tocotrienols. There appear to be no studies examining 
the antioxidant actions of specific tocotrienol isoforms in the vasculature. Thus there 
are studies with promising but limited data on the actions of mixed tocotrienols.  
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Tocomin is a mixture that is derived from a palm oil extract rich in tocotrienols 
(tocotrienol rich fraction: 40%, and palm olein: 38%) but also containing some α-
tocopherol (11%). It is manufactured by Carotech and is the drug of interest that will 
be studied in this thesis. The ability of tocomin to reduce oxidative stress has not been 
widely studied. A study conducted by Sen et al. (2000) demonstrated that tocomin 
supplementation in healthy women achieved plasma levels of tocotrienols 12 to 30 
times more than the concentration of α-tocotrienol required to protect against stroke-
related neurodegeneration. Another study conducted by the same research group 
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Khanna et al. (2005) later demonstrated that 8-week tocomin supplementation (1g/kg) 
protected spontaneously neuronal cells against glutamate- and stroke-induced neuro-
degeneration. 
The effect of tocotrienol rich fractions of palm oil on endothelial function during 
disease states where there is increased oxidative stress in the vasculature has not been 
extensively studied. A study conducted by Muharis et al. (2010) demonstrated that a 
palm oil fraction rich in tocotrienols possessed potent antioxidant capacity and 
improves endothelium-dependent relaxation in the arteries of STZ-induced type 1 
diabetic rats and spontaneous hypertensive rats.  
Hence based on the lack of current literature on the antioxidant activity and affect of 
tocotrienols on vascular function during disease states of increased oxidative stress such 
as diabetes and obesity, further investigation into the function of tocotrienols is 
warranted. 
 
 
 
 
 
 

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Therefore the aims and hypotheses to be investigated were; 
 
Aim 1: Compare vascular and antioxidant activity of three tocotrienol isomers (α, δ and 
γ) and tocomin to α-tocopherol. β-tocotrienol was not studied in this thesis because we 
were not able to obtain any β-tocotrienol. Also there has been no literature that has been 
able to demonstrate any pharmacological benefit of β-tocotrienol in any pathology 
(Ahsan et al., 2014). 
 
Hypothesis 1: Tocotrienols are significantly more potent antioxidants compared to α-
tocopherol. 
 
Aim 2: Determine whether α, δ and γ-tocotrienols in isolation or in combination and 
tocotrienol rich tocomin can improve endothelium-dependent relaxation in the presence 
of oxidative stress. 
 
Hypothesis 2: Tocotrienols and tocomin improve endothelium-dependent relaxation in 
the presence of oxidative stress in the rat aorta. 
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Aim 3: Investigate whether the acute presence of tocotrienol rich tocomin can improve 
endothelium-dependent relaxation of aortae isolated from diabetic and obese rats. 
 
 
Hypothesis 3: Acute exposure of tocotrienol rich tocomin improves endothelium-
dependent relaxation in animal models of type 1 diabetes and obesity in the rat aorta. 
 
Aim 4: Investigate whether the 4 week in vivo treatment of diabetic and obese rats with 
tocotrienol rich tocomin can reduce oxidative stress and improve endothelium-
dependent relaxation in the aortae. 
 
Hypothesis 4: In vivo treatment of tocotrienol rich tocomin improves endothelium-
dependent relaxation in animal models of type 1 diabetes and obesity. 
 
Aim 5: Determine any potential mechanism of action through which tocomin may 
improve endothelium-dependent relaxation in aortae from diabetic and obese rats. 
 
Hypothesis 5: In vivo treatment with tocotrienol rich tocomin improves endothelium-
dependent relaxation by increasing the expression of eNOS and decreasing the 
expression of Nox2 in aortae from diabetic and obese rats. 

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Chapter 2 
General methods 
 



















 

59 
	60 	



All procedures involved were approved by the Animal Experimentation Ethics 
Committee of RMIT University and conformed with the Australian National Health 
and Medical Research Council of Australia code of practice for the care and use of 
animals for scientific purposes. Numbers of the approvals used throughout the duration 
of the project were;  
1. #0822 
2. #1011 
3. #1121 
4. #1211 
5. #1245  
6. #1309  
7. #1417 
 
Refer to Appendix for Ethics approval. 
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Male 6-8 week old Wistar rats (240-280g) (Animal Resource Centre, Perth, WA, 
Australia) were randomly divided into 2 groups: normal and diabetic. The rats were 
housed in groups of 2-4 under a light/dark cycle (12 h/12 h), in a temperature-controlled 
room (22°C) at the RMIT Animal Facility with water ad libitum. Type 1 diabetes was 
induced by a single injection of streptozotocin (STZ, 50 mg/kg) into the tail vein after 
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an overnight fast. The control groups received an equivalent volume of vehicle (0.1 M 
citrate buffer, pH 4.5) alone. Induction of diabetes was considered successful when 
blood glucose levels (BGL) exceeded 15 mM. Bodyweight was measured on a weekly 
basis to monitor any potential weight loss. BGL was measured weekly using a one-
touch glucometer (Roche, Sydney, New South Wales) after obtaining blood from a tail 
prick. Diabetic rats whose BGL exceeded 15 mM or which had 5% or greater weight 
loss (compared to initial bodyweight) were administered with long-acting insulin 
(Protophane; 3-5 units 3 times per week i.p. Novo Nordisk, Australia) to halt any further 
weight loss and promote health of the rat in the absence of euglycaemia. 
 
The rats were killed 10 weeks post STZ or vehicle injection by asphyxiation by CO2 
inhalation, followed by decapitation and their chests were opened to isolate the thoracic 
aortae. The rats were fasted overnight prior to the euthanasia. Fasting blood samples 
were obtained from the carotid arteries following decapitation. Glycated haemoglobin 
(HbA1c) were measured at the end of the experimental period using the In2itTM A1c 
system (II) analyser (Bio-Rad, Hercules, CA, USA).  
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Male Wistar Hooded rats (University of Adelaide, Australia) weighing 180–200 g at 
the start of feeding period were housed in groups of four under a light/dark cycle 
(12 h/12 h), in a temperature controlled room (22°C) at the RMIT Animal Facility with 
water ad libitum. Animals were randomly assigned to either a control diet (SD, 
Standard AIN93G rodent diet, 7% total fat including 1.05% total saturated fatty acids; 
Specialty Feeds, Perth, Australia) or high-fat western diet (WD, SF00-219, 21% total 
fat including 1.80% total saturated fats and 0.15% cholesterol; Specialty Feeds, Perth, 
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Australia). Animals were allowed adlibitum access to their designated diets for 12 
weeks. Food intake and bodyweight were measured weekly. The rats were killed 12 
weeks after the feeding period by asphyxiation by CO2 inhalation, followed by 
decapitation, and their chests were opened to isolate the thoracic aortae. Blood samples 
were obtained from the carotid arteries following decapitation. BGL’s at the end of the 
feeding period were measured using a one-touch glucometer (Roche, Sydney, New 
South Wales). HbA1c was also measured at the end of the feeding period using the 
In2itTM A1c system (II) analyser (Bio-Rad, Hercules, CA, USA). 
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For the study in Chapter 5, six weeks post induction of diabetes or injection of vehicle, 
tocomin treatment (40 mg/kg/day s.c.) or vehicle (peanut oil) was commenced for a 
period of 4 weeks until the end of the experimental period. For the western diet rats, 8 
weeks into the feeding period tocomin treatment (40 mg/kg/day s.c.) or vehicle (peanut 
oil) was commenced for a period of 4 weeks until cessation of the study. 
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The thoracic aorta was isolated and immediately placed in ice-cold Krebs bicarbonate 
solution (118 mM NaCl, 4.7 mM KCl, 1.18 mM MgSO4, 1.2 mM KH2PO4, 25 mM 
NaHCO3, 11.1 mM D-glucose, and 1.6 mM CaCl2, pH 7.4). The aorta was then cleared 
of fat and connective tissue and cut into 2-3 mm long segments. The aortic rings were 
mounted between two stainless steel wires, one of which was linked to an isometric 
force transducer (model FT03, Grass Medical Instruments, Quincy, MA, USA) 
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connected to a Powerlab (model 8/30 AD Instrument Co., Sydney, Australia), and the 
other end anchored to a glass rod submerged in a standard 10 mL organ bath. The organ 
bath was filled with Krebs-bicarbonate solution. The bath medium was maintained at 
37°C, pH 7.4 and continuously aerated with 95% O2, 5% CO2. Aortic rings were 
equilibrated for 45 minutes at a resting tension of 1 g, and then were contracted with an 
isotonic, high potassium physiological salt solution (KPSS, 122.7 mM KCl, pH 7.4 in 
which K+ ions replaced Na+ ions in the solution) for 20 minutes to achieve maximal 
contraction. After which KPSS was replaced with krebs solution to re-equilibrate, the 
rings were sub-maximally contracted with phenylephrine to 40-60 % of KPSS 
contraction (PE, 0.01–0.3 μM) and endothelial integrity was tested by the addition of a 
single concentration of acetylcholine (ACh, 10-5 M). Where relaxation was greater than 
80% of the pre-contraction, the endothelium was considered to be intact and the aortic 
ring was included in the study. Some additional segments of the thoracic aortae were 
used to measure superoxide production (Section 2.3). 
 
Cumulative concentration response curves to ACh (0.1 nM–10 μM) and sodium 
nitroprusside (SNP, 0.1 nM–10 μM) were determined using aortic rings contracted with 
phenylephrine (10−8 to 10−7 M) to 40%–60% of maximal contraction. Responses to 
ACh and SNP were also tested in the presence or absence of inhibitors/antagonists that 
were added to the baths 20 minutes prior to conducting the response curves. The 
negative logarithm of the concentration at which 50% relaxation occurred (pEC50) and 
maximum relaxation (Rmax) values were calculated from the individual cumulative dose 
response curves using Graphpad Prism 6.  
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Basal NO activity in blood vessels is assessed by measuring basal NO release. 
Following maximal contraction of the aortae with KPSS, the tissues were washed and 
relaxed to basal tension and then pre-contracted with PE (10–100 nM) to approximately 
20–30% of the maximal KPSS contraction. Under those conditions the further addition 
of L-NAME (100 μM), a NOS inhibitor, causes further contraction the level of which 
correlates with the level of the basal release of NO (Chan et al., 2003, Mian and Martin, 
1995). 

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Two various chemi-luminessence assays were used to determine superoxide production 
in vascular tissue and the superoxide scavenging capacity of α-tocopherol, tocomin, 
and α, γ and δ-tocotrienols in vascular tissue and tissue-free systems. 
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Superoxide production was measured by lucigenin-enhanced chemi-luminescence 
using hypoxanthine plus xanthine oxidase as a generator of oxygen radicals. Krebs-
HEPES buffer (composition: NaCl 99.90 mM, KCl 4.7 mM, KH2PO4 1.0 mM, 
MgSO4.7H2O 1.2 mM, D-glucose 11.0 mM, NaHCO3 25.0 mM, CaCl2·2H2O 2.5 mM, 
Na HEPES 20.0 mM, 300 μL, pH 7.4) containing lucigenin (5mM) and appropriate 
treatments were placed into a 96-well OptiPlate, followed by the addition of 1unit/mL 
xanthine oxidase (XO). A background reading was performed after which 
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hypoxanthine (HX) (10−4 M) was added to all wells and superoxide production was 
measured. Superoxide inhibition was quantified by the superoxide reading subtracted 
from the background. Results are expressed as a percentage of the counts in the 
presence of the control. 
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Superoxide production in aortic rings was measured using lucigenin-enhanced chemi-
luminescence. The principles of this assay are based on methods developed by Guzik 
and Channon et al. (2005). The methods for this assay are as described by Leo et al. 
(2011b) with the following modification. The thoracic aorta was isolated, cleared of fat 
and connective tissue, and cut into 2–3 mm long segments which Krebs-HEPES buffer. 
Aortic ring segments were incubated at 37°C for 45 min in Krebs-HEPES buffer in a 
Costar cell culture plate in the presence of NADPH (100 mM) as a substrate for 
NADPH oxidase, DETCA (3 mM), to inactivate endogenous SOD and therefore 
maximize superoxide detection, either in the absence or presence of a drug (i.e. tocomin, 
α-tocopherol or α, δ or γ-tocotrienol, etc). In addition superoxide was measured in the 
presence of diphenylene iodonium (DPI, 5 mM), a flavoprotein inhibitor that inhibits 
NADPH oxidase, as a positive control for 45 minutes. 300 μL of Krebs-HEPES buffer 
containing lucigenin (5 mM) and the appropriate treatments were placed into a 96-well 
Optiplate, and superoxide production was measured. The aortic segments were then 
transferred to the corresponding wells of the optiplate and the photon emission was 
recounted. Tissue was dried in a 37°C oven and was weighed. Superoxide production 
was quantified by normalizing arbitrary units of superoxide production and expressed 
as a ratio to dry tissue mass (AU/mg dry tissue). 
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Superoxide production in aortic rings was also measured using L-012 chemi-
luminescence. The principles of this assay are based on methods developed by Miller 
et al. (2005) with the following modifications. Aortic segments were cleared of fat and 
connective tissue and cut into 2-3-mm long segments in were incubated at 37°C for 30 
min in Krebs-HEPES buffer either alone or in the presence of apocynin, a non specific 
Nox inhibitor (300 μmol/L) or the general flavoprotein inhibitor diphenylene iodonium 
(DPI, 5 μM) in a Costar cell culture plate. Krebs-HEPES buffer (300 μL), containing 
L-012 (100 mM, Wako Pure Chemicals, Osaka, Japan) and the appropriate treatments 
were in a 96-well Optiplate, which was loaded into the Polarstar Optima plate reader 
(BMG Labtech, Melbourne, VIC, Australia) to measure background photon emission 
at 37°C. After background reading was completed, a single aortic segment was added 
to each well in the optiplate and photon emission was recounted. Superoxide production 
was quantified by subtracting the final reading from the background reading, 
superoxide counts were then normalized as arbitrary units of superoxide production and 
expressed as a ratio to dry tissue mass (AU/mg dry tissue). 
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Western blots were performed as described previously by Laemmli (1970) and 
Woodman and Chan (2004) with the following modifications. For the tocomin diabetic 
study described in Chapter 5, aortae from three animals from the same treatment group 
were pooled due to limited availability of tissue, and considered as n = 1. For all others 
studies in the project, tissue was homogenized individually. The tissues were 
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homogenized in 200 mL of ice-cold lysis buffer (100 mM NaCl, 10 mM Tris, 2 mM 
EDTA, 0.5% w/v sodium deoxycholate, 1% v/v Triton X-100, pH 7.4, protease and 
phosphatase inhibitor cocktails (Roche, Sydney, NSW, Australia). Total protein 
concentration of the samples was quantified using the Bio-Rad Bradford assay where 
bovine serum albumin (BSA) was the protein of choice for preparing the standard curve. 
SDS-PAGE gels prepared where the percentage of acrylamide gels used for western 
blotting varied according to the molecular mass of the protein of interest (refer to table 
2.1).  Protein samples were thawed and heated at 95°C for 5 minutes. Equal amounts 
of protein homogenate were loaded onto the SDS-PAGE gels and ran at 100V till the 
lowest molecular mass marker was at the bottom of the gel. Proteins in the SDS gel 
were transferred onto a nitrocellulose membrane (0.45 μm pore size) using a wet 
transfer at 90V for 90 minutes at 4°C. A successful transfer was confirmed upon 
Ponceau-S stain. Membranes were blocked in 0.25% BSA in tris-buffered saline with 
tween 20 (TBST pH 7.4) for 1 hour at room temperature and incubated with anti-
mouse/rabbit primary antibodies probing for proteins of interest (all antibody dilutions 
were 1:1000 in TBST, overnight, 4°C) (refer to Table 2.1). Membranes were washed 
the following the day (3 x 10 minutes) in TBST followed by incubation in horseradish 
peroxidase (HRP)-linked mouse/rabbit secondary antibody for 1 hour at room 
temperature. Membranes were washed and then visualized on the ChemiDoc XRS (Bio-
Rad, Sydney, NSW, Australia). All proteins were detected using either enhanced 
chemi-luminescence (Amersham, GE Healthcare, Sydney, NSW, Australia) or 
Supersignal West Femto (Thermo Scientific, Rockford, IL, USA).  Membranes were 
then blocked in 0.1% sodium azide (HRP inhibitor) for 1 hour at room temperature and 
then re-probed with the loading control primary antibody (anti-mouse/rabbit β-actin 
(1:2000)) and secondary antibody as described above. All protein bands were quantified 
 

67 
by densitometry using ImageLab software (Bio-Rad, Sydney, NSW, Australia) and 
expressed as a densometric ratio of the primary protein to β-actin. 
 
Table 2.1: Percentage of acrylamide gels used to detect various proteins 
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All results are expressed as mean±SEM unless stated otherwise, where n represents the 
number of animals per group. Concentration-response curves from the rat isolated 
aortae were constructed and fitted to a sigmoidal curve using non-linear regression 
(Graphpad Prism version 6.0, San Diego, CA, USA) to calculate the sensitivity of each 
agonist (pEC50). Maximum relaxation (Rmax) to ACh was measured as a percentage of 
precontraction to phenylephrine. The negative logarithm of the concentration at which 
50% relaxation occurred (pEC50) and maximum relaxation (Rmax) values were calculated 
from the individual cumulative dose response curves using Graphpad Prism 6. Group 
pEC50 and Rmax values were compared using a one-way or two-way ANOVA with post-
hoc analysis using Sidaks test. p<0.05 was considered statistically significant. 
 
Basal NO levels are expressed as the L-NAME contraction as a percentage of the KPSS 
contraction±SEM. The values were compared using a student t-test or a two-way 
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ANOVA with post-hoc analysis using Sidaks test. p<0.05 was considered statistically 
significant. 
 
Results from superoxide production and antioxidant capacity using hypoxanthine were 
expressed as a percentage of the counts in the presence of the control±SEM. The level 
of superoxide inhibition at each concentration was compared to vehicle for each 
compound using one-way ANOVA with post-hoc multiple comparisons using Dunnet’s 
test. p<0.05 was considered statistically significant. 
 
Superoxide levels from rat aortic rings are expressed as arbitrary units (AU) per 
milligram of dry tissue ±SEM. Results were compared by either a Student’s unpaired 
t-test or one-way ANOVA with a post hoc Dunnett’s test as appropriate. p<0.05 was 
considered statistically significant. 
 
All western blotting results were quantified by densitometry using ImageLab software 
(Bio-Rad, Sydney, NSW, Australia) and expressed as a densometric ratio of the primary 
protein to β-actin ±SEM. The quantification for the expression of pAkt is expressed as 
a ratio of pAkt to Akt±SEM.  
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Chapter 3 
 
The effect of tocotrienols on 
vascular function in the presence of 
oxidative stress. 
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Vitamin E, in addition to the four isoforms of tocopherol, contains four isoforms of 
tocotrienol.  While there has been extensive investigation of the biological activity of 
the tocopherols there has been much less attention paid to the tocotrienols.  There is, 
however, emerging evidence that the tocotrienols have molecular targets distinct from 
those of the tocopherols that may result in new therapeutic opportunities (Aggarwal et 
al., 2010). There are now a number of studies demonstrating cardioprotective actions 
of tocotrienols.  For example, γ-tocotrienol is known to inhibit HMG-CoA reductase 
and therefore to decrease cholesterol synthesis (Parker et al., 1993). Further, extracts of 
palm oil, a rich source of tocotrienols, have been demonstrated to activate the NO-
cGMP pathway and, as a consequence, to decrease myocardial reperfusion injury 
(Esterhuyse et al., 2005) perhaps due to scavenging of ONOO- (Berbee et al., 2011). 
The antioxidant activity of tocotrienols may also contribute to protective actions in the 
vasculature (Aggarwal et al., 2010). For example, Newaz and Yousefipour (2003) 
demonstrated that treatment of spontaneously hypertensive rats with γ-tocotrienol 
increased NOS activity and lowered arterial pressure, and γ-tocotrienol has also been 
shown to reduce oxidative stress and inflammation in rats with STZ-induced diabetes 
(Kuhad and Chopra, 2009). Further Norsidah et al., (2013) reported that a palm oil 
extract rich in tocotrienols, when orally administered to rats with 
hyperhomocysteinemia, reduced aortic oxidative stress and increased the plasma level 
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of NO metabolites. In addition, Muharis et al. (2010) recently demonstrated that a palm 
oil fraction rich in tocotrienols restored endothelium-dependent relaxation in arteries in 
rats with STZ-induced type 1 diabetes but it is not clear whether this may have been 
consequent to a lowering of glucose levels as reported by Budin et al., (2009). There is 
evidence that the beneficial vascular effects of tocotrienols may extend to man given 
the report that 2 months treatment with tocotrienols improves pulse wave velocity in 
healthy males (Rasool et al., 2008). 
 
The mechanism(s) of the beneficial effects of tocotrienols have not been well 
investigated nor, to the best of our knowledge, has there been any examination of the 
vascular actions of individual tocotrienol isomers.  Therefore, the aims of this study 
were to compare the antioxidant activity of α-, δ- and γ-tocotrienols with α-tocopherol 
and tocomin, a palm oil extract rich in tocotrienols (tocotrienol rich fraction: 40%, and 
palm olein: 38%) but also containing some α-tocopherol (11%).  Given the antioxidant 
activity of these compounds we were further interested to investigate their capacity to 
protect NO-mediated vascular relaxation as an indication of whether they may be 
effective in preventing endothelial dysfunction in vascular diseases involving oxidant 
stress, for example as a result of diabetes (Leo et al., 2011b, Leo et al., 2010b).  It has 
been reported that tocotrienols are incorporated into cellular membranes more rapidly 
than tocopherol (Saito et al., 2010, Saito et al., 2004, Saito et al., 2003) and that this 
may contribute to greater antioxidant efficacy.  We therefore hypothesized that the 
tocotrienols would more effectively preserve endothelium-dependent relaxation in the 
presence of oxidative stress. 
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The rats were killed as described in Chapter 2.2. Responses to ACh and SNP were 
tested in the presence of pyrogallol which is well established to auto-oxidise to generate 
superoxide and subsequently impair endothelium-dependent relaxation by inactivating 
NO (Ignarro et al., 1998). Aortae were exposed for 20 minutes to tocotrienol rich 
tocomin (10-6 - 10-4 mg/mL), α-tocopherol (10-4 - 10-2 mg/mL) or tocotrienol isomers 
(α, δ or γ-tocotrienol (10-3 - 10-1  mg/mL to determine the effect of varying 
concentrations of tocomin, α-tocopherol or α, δ or γ-tocotrienol on endothelium-
dependent and -independent relaxation in the presence of pyrogallol (30 μM).  
 
Responses to ACh and SNP were also tested in the presence of pyrogallol plus various 
combinations of α-tocopherol and tocotrienol isomers to replicate tocomin (10% δ-
tocotrienol: 20% α-tocotrienol: 50% γ-tocotrienol: 20% α-tocopherol) and other 
tocotrienol combinations (α+γ)-tocotrienols, and (α+δ+γ)-tocotienols at a concentration 
of 10-4 mg/mL. These experiments were conducted to determine whether an interaction 
between α-tocopherol and the tocotrienols is necessary to improve endothelium-
dependent relaxation in the presence of oxidative stress.      
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The general method for measuring the superoxide scavenging capacity of α-tocopherol, 
tocomin and tocotrienol isomers is as described in Chapter 2.3.1 with the following 
modification. Krebs-HEPES buffer (300 μL) containing lucigenin (5 mM) and varying 
concentrations of α-tocopherol, tocomin and tocotrienol isomers were placed into a 96-
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well Optiplate, followed by the addition of 1 unit/mL XO. A background reading was 
performed after which hypoxanthine (10-4 M) was added to all wells and superoxide 
production was measured. Superoxide inhibition was quantified by the superoxide 
reading subtracted from the background. Results are expressed as a percentage of the 
counts in the presence of the control. 
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The general method for measuring the superoxide scavenging capacity of α-tocopherol, 
tocomin and tocotrienol isomers is as described in Chapter 2.3.2 with the following 
modification. Aortic ring segments were incubated at 37°C for 45 min in Costar cell 
culture plates in Krebs-HEPES buffer in the presence of NADPH (100 mM), and either 
alone or in the presence of varying concentrations and combinations of tocomin, α-
tocopherol or α, δ or γ-tocotrienol. In addition superoxide was measured in the presence 
of diphenylene iodonium (DPI, 5 μM), a flavoprotein inhibitor. 300 μL of Krebs-
HEPES buffer containing lucigenin (5 mM) and the α-tocopherol, tocomin and 
tocotrienol isomers were placed into a 96-well Optiplate. A background reading was 
taken and then aortae segments were transferred to the optiplate in their respective 
treatment wells and superoxide production was measured and quantified. 

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All drugs were purchased from Sigma Aldrich except for acetylcholine perchlorate 
(BDH Chemicals, Poole, Dorset, UK), tocomin and α, δ and γ-tocotrienols (Carotech, 
Malaysia). All drugs were dissolved in distilled water, with the exception of tocomin, 
α-tocopherol and α, δ and γ-tocotrienols that were dissolved in 0.1% DMSO. A mixture 
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of α-tocopherol and α, δ and γ-tocotrienols which resembles tocomin was prepared 
(10%  -tocotrienol: 20%  -tocotrienol: 50%  -tocotrienol: 20%  –tocopherol), 
henceforth referred to as the tocomin mixture. Various tocotrienol combinations were 
also prepared using the following proportions; (α+γ)-tocotrienols (20% α-tocotrienol: 
50% + γ-tocotrienol: 30% DMSO) and (α+δ+γ)-tocotienols (10% δ-tocotrienol: 20% + 
α-tocotrienol: 50% + γ-tocotrienol: 20% DMSO).     
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Statistical analysis was performed as is described in Chapter 2.5. 
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Superoxide production induced by the presence of hypoxanthine/xanthine oxidase is 
shown in Figures 3.1 and 3.2. α-Tocopherol caused an approximately 50% reduction in 
superoxide at a concentration of 10-2 mg/ml (Figure 3.1A). At the same concentration, 
all of the tocotrienol isomers caused approximately 80% reductions in superoxide 
(Figure 3.1C E&G). Tocomin (Figure 3.1I) caused a 50% inhibition of superoxide 
similar to α-tocopherol but at a concentration 10-100 times lower. The tocomin mixture 
and various combinations of tocotrienols were also able to scavenge superoxide at 
similar concentrations to the individual tocotrienol isomers (Figure 3.2A-C). Tocomin 
was the most effective at scavenging superoxide compared to the tocomin mixture and 
the various tocotrienol combinations at a concentration 10-100 times lower. 
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When examined using aorta, all of the compounds of interest were able to significantly 
reduce superoxide levels but the potency and efficacy was quite different Interestingly, 
the superoxide scavenging capacity in the aorta was different in comparison to the 
HX/XO assay. α-Tocopherol and tocomin (Figures 3.2 B&J) produced relatively 
greater inhibition of aorta-derived superoxide. The tocomin mixture and combinations 
of tocotrienols were able to quench superoxide but not as effectively as tocomin in the 
HX/XO assay (Figure 3.2). In contrast, only tocomin and the tocomin mixture were 
able to scavenge superoxide in the aorta in comparison to the various combinations of 
tocotrienols (Figure 3.2D). The relative potency between α-tocopherol and tocomin 
remained the same in this assay with tocomin being equally effective at approximately 
100 fold lower concentration. 
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Figure 3.1 Superoxide generated by hypoxanthine (100μM)/xanthine oxidase (0.01U/mL) or 
rat aorta in the presence of NADPH. 𝛼-tocopherol (A&B), 𝛼-tocotrienol (C&D), 𝛿 -tocotrienol 
(E&F), 𝛾 -tocotrienol (G&H), and tocomin (I&J). *Significantly different to control 𝑝<0.05. 
Results are shown as mean ± SEM. p<0.05. One-way ANOVA. Dunnett’s multiple 
comparisons test. n=3–6 experiments. 
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Figure 3.2 Superoxide generated by hypoxanthine (100 𝜇M)/xanthine oxidase (0.01U/mL) (A-
C) or in rat aorta in the presence of NADPH (D): 𝛼 +𝛾  -tocotrienols (A), 𝛼+𝛿+𝛾 -tocotrienols 
(B), 𝛼-tocopherol + (𝛼 +𝛾+𝛿 –tocotrienols) (C), tocomin, tocomin mixture and 𝛼 +𝛿 +𝛾  –
tocotrienols (D). Data is expressed as mean±SEM. *Significantly different to control Results 
are shown as mean ± SEM. p<0.05. One-way ANOVA. Dunnett’s multiple comparisons test. 
n=3–6 experiments. 
0
20
40
60
80
100
Su
pe
ro
xi
de
 c
ou
nt
s 
(%
co
nt
ro
l)
tocomin mixture
T3(α+γ+δ) + (α-TC) 10-4 mg/mL
* *
control 10-6 10-5 10-4 10-3 10-2 10-1
*
0
20
40
60
80
100
Su
pe
ro
xi
de
 c
ou
nt
s 
(%
co
nt
ro
l)
α+γ tocotrienol  (mg/mL)
*
* *
control 10-6 10-5 10-4 10-3 10-2 10-1
0
1000
2000
3000
4000
5000
Su
pe
ro
xi
de
 A
U
/m
g 
dr
y 
tis
su
e
Control tocomin
10-4mg/mL
T3(α+γ+δ)
10-4 mg/mL
T3(α+γ)
10-4 mg/mL
*
*
tocomin mixture
10-4 mg/mL
A)
D)
B)
C)
0
20
40
60
80
100
Su
pe
ro
xi
de
 c
ou
nt
s 
(%
co
nt
ro
l)
* *
*
10-6 10-5 10-4 10-2 10-110-3
α+δ+γ tocotrienol (mg/mL)
control
 78 
80807 %'$'!&"!
The effect of pyrogallol-induced oxidative stress and the acute addition of varying 
concentrations of α-tocopherol, the tocotrienols and tocomin is shown in Figure 3.2.  
Endothelium-dependent relaxation in response to ACh was significantly inhibited in 
the presence of pyrogallol-induced oxidative stress with a significant decrease in Rmax 
without affecting pEC50 (Table 3.1). O2
- 
scavenging enzyme SOD, α-tocopherol (Figure 
3.3A, 10-2 mg/mL) and tocomin (Figure 3.3F, 10-4 mg/mL) in the presence of pyrogallol 
were able to significantly improve endothelium-dependent relaxation however, 
tocomin improved endothelium-dependent relaxation at a concentration 100 times 
lower compared to α-tocopherol (Table 3.1). None of the tocotrienol isomers (α, δ and 
γ-tocotrienols) improved endothelium-dependent relaxation even at concentrations 100 
times higher than that of α-tocopherol (Table 3.1). Endothelium-independent relaxation 
to SNP was not affected by pyrogallol, α-tocopherol, tocomin or the tocotrienols (Table 
1).  
 
The effect of pyrogallol-induced oxidative stress and the acute addition of varying 
combinations of α-tocopherol and α, δ and γ-tocotrienols (10-4  mg/mL) is shown in 
Figure 3.3. Both tocomin and the mixture of  (T3(α+δ+γ) + (α-TC)) (Figure 3.3E, 10-4  
mg/mL) significantly improved endothelium-dependent relaxation in the presence of 
pyrogallol (Table 3.1 Figure 3.3). Other preparations in the absence of α-TC, ie. 
T3(α+γ) and (α+δ+γ)-tocotienols (10-4 mg/mL) did not  improve endothelium-
dependent relaxation (Figure 3E Table 1). Endothelium independent-relaxation was not 
affected by the presence of pyrogallol, α-tocopherol or α+δ+γ-tocotrienols (Table 1). 
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Table 3.1: The effect of tocomin, α-tocopherol (TC) and 3,5"40&##&$"# %
192 on ACh-induced endothelium-dependent and SNP-induced endothelium-
independent relaxation of rat aortae in the presence of pyrogallol-induced 
oxidative stress. 

  ACh 
 n pEC50 (M) Rmax (%) pEC50 (M) Rmax (%)

	      
Control F 7.09±0.18 95±8 8.71±0.10 @?G±7
Pyrogallol F 7.13±0.18 47±4# 8.46±0.14 HF±5
Pyrogallol + α-TC 10-4 mg/mL D 6.52±0.21 47±5# 8.55±0.12 HC±4
Pyrogallol + α-TC 10-3 mg/mL F 6.84±0.12 46±8# 8.35±0.28 HE±5
Pyrogallol + α-TC 10-2 mg/mL F 6.97±0.15 70±2* 8.57±0.42 H?±5
	     
Control D 7.08±0.16 86±10 8.58±0.25 HF±3
Pyrogallol D 6.97±0.15 51±2# 8.67±0.25 HE±7
Pyrogallol + α-T3 10-3 mg/mL C 6.25±0.22 47±4# 8.41±0.26 @?D±4
Pyrogallol + α-T3 10-2 mg/mL D 6.58±0.16 45±5# 8.40±0.09 HC±7
Pyrogallol + α-T3 10-1 mg/mL D 6.82±0.23 58±5# 8.12±0.02 @?D±4
	     
Control D 6.98±0.12 80±3 G4BG±0.28 HF±4
Pyrogallol C 6.83±0.45 42±10# G4CH±0.20 HH±3
Pyrogallol + 7-T3 10-3 mg/mL C 6.74±0.08 46±9# G4FB±0.07 HG±2
Pyrogallol + 7-T3 10-2 mg/mL D 6.75±0.29 43±8# G4D@±0.05 HD±8
Pyrogallol + 7-T3 10-1 mg/mL B 6.64±0.30 46±8# G4E?±0.20 HH±2
	     
Control E 6.71±0.24 93±4 G4D?±0.80 HB±4
Pyrogallol C 6.51±0.15 DH±4# G4CD±0.20 HG±2
Pyrogallol + 6-T3 10-3 mg/mL C 6.16±0.17 53±4# G4BC±0.12 @?B±1
Pyrogallol + 6-T3 10-2 mg/mL E 6.71±0.27 DD±7# G4DH±0.15 HD±4
Pyrogallol + 6-T3 10-1 mg/mL B 6.65±0.22 EF±1# G4EG±0.25 HF±1
     
Control D 7.19±0.08 92±3 G4EH±0.18 HF±4
Pyrogallol D 7.06±0.13 58±5# G4AD±0.05 HH±2
PyrogallolJ D F4@?±0.07 88±5* G4@F±0.14 @?E±C
Pyrogallol + tocomin 10-6 mg/mL C 6.84±0.14 63±6# G4@C±0.24 @??±7
Pyrogallol + tocomin 10-5 mg/mL D 6.94±0.13 69±5# G4AB±0.18 @?B±4
Pyrogallol + tocomin 10-4 mg/mL D 6.70±0.20 81±6* G4@F±0.14 HH±2
	      
Control E 7.20±0.15 93±12 8.68±0.15 96±2
Pyrogallol D 6.77±0.07 50±4# 8.48±0.09 100±2
Pyrogallol + tocomin 10-4 mg/mL D 7.19±0.13 80±3* 8.34±0.16 105±5
P+T3 (α+δ+γ)+ (α-TC) 10-4 mg/mL D 7.02±0.11 73±2* 8.49±0.17 102±2
P + T3 (α+γ) 10-4 mg/mL D 6.86±0.29 65±6# 8.20±0.21 102±1
P + T3 (α+δ+γ) 10-4 mg/mL D 6.57±0.23 61±13# 8.12±0.08 103±2
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Figure 3.3 Endothelium-dependent and -independent relaxation in rat aortae in the presence of 
pyrogallol (P): Cumulative concentration-response curves to ACh in the absence (control) or 
presence of pyrogallol with varying concentrations of α-tocopherol (A), α-tocotrienol (B), δ-
tocotrienol (C), γ-tocotrienol (D), tocomin (E) and tocotrienol isomers and α-tocopherol as 
present in the proportions found in tocomin (ie. α-T3- 20%, δ-T3 10% and γ–T3 50% and α-
TC 20%) (F). *Rmax Significantly different to control. #Rmax Significantly different to pyrogallol. 
Data is expressed as mean±SEM. p<0.05. Sidak’s multiple comparison test. n=3-7. See Table 
3.1 for values and statistical comparison. 
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This study demonstrated that the tocotrienol isomers were more effective at scavenging 
superoxide radicals produced by hypoxanthine/xanthine oxidase in comparison to those 
generated by isolated aortic segments in the presence of NADPH.  Tocomin and α-
tocopherol restored endothelial function in the presence of oxidative stress but α, δ and 
γ-tocotrienols were ineffective. α-Tocopherol was less effective than the tocotrienol 
isomers at similar concentrations when superoxide was generated by 
hypoxanthine/xanthine oxidase but more effective against superoxide generated by 
vascular tissue. Tocomin, an extract of palm oil containing predominantly tocotrienols 
but with some tocopherol, was effective in both assays at 100 fold lower concentrations 
than α-tocopherol.  Consistent with their relatively lower antioxidant activity in isolated 
vascular tissue, the tocotrienol isomers failed to improve endothelium-dependent 
relaxation in the presence of oxidant stress.  Surprisingly tocomin was the most 
effective compound at improving endothelium-dependent relaxation and this effect 
could be replicated by a mixture of α-tocopherol and α, δ and γ-tocotrienols, suggesting 
that the tocotrienol isomers provide more effective vasoprotection when acting together 
in combination with α-tocopherol. 
 
In the present study the antioxidant capacity of α-tocopherol, tocomin, α, β, or γ-
tocotrienols and various combinations of tocotrienol isomers was examined using 
hypoxanthine/xanthine oxidase to generate superoxide in a tissue free system or 
superoxide was produced by NADPH oxidase in segments of rat isolated aorta in the 
presence of NADPH. These assays have been used previously when testing the 
antioxidant activity of flavonols as a tool to predict efficacy as vasoprotectants in 
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vascular disease (Chan et al., 2003).  XO is located on blood vessel walls  and is an 
important enzyme that catalyzes the conversion of hypoxanthine to xanthine as a part 
of purine metabolism producing O2
-
 and hydrogen peroxide as a by-product (Cantu-
Medellin and Kelley, 2013). XO induced free radical production has been implicated 
in the pathogenesis of diabetes related vascular complications (Desco et al., 2002). α-
Tocopherol and α, δ and γ-tocotrienol were able to scavenge O2- at concentrations as 
low as 10-3 mg/mL whereas tocotrienol rich tocomin was able to achieve the same effect 
at concentrations as low as 10-5 mg/mL. Tocopherol and tocotrienols have been 
demonstrated to exert their antioxidant activity by physically quenching superoxide 
(Kamal-Eldin and Appelqvist, 1996). Our study that demonstrates that α-tocopherol is 
10 times more potent than α, δ and γ-tocotrienols at scavenging hypoxanthine induced 
O2
-
. This is surprising given the report by Yoshida et al., (2003) that tocopherol and 
tocotrienol isomers have a similar antioxidant activity when tested in homogenous 
solutions.  A further surprising observation was that the tocotrienol isomers were less 
effective at scavenging superoxide derived from the aortic segments as this suggests a 
limited ability to access the tissue derived reactive oxygen species.  This is in contrast 
to previous observations that tocotrienols are rapidly incorporated into cell membranes 
which was suggested to be a contributing factor to their antioxidant efficacy (Saito et 
al., 2003). 
 
The relative antioxidant efficacy of the compounds under examination was different 
when aortic segments provided the source of superoxide. Tocomin, containing a 
mixture of tocotrienol isomers and α-tocopherol was more effective than the individual 
isomers and various tocotrienol combinations at reducing oxidative stress whereas in 
the hypoxanthine/xanthine oxidase assay the opposite situation was observed. The 
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antioxidant effect of tocomin could be replicated with the tocomin mixture.  As noted 
above this may indicate an increase in activity when the tocotrienol isomers are 
combined or perhaps there is also an interaction with α-tocopherol. 
 
Our next aim was to investigate whether the compounds could effectively improve 
endothelium-dependent relaxation impaired by the presence of oxidative stress.  
Endothelium-derived NO rapidly reacts with O2
-
 (rate constant 2 × 1010M/sec) (Kissner 
et al., 1997), which reduces its relaxant activity. Superoxide dismutase (SOD) also 
reacts rapidly with O2
- (rate constant 1-2 × 1010 M/sec) (Ferrer-Sueta et al., 2002) and 
in so doing enhances NO bioavailability and may enhance endothelium-dependent 
relaxation (Jackson et al., 1998). However, antioxidant capacity alone does not 
guarantee the ability to enhance endothelium-dependent relaxation. For example, the 
well-known antioxidant ascorbate (vitamin C) does not enhance endothelium-
dependent relaxation in arteries when endogenous O2− levels are enhanced by inhibiting 
SOD (Rasool et al., 2008). This is probably due to the relatively slow rate of reaction 
between ascorbate and O2
-
 (2 × 105 M/sec) (Gotoh and Niki, 1992) since exogenous 
SOD did enhance relaxation. Therefore, one of the aims of this study was to determine 
whether the tocotrienols scavenged O2
-
 rapidly enough to enhance endothelium-
dependent relaxation in the presence of basal O2
-  levels and when high concentrations 
of O2
-
 were generated by pyrogallol (Upadhyay et al., 2010). Surprisingly none of the 
tocotrienols were effective at improving endothelium-dependent relaxation, even at 
concentrations that decreased detection of superoxide generated by vascular tissue.  By 
contrast, the less effective antioxidant α-tocopherol did improve ACh-induced 
relaxation.  Significantly, tocomin was the compound that most effectively improved 
endothelium-dependent relaxation in the presence of pyrogallol-induced oxidative 
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stress. These observations make an interesting comparison to reports that a tocotrienol 
rich extract was able to acutely improve impaired endothelium-dependent relaxation in 
aortae removed from spontaneously hypertensive rats or rats with type 1 diabetes 
caused by STZ Muharis et al., (2010). A third component of tocomin, palm olein 
consisting mainly of triglycerides, was unlikely to account for the protective actions as 
it was reported to be without effect in the study by Muharis et al., (2010). 
 
Thus we speculated that the combination of multiple tocotrienol isomers and/or the 
additional presence of α-tocopherol is necessary to preserve endothelium-dependent 
relaxation. By testing the preparations with the same proportion of α, δ and γ-
tocotrienols and α-tocopherol present in tocomin we determined that only the 
preparation containing α-tocopherol plus α, δ and γ-tocotrienols preserved endothelial 
function in the presence of oxidative stress. This data suggests an important interaction 
between α-tocopherol and tocotrienols to promote protection of vascular function. The 
mechanism of this positive interaction between α-tocopherol and the tocotrienols is 
worthy of further investigation.  
 
In conclusion, the capacity of tocomin to preserve endothelium-dependent relaxation 
has been previously reported with superoxide dismutase preservation of relaxation in 
the presence of oxidative stress (Ignarro et al., 1998). Whilst α-tocopherol and 
tocotrienols have been reported to supress signaling processes for example through the 
inhibition of NF-κB and STAT (Ahsan et al., 2014), the rapid effect seen in this study 
seems more likely due to antioxidant activity. 
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It has been suggested that tocotrienols may have superior antioxidant activity to 
tocopherols, and we did find that to be true when superoxide is generated by 
hypoxanthine/xanthine oxidase in vitro. By contrast α, δ and γ-tocotrienols and various 
combinations in the absence of α-tocopherol were largely ineffective in improving NO 
mediated, endothelium-dependent relaxation in the presence of oxidative stress.  
However, tocomin, an extract from palm oil rich in tocotrienols and with a minor 
component of α-tocopherol, was found to be the most effective compound tested. The 
efficacy of tocomin could be replicated by the presence of α-tocopherol with α, δ and 
γ-tocotrienols but not by the combined presence of the 3 tocotrienols alone. Thus the 
combination of tocotrienol isomers and tocopherol may prove to be an effective 
approach to the preservation of endothelial function where there is disease-induced 
oxidative stress such as in diabetes and hypertension. 
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Chapter 4 
 
 
 
The effect of acute tocomin on 
endothelium -dependent relaxation 
of aortae from diabetic and western 
diet fed rats.  
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Diabetes is a complex and progressive metabolic disease that is classically diagnosed 
by hyperglycaemia and disturbances to carbohydrate, protein and fat metabolism due 
to a marked reduction in the production and efficacy of the hormone insulin (Alberti 
and Zimmet, 1998). Type 2 diabetes is the most common form of diabetes that accounts 
for more than 90% of cases worldwide (Chen et al., 2012). The consumption of a high 
fat western diet has been implicated in the increasing incidence of type 2 diabetes and 
obesity worldwide (Caballero, 2007). 

 
Both diabetic and obese patients have an increased risk of developing cardiovascular 
complications (Barton et al., 2012) that is usually preceded by endothelial dysfunction 
(Pricci et al., 2003). Obesity has become a worldwide pandemic where 39% of adults 
aged 18 years are obese and in 2013, 42 million children were obese worldwide (WHO, 
2015). Obesity is a non-communicable disease that is usually defined as a body mass 
index (BMI) greater than 30 kg/m2  (WHO, 2015). It is diagnosed using a combination 
of measurements including BMI, waist to hip ratio and an accumulation of excess 
visceral body fat mostly in the abdominal area (Australian Institute Welfare Health, 
2015). Obesity can be related to increased dietary energy consumption, alcohol 
consumption and sedentary lifestyles. Obesity is a classic characteristic of metabolic 
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syndrome that is defined as a cluster of disorders comprising of hyperglycemia/insulin 
resistance, obesity and dyslipidemia (Huang, 2009). Metabolic syndrome also increases 
one’s predisposition to diseases such as type 2 diabetes, stroke and CVD (Matsuda and 
Shimomura, 2013).  
 
Endothelial dysfunction is an established risk factor and predecessor of cardiovascular 
disorders such as atherosclerosis (Hadi et al., 2005). The vascular endothelium is a thin 
layer of cells that internally lines all blood vessels and has an important function of 
regulating vascular tone by producing NO, dihydrogen sulfide (H2S), prostacyclin and 
 ِ◌EDH (Figure 1.2). Excessive ROS production can lead to endothelial dysfunction 
(Bernabé et al., 2013, Vessieres et al., 2013, Leo et al., 2011b). NADPH oxidases (e.g. 
Nox2) are the major producers of superoxide during diabetes and obesity (De Silva et 
al., 2011, Marinou et al., 2009). Furthermore, Nox2 driven oxidative stress can cause 
impairment of endothelium-dependent relaxation through inactivation of NO (Bedard 
and Krause, 2007).  
 
eNOS is the major producer of NO in the vasculature, whose activity is regulated by 
several regulatory proteins. Caveolin-1 (cav-1) is an inhibitor of eNOS activity (Li et 
al., 2014). Phosphorylated Akt (pAkt) is a protein that phosphorylates eNOS, which 
will subsequently stimulate NO production by phosphorylating eNOS at its Ser1177 
site and increase the binding of calmodulin (CaM) to eNOS which is the stimulatory 
protein for eNOS (Fleming and Busse, 1999). 
 
Due to the increased production of ROS during diabetes and obesity, it can be proposed 
that antioxidants may serve as a useful therapy to alleviate oxidant stress and hence 
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reduce cardiovascular complications. Vitamin E is a family of antioxidants, consisting 
of tocopherols and tocotrienols. The ability of α-tocopherol to improve vascular 
relaxation in animal models of diabetes has been extensively reported (Guamieri et al., 
1996, Keegan et al., 1995). Also, small and large-scale human clinical trials have been 
performed which have been unable to demonstrate any benefit of vitamin E (α-
tocopherol) supplementation in patients with diabetes and cardiovascular disease (Lonn 
et al., 2005, The Alpha Tocopherol Beta Carotene Cancer Prevention Study Group, 
1994). These studies were not performed in diabetic or obese patients exclusively, 
however they were performed in patients with CVD that have complications of long-
term diabetes and obesity. Some suggestions put forward as to why tocopherol 
supplementation studies have not proven successful in humans include the advanced 
age of participants, the diabetes and/or vascular disease being too far advanced that 
treatment with antioxidants such as vitamin E is not beneficial, and the potential for α-
tocopherol to become a pro-oxidant at high concentrations (Paravicini and Touyz, 2008, 
Bowry et al., 1992). 
 
As discussed in the previous chapter amongst the vitamin E family, tocotrienols are a 
more potent antioxidant than tocopherols” (Serbinova et al., 1991). Also as 
demonstrated in Chapter 3, tocotrienol rich tocomin is up to 100 times more potent than 
α-tocopherol in improving vascular relaxation in the presence of pyrogallol-induced 
oxidative stress. Tocomin is a tocotrienol rich complex whose ability to improve NO 
mediated endothelium-dependent relaxation or the mechanism through which this may 
occur in a diabetic or obesity animal model has not been extensively studied. Therefore, 
based on the findings from Chapter 3 the aim of this study was to investigate whether 
acute exposure of rat aortae to α-tocopherol and tocomin can improve vascular 
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relaxation in type 1 diabetic and obesity animal models and whether tocomin is more 
potent than α-tocopherol in animal models of diabetes and obesity. We also wanted to 
compare the expression of eNOS, Nox2 and eNOS modulating proteins in the aortae 
from diabetic and obese rats to compare and contrast the potential mechanisms of 
endothelial dysfunction in both animal models. 
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Male Wistar rats (n=20) were used for this study. The induction of diabetes is as 
described in Chapter 2.1.1. 
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Male Wistar-Hooded rats (n=20) were used for this study. The feeding regime and 
experimental design is as described in Chapter 2.1.2. 
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The epididymal fat of the standard diet (SD) and western diet (WD) rats was collected 
and weighed at the end of the experimental period. Epididymal fat is composed of white 
adipose tissue, which is used to store excess body fat, thus making it a good indicator 
of any changes in the body lipid content (Mathai et al., 2008). The epididymal fat was 
not measured in the diabetic rats which lost weight in comparison to controls. 
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The rats were killed and the aorta was isolated as described in Chapter 2.2. Responses 
to ACh and SNP were tested in the presence or absence of the O2
- 
scavenging enzyme 
SOD, α-tocopherol (α-TC, 10-2 mg/mL) and tocomin (10-4 mg/mL). Responses were 
also tested in the presence of the eNOS inhibitor L-NNA to investigate the effect of 
inhibition of eNOS derived NO in the aortae from western diet fed rats. All drugs and 
inhibitors were added 20 minutes prior to testing vascular function.  
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Superoxide production in the thoracic aorta in the presence of tocomin was measured 
using lucigenin enhanced chemi-luminescence as is described in Chapter 2.3.2. 
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Basal NO levels that measures KPSS induced contractions was only assessed in the SD 
and WD rat as is described in Chapter 2.3.1. 
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Protein expression (caveolin-1, calmodulin, Nox2, pAkt, Akt and eNOS) was measured 
using western blotting. The protocols are as described in Chapter 2.4. 

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All drugs were purchased from Sigma Aldrich except for acetylcholine perchlorate 
(BDH Chemicals, Poole, Dorset, UK) and tocomin (Carotech, Malaysia). All drugs 
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were dissolved in distilled water, with the exception of tocomin and α-tocopherol that 
were dissolved in DMSO. L-NNA and L-NAME was dissolved in physiological krebs 
solution. All antibodies were sourced from Genesearch Australia or Merck Millipore 
(USA).  
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Statistical analysis was performed as described in Chapter 2.5. 
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The final body weight of the diabetic rats was significantly lower than that of sham rats 
at the end of the experimental period (Table 4.1). The blood glucose and HbA1c levels 
of diabetic rats was significantly greater than that of the sham rats (Table 4.1).  
 
The body weight of the western diet fed rats was significantly greater than that of the 
standard diet fed rats (Table 4.1) at the end of the experimental period.  However, the 
blood glucose and HbA1c levels were not significantly different in the standard diet 
and western diet fed rats (Table 4.1).  
 
The epididymal fat mass was significantly increased in the WD fed rats compared to 
the standard diet fed rats as a whole and in proportion to the total bodyweight (Table 
4.1). 
 
 
 
 93 
 
 
Table 4.1: Mean body weight, fasting blood glucose, HbA1c levels and 
epididymal fat mass at the end of the experiment of sham and diabetic and SD 
and WD rats. 
 
    
 n sham diabetic " SD WD
       
Final Body Weight (g) G C@D±@@ BFA±@F9 G C?F±H CEC±G<
Blood Glucose (mM) E D4E±?4B AF4A±A9 G D4E±?4B E4A±?4C
	@7I8 F D4A±?4@ @B±?4B9 7 D4@±?4B D4@±?4@
(""0%$+%**7 8 5   8 G4E±B4H @B4D±?4F<
(""0%$+7I'0." !+8 5   8 @4C±?4@ A4C±?4A<
 
*Significantly different to sham  
^Significantly different to SD 
K&'+)')  
Results are shown as mean ± SEM 
Students unpaired t test. pM0.05. 
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Nox-dependant superoxide production was significantly elevated in aortae from both 
diabetic and western diet fed rats when compared to their respective control. Aortae 
from diabetic rats that were treated with tocomin (10-4 mg/ mL) had significantly 
reduced Nox-dependant superoxide production. Treatment with the non-selective Nox 
inhibitor diphenyliodonium (DPI) also attenuated superoxide levels in both groups of 
rats (Figure 4.1).  

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Figure 4.1 Superoxide generated in rat aorta in the presence of NADPH: sham and diabetic rat 
aortae (A) SD and WD rat aortae (B). #Significantly different to sham. ^Significantly different 
to diabetic. *Significantly different to SD. $Significantly different to WD. Results are shown as 
mean ± SEM. p<0.05. One-way ANOVA. Dunnett’s multiple comparisons test. n=3–6 
experiments. 
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The contractile response of the aortae to the presence of the eNOS inhibitor L-NAME 
(100 μM), was significantly decreased in the WD rat aorta in comparison to the SD 
(Figure 4.2). The contraction in the presence of L-NAME is an indication of basal NO 
release from the blood vessels. These results indicate that basal NO release from the 
aortae from the western diet rats is decreased when compared to the aortae from the 
standard diet fed rats. 
  
 
 
Figure 4.2 Contraction to L-NAME in the SD and WD rat aortae. *Significantly different to 
SD. Results are shown as mean ± SEM. p<0.05. Student’s unpaired t-test. n=10 
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Diabetes significantly reduced maximum relaxation (Rmax) and sensitivity (pEC50) to 
ACh (Table 4.2; Figure 4.3). Acute exposure to α-TC (10-2 mg/ mL) significantly 
improved maximum relaxation without affecting sensitivity to ACh endothelium-
dependent relaxation in diabetic rat aorta (Table 4.2; Figure 4.3). Tocomin (10-4 mg/ 
mL) was also able to significantly improve maximum relaxation (Table 4.2; Figure 4.3) 
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without affecting sensitivity to ACh (Table 4.2; Figure 4.3) but at a concentration 100 
times lower in comparison to α-TC (10-2 mg/ mL). Both α-TC (10-2 mg/ mL) and 
tocomin (10-4 mg/ mL) were equally effective in improving endothelium-dependent 
relaxation in the diabetic rat aorta as the major O2
-
 scavending enzyme SOD. 
Endothelium-independent relaxation was not affected by diabetes, α-tocopherol or 
tocomin (Table 4.2; Figure 4.6A).  




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Table 4.2: The effect of acute α-tocopherol (TC) and tocomin on ACh-induced 
endothelium-dependent and SNP-induced endothelium-independent relaxation 
of rat aortae taken from rats with diabetes or a high fat western diet. 
 

  ACh  
 n pEC50 (M) Rmax (%)   n pEC50 (M)     Rmax (%)

       
Control E 7.08±0.08 85±4 F 8.07±0.11    99±3
α-tocopherol 10-2 mg/mL C 7.00±0.08 83±2 E 7.86±0.13 98±2
tocomin 10-4 mg/mL C 7.08±0.11 80±3 E 8.02±0.13 97±2
	      
Control E 6.15±0.16* 65±3* D 7.61±0.26 94±3
 B 7.13±0.40 H@±5$ 5  
α-tocopherol 10-2 mg/mL E 6.80±0.16 90±2$ C 7.85±0.35 91±6 
tocomin 10-4 mg/mL D 6.94±0.21 87±3$ D 7.91±0.37 101±3
	      
Control F 7.35±0.14 84±4 E G4CG±0.11 94±1
α-tocopherol 10-2 mg/mL B 6.74±0.22 96±6 5  NR
tocomin 10-4 mg/mL D 7.13±0.17 87±4 E G4B@±0.15 95±2
L-NNA C 6.97±0.26 18±2^ 5  
L-NNA + tocomin C 7.23±0.31 23±3^ 5  
			      
Control G 6.80±0.10^ 84±4 D G4C@±0.11 96±3
α-tocopherol 10-2 mg/mL C 7.23±0.07# 87±3 5  
tocomin 10-4 mg/mL E 7.27±0.12# 83±5 C G4AA±0.14 97±2
L-NNA D 6.23±0.27# 12±2# 5  
L-NNA + tocomin D 6.98±0.10! 25±5# 5  
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Figure 4.3 Cumulative concentration–response curves to ACh in the absence or presence of α-
tocopherol, tocomin or SOD (1000U) in endothelium-intact aortae isolated from sham and 
diabetic rats. #pEC50  Significantly different to sham. *Rmax Significantly different to sham. 
^Rmax Significantly different to diabetic. Data is expressed as mean±SEM. p<0.05. Sidak’s 
multiple comparison test. n=3-7. See Table 4.2 for values and statistical comparison. 
 
Figure 4.4 Cumulative concentration–response curves to ACh in the absence or presence of α-
tocopherol (10-2  mg/ mL) and tocomin (10-4  mg/ mL) in endothelium-intact aortae isolated from 
SD or WD rat aortae. ^pEC50  Significantly different SD. *pEC50  Significantly different WD. 
Data is expressed as mean±SEM. p<0.05. Sidak’s multiple comparison test. n=4-8. See Table 
4.2 for values and statistical comparison. 
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WD significantly reduced sensitivity to ACh (pEC50) without affecting maximum 
relaxation in the aortae (Table 4.2; Figure 4.4). α-TC (10-2 mg/ mL) significantly 
improved sensitivity to ACh but did not affect maximum relaxation in WD rat aorta 
(Table 4.2; Figure 4.4)4 Acute exposure to tocomin (10-4  mg/ mL) also significantly 
improved ACh sensitivity without affecting maximum relaxation (Table 4.2; Figure 
4.4). In the presence of the eNOS inhibitor L-NNA, maximum relaxation and sensitivity 
to ACh was significantly decreased in both SD and WD rat aortae (Table 4.2; Figure 
4.5B). Acute treatment of the WD aortae with tocomin (10-4 mg/ mL) in the presence 
of L-NNA significantly increased sensitivity to ACh in comparison to the SD without 
improving maximum relaxation (Table 4.2; Figure 4.5B).


Figure 4.5 Cumulative concentration–response curves to ACh in the absence or presence of 
tocomin (10-4 mg/mL) and L-NNA in endothelium-intact aortae isolated from SD and (A) WD 
(B) rats. $Rmax Significantly different to SD. %Rmax Significantly different to WD. ^pEC50 
Significantly different to WD. #pEC50 Significantly different to WD + L-NNA. Data is 
expressed as mean±SEM.  p<0.05. Sidak’s multiple comparison test. n=3-8. See Table 4.2 for 
values and statistical comparison. 

The response to SNP was not affected by diabetes, a western diet, α-tocopherol or 
tocomin (Figure 4.6) indicating that smooth muscle function was not affected by 
diabetes, a western diet, α-tocopherol and tocomin. 
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Figure 4.6 Cumulative concentration–response curves to SNP in the absence or presence of α-
tocopherol (10-2 mg/mL) or tocomin (10-4 mg/mL) in endothelium-intact aortae isolated from 
sham and diabetic and (A), SD and WD (B) rats. Data is expressed as mean±SEM. Sidak’s 
multiple comparison test. n=3-8. See Table 4.2 for values and statistical comparison. 
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The expression of the superoxide-producing enzyme Nox2 was significantly increased 
in aortae from both diabetic and WD rats in comparison to the sham and SD rats 
respectively (Figures 4.7 A&B). The total expression of the NO producing enzyme 
eNOS was also significantly lower in aortae from diabetic and WD rats in comparison 
to the sham and SD rats (Figures 4.7 C&D). In addition, in WD rat aortae the expression 
of calmodulin (CaM) (Figures 4.8D) and ratio of phosphorylated Akt (pAkt) to Akt at 
the Ser473 site was decreased in comparison to the SD rat aortae (Figures 4.8B). The 
expression of CaM and pAkt/Akt was not affected by diabetes (Figures 4.8 A&C). 
Caveolin-1 expression was increased in the WD rat aorta in comparison to SD rats 
(Figure 4.8F). The expression of cav-1 was not affected by diabetes (Figure 4.8E).  
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Figure 4.7 Protein expression of NADPH oxidase (Nox2; A&B) total endothelial NOS (eNOS; 
C&D) from sham /diabetic and SD/WD rat aortae. Representative blots are shown for each
corresponding graph. *Significantly different to sham. #Significantly different to SD. Results 
are shown as mean ± SEM, p<0.05. Student’s unpaired t-test; n = 3–5 experiments. 
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Figure 4.8 Protein expression of pAkt/Akt (A&B) calmodulin-1 (C&D) and caveolin-1 (E&F). 
Representative blots are shown for each corresponding graph. Results are shown as means 
±SEM; *Significantly different to sham. #Significantly different to SD. Results are shown as
mean ± SEM, p<0.05. Student’s unpaired t-test; n = 3–5 experiments. 
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There is substantial evidence in the literature that diabetes and a high-fat western diet 
causes oxidative stress and contributes to the impairment of endothelium-dependent 
relaxation in the vasculature. This study examined the effect of acutely exposing aortae 
from type 1 diabetic and high-fat western diet fed rats to α-tocopherol and tocotrienol 
rich tocomin and its effect on oxidative stress and vascular function. 
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When comparing the metabolic factors of the 2 animal models diabetes caused a 
significant increase in BGL and HbA1c in comparison to the sham rats. The high-fat 
WD did not cause any increase in blood glucose levels or HbA1c at the end of the study. 
The type 1 diabetic rats lost weight in comparison to the sham rats whereas the WD 
group had a significantly higher body weight and epididymal fat mass proportionate to 
bodyweight at the end of the feeding period (Table 4.1). This is similar to the 
observation previously made when using the same diet (Kosari et al., 2012). 
Epididymal fat mass provides an established indication of obesity (Soret et al., 1974). 
Both diabetes and a WD caused a significant increase in the O2
-
 generated by the aortae 
(Figure 4.1 A&B) and this correlated with an increase in the expression of the NADPH 
oxidase subunit Nox2 (Figure 4.7 A&B). Nox2 is the major O2
-
 producing enzyme in 
the vasculature (Paravicini and Touyz, 2008) and the association between increased 
oxidative stress and increased Nox2 expression in the vasculature during diabetes and 
a high fat diet and CVD has been previously reported (Wang et al., 2016, Joshi and 
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Woodman, 2012, Malakul et al., 2008). Acute treatment of the aortae with tocotrienol 
rich tocomin was able to significantly reduce the O2
- in the diabetic and WD aortae 
(Figure 4.1). This demonstrates that tocomin is an effective antioxidant. The ability of 
tocotrienols to reduce oxidative stress induced protein damage has been previously 
demonstrated by Adachi and Ishii (2000). These results also correlate with the 
observations in Chapter 3 where acute tocomin treatment of rat aortae subjected to 
oxidative stress was able to reduce O2
- 
production. The WD-induced oxidative stress 
was accompanied by a decreased contractile response to the eNOS inhibitor L-NAME 
and impaired endothelium dependent relaxation to ACh (Figures 4.2 & 4.5). Although 
basal NO levels from the diabetic aortae would have been useful to measure in this 
study they were not measured due to a lack of aortic tissue however, it has been 
previously demonstrated that under these conditions NO bioavailability is significantly 
reduced (Leo et al., 2012). 
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At the end of the experimental period the diabetic rat aorta had endothelial dysfunction 
that was seen as impaired responses to ACh in comparison to the sham rats (Table 4.2; 
Figure 4.3) without any changes to SNP. In contrast the diabetic rat aortae, the WD rat 
aorta also demonstrated endothelial dysfunction in comparison to the SD rat aorta 
however the WD aortae only had reduced sensitivity to ACh and no impairment of 
maximum relaxation (Table 4.2; Figure 4.4). The observations from this study are 
interesting because they are indicative that a WD causes selective impairment of 
endothelial function in the rat aortae as has been previously reported (Jenkins et al., 
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2016, Wang et al., 2016). Both diabetic and WD rat aortae also had a decreased eNOS 
expression (Figure 4.7 C&D). This observation is interesting as it indicates that despite 
decreased expression of major NO producing enzyme eNOS and increased Nox2 
expression in both diabetic and WD rat aortae, the manifestation of endothelial 
dysfunction is different during diabetes and obesity. A possible explanation for the 
varying mechanisms in both the diabetic and WD rat aortae will be discussed later.  
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The acute treatment of the aortae from diabetic and the WD fed rats (Figure 4.4) rat 
aortae with α-tocopherol (10-2 mg/mL) and tocotrienol rich tocomin (10-4 mg/mL) 
significantly improved endothelium-dependent relaxation but tocomin was more 
effective at a concentration 100 times lower than α-tocopherol. The effectiveness of 
tocotrienols as antioxidants in comparison α-tocopherol has not been extensively 
studied. For example, Serbinova et al., (1991) demonstrated in rat microsomal 
membranes with NADPH-induced lipid peroxidation, α-tocotrienol to be 40-60 times 
more potent as an antioxidant in comparison to α-tocopherol. They also demonstrated 
α-tocotrienol to have higher physiological activity than α-tocopherol under conditions 
of oxidative stress due to its high recycling efficiency in the presence of ascorbic acid 
(vitamin C).  
 
In the presence of L-NNA maximum relaxation and sensitivity to ACh was significantly 
reduced (Table 4.2; Figure 4.5) in both the SD and WD aortae. This demonstrates that 
eNOS makes a major contribution to ACh-induced relaxation in this blood vessel. With 
the addition of tocomin in the presence of L-NNA there was a significant increase in 
 106 
sensitivity to ACh in the WD aortae (Figure 4.5B). This suggests that acutely tocomin 
may increase NO bioavailability through a greater contribution of a non-eNOS derived 
source of NO or that tocomin may stimulate a greater contribution of EDH-type 
relaxation. The contribution of an EDHF to enhance endothelium-dependent relaxation 
has been demonstrated by Ellis et al., (2008) where a high fat diet did not cause 
endothelial dysfunction in LDLR-/- rats. This was attributed to an increase contribution 
of EDH-type relaxation. 
 
Another interesting observation in this study was that in the absence of diabetes in a 
high-fat western diet and in the presence of endothelial dysfunction the aorta could still 
maintain maximum relaxation. In contrast, in the diabetic aorta there is decreased 
sensitivity and maximum relaxation to ACh (Figures 4.3 & 4.4). This could indicate 
that in the presence of oxidative stress and in the absence of elevated blood sugar level 
e.g. obesity there may be a greater contribution of a compensatory mechanism eg: 
prostacylins that may be playing a greater role to compensate any further loss of any 
vascular function. However, this would require further investigation to elucidate any 
potential compensatory mechanism of endothelium-dependent relaxation in the obese 
rat aorta. Endothelium-independent relaxation was not affected by diabetes, a western 
diet, α-tocopherol or tocomin. (Table 4.2; Figure 4.6). 
 
90909 &"&%!2&"! "'&"$+
#$"&!%0
When comparing the expression of eNOS and its modulatory proteins in the diabetic 
and obese rat aorta we may be able to elucidate the potential mechanisms of endothelial 
dysfunction. 
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pAkt stimulates eNOS by phosphorylating it at the Ser1177/1179 site in response to 
various stimuli such as shear stress (Zhao et al., 2015, Dimmeler et al., 1999, Fleming 
and Busse, 1999). The ratio of pAkt to Akt indicates the level of Akt-induced eNOS 
activation (Dimmeler et al., 1999). Our study demonstrated that diabetes did not affect 
pAkt/Akt expression however total eNOS expression was still decreased (Figures 4.7 
& 4.8). Therefore, these results suggest that a decrease in Akt-induced eNOS activation 
is not the cause for endothelial dysfunction in the aorta during diabetes rather there is 
another mechanism that is causing endothelial dysfunction and a decrease in eNOS 
expression in the diabetic rat i.e. increased O2
-
 production.  
 
During states of increased oxidative stress such as diabetes there can be up-regulation 
of other physiological pathways e.g. the polyol pathway (Giacco and Brownlee, 2010). 
These pathways can lead to the depletion of vital cofactors that are essential for NO 
production such as NADPH and BH4 (Chen et al., 2008). This can cause in eNOS to 
uncouple into a monomeric state (Satoh et al., 2005). In this case O2 can become an 
electron acceptor rather than L-arginine therefore making eNOS behave in a similar 
manner to Nox2 further exaggerating O2
-
 production (Triggle and Ding, 2010). Hence, 
it can be hypothesized that the decreased eNOS expression seen in this study in the 
diabetic rat aortae is due to the uncoupling of eNOS that has resulted from an increase 
in oxidative stress. This may lead to subsequent CaM-induced eNOS activation, 
however this would require further investigation.  
 
In contrast to the diabetic rat aorta in the WD aortae a decrease in pAkt/ Akt expression 
was accompanied with a decrease in total eNOS expression. These results indicate that 
in the presence of oxidative stress there is a decrease in eNOS expression and Akt-
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induced eNOS activation in the WD rat aortae however a greater contribution of an 
EDH allows maximum relaxation to be maintained in the presence of a decrease in the 
sensitivity to ACh.  
 
CaM and cav-1 expression was also investigated in the study. CaM and cav-1 are 
regulatory proteins of eNOS where CaM is stimulatory to eNOS that binds to eNOS in 
response to increase Ca2+ concentrations and cav-1 is inhibitory that binds to eNOS in 
response low increase Ca2+ concentrations (Zhao et al., 2015, Fleming and Busse, 1999). 
CaM and cav-1 expression was not altered in the diabetic rat aorta in comparison to the 
sham aorta (Figure 4.8C&E). Unaltered CaM and cav-1 expression I diabetic aorta are 
not consistent with similar studies. A study that was conducted by Joshi and Woodman 
(2012) demonstrated that following 6-weeks of type 1 diabetes in the presence of 
increased oxidative stress, endothelium-dependent relaxation was preserved in the rat 
aorta. This was due to an increased expression of eNOS and CaM expression that 
increased NO bioavailability therefore preserving vascular function. However, in this 
study following 10-weeks of diabetes, in the rat aortae there was absolute endothelial 
dysfunction with no effect on the expression of eNOS regulatory proteins cav-1, CaM, 
pAkt and AKt. Therefore this study suggests that in advanced diabetes endothelial 
dysfunction is potentially due to decreased NO bioavailability that is a result of 
increased oxidative stress and increased Nox2 expression and any possible 
compensatory mechanisms e.g. EDHF is not sufficient to preserve endothelial function. 
 
In contrast to the diabetic aortae CaM expression was decreased and cav-1 expression 
was increased in the WD rat aortae in comparison to the SD (Figure 4.8D&F). As 
mentioned previously CaM and cav-1 are complimentary to each other’s function i.e. 
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cav-1 is inhibitory to eNOS and CaM is stimulatory to eNOS. These results suggest that 
CaM and cav-1 play a greater role in endothelial dysfunction in the obese rat aorta in 
comparison to the diabetic rat aorta. pAkt promotes eNOS activity by the 
phosphorylation of Ser1177/Ser1179 and Thr495, among other key sites (Siragusa and 
Fleming, 2016, Wang et al., 2016) thus promoting the binding of CaM to eNOS. This 
study suggests that the decrease in CaM expression in the WD aorta observed in this 
study could potentially due be to decreased Akt-eNOS phosphorylation, however eNOS 
phosphorylation was not investigated in this study. Also, the decrease in eNOS 
expression could be due to an increase in oxidative stress coupled with an increase in 
Nox2 expression.  
 
Increased cav-1 expression has been associated with obesity and CVD where caveolins 
especially cav-1 has been associated with regulating lipid levels and free cholesterol 
transport (Martin and Parton, 2005). A study conducted by Cohen et al., (2004) 
demonstrated that increased cav-1 expression is associated with increased lipid 
accumulation in mice. Another studied conducted by Feng et al., (2003)   demonstrated 
increased cholesterol loading in the ER of foam cells was associated with increased 
cav-1 expression. Accumulation of cholesterol in foam cells form fatty streaks in the 
vasculature that is a hallmark characteristic of atherosclerosis (Martin and Parton, 2005). 
Cav-1 expression in the adipocytes of the WD rats was not measured in this study 
however this study demonstrates that increased cav-1 expression is associated with 
obesity that was seen as in increase in epididymal fat mass and contributes to 
endothelial dysfunction in the aorta of a high-fat fed rats and increases oxidative stress 
in the aorta of the WD rat aortae.   
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In conclusion, this study demonstrated that both diabetes and a high-fat western diet 
cause endothelial dysfunction in the diabetic and WD aortae in comparison to the sham 
and SD aortae respectively. Diabetes causes reduced sensitivity to ACh and reduced 
maximum relaxation in the rat aortae in comparison, a WD reduced sensitivity to ACh 
but was able to achieve maximum relaxation. Endothelial dysfunction can be attenuated 
acutely in the diabetic and WD rat aorta by the addition of α-tocopherol (10-2 mg/mL) 
and tocomin (10-4mg/mL), hence making tocomin up to 100 times more potent than α-
tocopherol. These results are consistent with our findings in Chapter 3 where acute 
exposure to tocomin and α-tocopherol was able to improve vascular function during 
pyrogallol-induced oxidative stress. We have also demonstrated that there is a decrease 
in NO bioavailability in WD rat aortae in comparison to SD aortae that correlates with 
endothelial dysfunction in the WD rat aorta.  
 
Similarly O2
- production was increased in both the diabetic and WD rat aortae that was 
associated with increased Nox2 expression. The acute treatment of the aortae with 
tocomin was able to attenuate O2
-
production in both diabetic and WD rat aortae. 
Endothelium-dependent relaxation was almost completely abolished in the presence of 
the eNOS inhibitor L-NAME indicating that endothelium-dependent relaxation in the 
WD aortae is almost entirely mediated through eNOS derived NO. Sensitivity to ACh 
in the presence of L-NAME can be improved with the acute presence of tocomin 
without improving maximum relaxation suggesting the possible mechanism through 
which acute exposure to tocomin improved endothelium-dependent relaxation in the 
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WD aortae is through a non-eNOS source of NO or a greater contribution of EDHF-
type relaxation. 
 
This study also demonstrates the mechanisms of endothelial dysfunction in the diabetic 
and WD rat aortae in comparison to the sham and SD aortae respectively. Increased O2
- 
production in the diabetic and WD aortae can be attributed to increased Nox2 
expression. Both diabetic and WD aortae also had decreased eNOS expression. 
However during diabetes the expression of pAkt/ Akt is not affected, neither is the 
expression of CaM and cav-1 suggesting that in advanced diabetes (10-weeks) 
pAkt/Akt, cav-1 or CaM do not provide any compensatory mechanism to improve 
endothelium-dependent relaxation. Also due to the increased oxidative stress resulting 
from increased Nox2 expression and the up-regulation of other O2
- producing pathways 
eg; the polyol pathway and mitochondrial activity, may potentially be causing the 
uncoupling of eNOS resulting in a decreased NOS expression hence further 
exacerbating oxidative stress and endothelial dysfunction. In contrast in the WD aorta 
in the presence of oxidative stress, decreased eNOS functionality was associated with 
decreased Akt activity as demonstrated by a decreased pAkt/Akt ratio and also a 
decrease in CaM expression. This study has also demonstrated that increased cav-1 
expression in the WD rat aortae contributes to endothelial dysfunction during obesity. 
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Chapter 5 
 
The effect of 4-week tocomin 
treatment on endothelium-
dependent relaxation in aortae 
from diabetic and western diet fed 
rats. 
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The increasing incidence of diabetes and obesity in western societies is clearly 
correlated with the incidence of CVD (Grundy, 2004). There is growing evidence that 
a contributing mechanism to the development of diabetes and obesity-induced 
cardiovascular disease is an associated increase in oxidative stress (Furukawa et al., 
2004). A well-characterized trigger for the initiation and progression of vascular disease 
is an impairment of endothelial function. Feeding rats and mice a “western” diet (WD), 
that is, a diet with an elevated level of total and saturated fats, leads to impairment of 
endothelium-dependent relaxation (Jenkins et al., 2016, Wang et al., 2016, Roberts et 
al., 2005). The impairment of endothelium-dependent relaxation is strongly linked to 
diabetes- and obesity -induced increases in oxidative stress due to increased synthesis 
of superoxide anions in the vasculature. 
 
There has been considerable interest in the potential use of vitamin E to reduce 
cardiovascular disease but largely with disappointing outcomes from clinical trials 
(Mathur et al., 2015, Schmidt et al., 2015). Most clinical trials have focused specifically 
on the actions of α-tocopherol, the vitamin E form found most abundantly in 
mammalian tissues (Rigotti, 2007), but vitamin E has three additional isoforms of 
tocopherol (β, γ, δ) and four tocotrienols (α, β, γ, δ). There is growing evidence that 
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tocotrienols may exert biological activities similar to, but also distinct from, the 
tocopherols (Peh et al., 2016, Aggarwal et al., 2010).  
 
When investigating the capacity of tocotrienols to preserve endothelial function in the 
presence of oxidative stress in vitro we found that when present as individual isomers 
α-, δ-, and γ-tocotrienol failed to demonstrate any beneficial effect (Chapter 2). 
Importantly, this lack of preservation of endothelium- dependent relaxation was despite 
the demonstration of effective antioxidant activity in a separate assay. This contrasted 
with the ability of tocomin, a palm oil extract containing a high concentration of 
tocotrienols and a lesser component of tocopherol, to significantly improve 
endothelium-dependent relaxation in the presence of oxidative stress. Crucially, the 
protective actions of tocomin could be replicated by a mixture of tocotrienols with, but 
not without, tocopherol. Thus, we came to the conclusion that a mixture of tocotrienols 
and tocopherol may provide more effective protection of endothelial function against 
oxidative stress than any of the individual components in isolation. We also have 
demonstrated that acute tocomin exposure in diabetic and high fat fed WD rat aortae 
can improve vascular function (Chapter 4). Therefore the aim of the present study was 
to investigate whether the acute protective actions of tocomin can be replicated when 
subcutaneously administered in vivo to rats where oxidative stress is induced by 
diabetes and the consumption of a high-fat WD that causes endothelial dysfunction. 
 
 
 

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All procedures were approved by the Animal Experimentation Ethics Committee of 
RMIT University and conformed to the National Health and Medical Research Council 
of Australia code of practice for the care and use of animals for scientific purposes. 
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Male Wistar rats were used for this study. The induction of diabetes and experimental 
design is as described in Chapter 2.1.1. 
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Male Wistar-Hooded rats were used for this study. The feeding regime and 
experimental design is as described in Chapter 2.1.2. 
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The epididymal fat of the standard diet (SD) and western diet (WD) rats was collected 
and weighed at the end of the experimental period. Epididymal fat is composed of white 
adipose tissue, which is used to store excess body fat, thus making it a good indicator 
of any changes in the body lipid content. The epididymal fat was not measured in the 
diabetic rats because the rat weight was not significant and this information would be 
of no scientific benefit. 
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Six weeks post induction of diabetes or injection of vehicle, tocomin treatment (40 
mg/kg/day s.c.) or vehicle (peanut oil) was commenced for a period of 4 weeks until 
the end of the experimental period. For the Western Diet rats, 8 weeks into the feeding 
period tocomin treatment (40 mg/kg/day s.c.) or vehicle (peanut oil) was commenced 
for a period of 4 weeks until cessation of the study. The dosage of tocomin was 
established following an extensive literature review. There are previous studies that 
used tocotrienol rich fractions with dosage ranging from 5 g/kg/day- 200mg/kg/day 
(Bayorh et al., 2005, Budin et al., 2009). There was also a study that demonstrated γ-
tocotrienol to enhance NO activity in blood vessels from spontaneously hypertensive 
rats with doses ranging (15-150 mg/kg/day) (Newaz and Yousefipour, 2003). Therefore, 
because tocomin has a 40% tocotrienol content, the aim of our dose of choice was to 
have a total tocotrienol content that is lower than 15 mg/kg/day to determine whether a 
tocotrienol rich fraction can achieve a similar effect. 
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Cumulative concentration–response curves to ACh and SNP were determined using 
aortic rings contracted with PE to 40–60% of maximal contraction. Responses to ACh 
and SNP were also tested in the presence or absence of a small calcium activated 
potassium-channel (SKCa) inhibitor apamin (1 μM), intermediate calcium activated 
potassium-channel (IKCa) channel inhibitor TRAM-34 (1 μM), nitric oxide synthase 
(NOS) inhibitor, N-nitro-l-arginine methyl ester (L-NAME, 100 μM), and soluble 
guanylate cyclase (sGC) inhibitor, 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one 
(ODQ, 10 μM) to investigate the role of NO and endothelium-dependent 
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hyperpolarization (EDH) through the opening of potassium channels in the relaxant 
responses. All treatments were added to the baths 20 min prior to conducting the 
concentration–response curves. The negative logarithm of the concentration at which 
50% relaxation occurred (pEC50), and maximum relaxation (Rmax) values were 
calculated from the individual cumulative concentration response curves using 
Graphpad Prism 6. 
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Superoxide production in the sham and diabetic thoracic aorta was measured using 
lucigenin-enhanced chemi-luminescence as is described in Chapter 2.3.2. Superoxide 
production in the SD and WD thoracic aorta was measured using L-012-enhanced 
chemi-luminescence as is described in Chapter 2.3.3. 
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Protein expression was performed using western blotting. The protocol is as described 
in Chapter 2.4. 
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All drugs were purchased from Sigma Aldrich except for acetylcholine perchlorate 
(BDH Chemicals, Poole, Dorset, UK) and tocomin (Carotech, Malaysia). All drugs 
were dissolved in distilled water, with the exception of tocomin that were dissolved in 
peanut oil and L-NNA/ L-NAME was dissolved in physiological krebs solution. All 
antibodies were sourced from Genesearch Australia or Merck Millipore (USA).  
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Statistical analysis was performed as is described in Chapter 2.5. 

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The body weight of sham rats was significantly greater than that of diabetic rats (Table 
5.1) at the end of the experimental period. The BGL and HbA1c levels of diabetic rats 
was significantly greater than that of the sham rats (Table 5.1). 4-week treatment had 
no effect on bodyweight, BGL or HbA1c levels (Table 5.1) 

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Nox2 superoxide production was significantly elevated in diabetic rat aortae in 
comparison to the sham rat aorta. 4-week treatment of the WD rats with tocomin (40 
mg/kg/day) was able to significantly attenuate superoxide production in the tocomin 
treated diabetic rat aortae. Treatment with DPI, a non-selective inhibitor of NADPH 
oxidase also decreased superoxide levels in the aorta from standard diet and western 
diet fed rats (Figure 5.1).  
 

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Figure 5.1 Superoxide generated in rat aorta in the presence of NADPH from sham, diabetic, 
tocomin treated (sham+tocomin/diabetic+tocomin) and in the presence of DPI. Data is 
expressed as mean±SEM. *Significantly different to sham. #Significantly different to diabetic. 
Results are shown as mean ± SEM. p<0.05. Two-way ANOVA, Dunnett’s multiple 
comparisons test. n=3–6 experiments. 
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T
able 5.1: M
ean body w
eight, fasting blood glucose and H
bA
1c levels at the end of the experim
ental period for sham
, diabetic and 
tocom
in treated (sham
 + tocom
in/diabetic + tocom
in) rats. 
 
 
 
 
 
 
 
 
 
 
n 
sham
 
n 
diabetic 
n 
sham
 + tocom
in 
n 
sham
 + tocom
in 
 
 
 
 
 
 
 
 
 
F
inal B
ody W
eight (g) 
10 
522 ± 17 
7 
381 ± 22* 
7 
552 ± 17 
8 
374 ± 30* 
B
lood G
lucose (m
M
) 
9 
6.8 ± 0.3 
7 
32.2 ± 1.2* 
8 
7.4 ± 0.7 
7 
29.3 ± 3.1* 
H
bA
1c (%
) 
9 
5.7 ± 0.2 
7 
13.3 ± 0.3* 
7 
5.5 ± 0.2 
7 
11.8 ± 1.3* 
 
*Significantly different to sham
 
R
esults are show
n as m
ean±SEM
.  
Tw
o-w
ay A
N
O
V
A
, p<0.05.  
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The maximum response (Rmax), but not the sensitivity (pEC50), to the endothelium-
dependent dilator ACh was significantly reduced in the aortae from diabetic compared 
to sham rats (Table 5.2; Figure 5.2A). Responses to SNP were not affected by diabetes 
(Table 5.2; Figure 5.2B). The 4-week treatment of the diabetic rats with tocomin (40 
mg/kg/day sc) significantly improved the maximum response to ACh in the aorta from 
diabetic, but not sham, rats. Tocomin treatment did not affect the endothelium-
independent relaxation to SNP in any group. 
 
In the presence of inhibitors of SKCa (apamin) and IKCa (TRAM- 34), ACh-induced 
relaxation is mediated by NO. The maximum response to ACh was significantly 
decreased in the diabetic rat aorta compared to the sham aorta (Table 5.2; Figure 5.2C). 
Following 4-week treatment with tocomin, there was no change in ACh-sensitivity in 
aortae from the sham rats, but the maximum response to ACh was significantly 
increased in the diabetic rat aorta by the tocomin treatment. Tocomin treatment had no 
effect on the endothelium-independent relaxant responses to SNP in any group (Table 
5.2; Figure 5.2D). This suggests that tocomin treatment improves endothelial release of 
NO from the diabetic rat aorta rather than influencing sensitivity to either endogenous 
or exogenous NO. 
 
In the presence of the eNOS inhibitor L-NNA alone, the maximum relaxation to ACh 
was significantly decreased in comparison to the sham in the absence of L-NNA 
however in the presence of L-NNA maximum relaxation was significantly deceased in 
the sham rat aortae in comparison to the diabetic aortae (Table 5.2; Figure 5.2E). These 
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results indicate the predominant contribution of NO to endothelium-dependent 
relaxation in this large artery and the minor contribution of a non-NO mediated 
mechanism eg: prostacyclin or EDHF. In the presence of the sGC inhibitor ODQ alone, 
ACh-induced relaxation was not different in the aortae from diabetic rats compared to 
sham rats (Table 5.4; Figure 5.3A), and tocomin did not affect responses in either 
groups. These results suggest that in both the shamand diabetic rat aortae eNOS derived 
NO is the main cause of endothelium-dependent relaxation and 4-week treatment of 
WD rats with tocomin does not improve maximum relaxation through an eNOS/sGC-
independent mechanism. The presence of TRAM-34 and apamin, in addition to L-NNA 
and ODQ, did not further attenuate responses to ACh in any group (Table 5.4; Figure 
5.3C) indicating an absence of contribution of calcium-activated potassium (KCa) 
channels to endothelium- dependent relaxation in this large artery. 
 
L-NNA did not significantly affect responses to SNP (Figure 5.2F). However, ODQ did 
significantly reduce the sensitivity and maximum response to SNP in aortae from both 
sham and diabetic rats (Table 5.2; Figure 5.3D). Tocomin did not affect responses to 
SNP under any of the tested conditions.
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Table 5.2: The effect of 4-week tocomin treatment on ACh-induced endothelium-
dependent and SNP-induced endothelium-independent relaxation of rat aortae 
during diabetes. 
 
 
  ACh 
 n pEC50 (M) Rmax 
(%)
pEC50 (M) Rmax (%)
	
      
control 7 6.95±0.23 93±4 8.42±0.15 97±3 
tram + apamin 5 7.27±0.21 91±5 8.38±0.40 97±1 
L-NNA 3 6.51±0.26* 16±3* 8.21±0.27 92±5 
ODQ 8 6.51±0.26* 8±2* 6.00±0.30 28±8 
L-NNA + ODQ + tram + apamin 7 ND 0* 5.88±0.36 58±6 
Diabetic (vehicle)      
control 7 6.75±0.13 76±4$ 8.54±0.17 93±3 
tram + apamin 5 6.67±0.06 72±4$ 8.80±0.29 100±2 
L-NNA 3 6.73±0.21 28±4* 8.71±0.16 103±2 
ODQ 5 6.73±0.29 10±4* 6.58±0.24 48±5 
L-NNA + ODQ + tram + apamin 4 ND 0* 6.96±0.28 34±8 
Sham + tocomin (40 mg/kg/day)      
control 7 6.93±0.09 83±4 8.36±0.25 96±2 
tram + apamin 3 6.79±0.10 82±5 8.10±0.20 100±2 
L-NNA 6 6.88±0.13 23±8* 8.50±0.26 96±5 
ODQ 7 6.90±0.06 11±7* 5.95±0.20 48±8 
L-NNA + ODQ + tram + apamin 6 ND 0* 5.81±0.20 33±9 
Diabetic + tocomin (40mg/kg/day)      
control 7 7.38±0.16 89±3# 8.54±0.14 101±4 
tram + apamin 5 7.1±0.10 80±5 8.56±0.33 94±3 
L-NNA 6 6.68±0.16 38±5* 8.47±0.23 100±3 
ODQ 7 6.80±0.21 16±7* 6.26-±0.48 48±8 
L-NNA + ODQ + tram + apamin 5 ND 3± 3* 5.83±0.28 43±8 

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Figure 5.2  Cumulative concentration–response curves to ACh and SNP in endothelium-intact 
aortae isolated from sham diabetic, and tocomin treated (sham + tocomin/diabetic + tocomin) 
rats in control (A&B) or the presence of Tram + apamin (C&D), and L-NNA (E&F). *Rmax 
Significantly different to sham. #Rmax Significantly different to diabetic. p<0.05. Data is 
expressed as mean±SEM. Sidak’s multiple comparison test. n=3-7. See Table 5.2 for values 
and statistical comparison. 
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Figure 5.3 Cumulative concentration–response curves to ACh and SNP in endothelium-intact 
aortae isolated from sham, diabetic, and tocomin treated (sham + tocomin/diabetic + tocomin) 
rats in the presence of L-NNA + ODQ (A&B) and L-NNA + ODQ + Tram + apamin (C&D). 
Data is expressed as mean±SEM. p<0.05. Sidak’s multiple comparison test. n=4-8. See Table 
5.2 for values and statistical comparison. 
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The effect of diabetes on the expression of Nox2 was significantly increased in aortae 
from diabetic in comparison to the sham rats (Figure 5.4). 4 week tocomin treatment 
significantly reduced Nox2 expression in aortae from diabetic rats. The total expression 
of the NO producing enzyme eNOS was significantly lower in aortae from diabetic in 
comparison to sham rats (Figure 5.5A). In addition, in the diabetic rat, aortae expression 
of calmodulin (CaM) and caveolin-1 was not decreased in comparison to the sham rats. 
The proportion of Akt that was phosphorylated was also not different in the diabetic 
rats in comparison to the sham (Figure 5.5B-D). Treatment with tocomin reversed the 
diet-induced changes in eNOS and Nox2 expression (Figure 5.5A). Treatment with 
tocomin did not affect expression of CaM and cav-1 neither the ratio of pAkt to Akt. 

Figure 5.4 Protein expression of NADPH oxidase (Nox2) from isolated aortae from sham, 
diabetic and tocomin treated (sham + tocomin/diabetic + tocomin) rats. Representative blots 
are shown for each corresponding graph. *Significantly different to sham. #Significantly 
different to diabetic. Results are shown as means ± SEM. p<0.05. Two-way ANOVA Dunnett’s 
multiple comparison test. n = 3-5 (pooled) experiments. 
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Figure 5.5 Protein expression of total eNOS (a), calmodulin-1 (B), caveolin-1 (C), and 
pAkt/Akt (D) from isolated aortae from sham, diabetic and tocomin treated (sham + 
tocomin/diabetic + tocomin) rats. Representative blots are shown for each corresponding graph. 
*Significantly different to sham. #Significantly different to diabetic. Results are shown as 
means ± SEM; p<0.05. Two-way ANOVA Dunnett’s multiple comparisons test. n = 3-5 
(pooled) experiments. 
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The body weight of the western diet fed rats was significantly greater than that of the 
standard diet fed rats at the end of the experimental period. The final bodyweight of the 
tocomin treated western diet rats was not significantly different to the standard diet fed 
rats. The epididymal fat mass was significantly increased proportionate to final 
bodyweight in both of the western diet fed rats when compared to the standard diet fed 
rats. 4-week treatment tocomin had no effect on epididymal fat mass (Table 5.3). 
 
The blood glucose and glycated hemoglobin (HbA1c) levels were not significantly 
different to the western diet fed rats. Blood glucose and glycated hemoglobin levels 
were not significantly affected by a western diet or 4-week tocomin treatment (Table 
5.3).
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   T
able 5.3: M
ean body w
eight, blood glucose, H
bA
1c levels, and epididym
al fat m
ass at the end of the experim
ental period for standard 
diet (SD
) and w
estern diet (W
D
) and tocom
in (SD
 + tocom
in/W
D
 + tocom
in) treated rats rats. 
  
 
 
 
 
 
 
 
 
 
n 
SD
 
n 
W
D
 
n 
SD
 +
 tocom
in 
n 
W
D
 +
 tocom
in 
 
 
 
 
 
 
 
 
 
F
inal B
ody W
eight (g) 
10 
415 ±
 10 
8 
458 ±
 12*  
10 
421±
 9 
10 
440±
 8 
B
lood G
lucose (m
M
) 
9 
8.4 ±
 1 
10 
8.6 ±
 0.9 
9 
8.8±
 1 
10 
9.0±
 1.3 
H
bA
1c (%
) 
9 
5.4 ±
 0.3 
10 
5.2 ±
 0.1 
8 
6.2±
 0.3 
10 
5.9±
 0.4 
E
pididym
al fat (g) 
10 
8.5±
 0.8 
10 
12.9 ±
 1.2* 
10 
9.8±
 1 
10 
12.4±
 0.9* 



	 
10 
2±
 0.2 
10 
2.8 ±
 0.2* 
10 
2.3±
 0.2 
10 
2.8±
 0.2* 
  
  
 
*Significantly different to SD
 
R
esults are show
n as m
ean±SEM
.  
Tw
o-w
ay A
N
O
V
A
, p<0.05.  
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Basal superoxide production was significantly elevated in aortae from rats fed the WD 
in comparison to the SD rat aortae. The 4-week treatment with tocomin (40 mg/kg/day 
sc) significantly attenuated superoxide production by the aortae from a WD fed rat 
without affecting superoxide production by the SD rat aortae (Figure 5.6). Treatment 
with apocynin, a non-selective inhibitor of NADPH oxidase, decreased superoxide 
levels in the aorta from WD fed rats. 
 
 
 
Figure 5.6 Superoxide generated in rat aorta in the presence of NADPH from SD, WD and 
tocomin treated (SD + tocomin/WD + tocomin) groups. *Significantly different to SD. 
#Significantly different to WD. Results are shown as mean±SEM. p<0.05. Two-way ANOVA 
Dunnet’s multiple comparisons test. n=3-6.   
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The contractile response of the aortae to the presence of the eNOS inhibitor L-NAME 
was significantly less in the aortae from WD rats compared to the SD rat aorta (Figure 
5.7). The 4-week treat-ment of the WD rats with tocomin significantly improved the 
contractile response to L-NAME indicating increased basal NO synthesis. 
 
 
Figure 5.7 Response to L-NAME in the presence of KPSS from SD, WD and tocomin treated 
(SD + tocomin/WD + tocomin) groups. *Significantly different to SD. #Significantly different 
to WD. Results are shown as mean±SEM. p<0.05. Two-way ANOVA Dunnet’s multiple 
comparisons test. n=3-8.   
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The sensitivity (pEC50), but not the maximum response, to the endothelium-dependent 
dilator ACh was significantly reduced in the aortae from WD compared to SD rats 
(Table 5.4; Figure 5.8A). Responses to SNP were not affected by a WD (Table 5.4; 
Figure 5.8B) indicating that a high-fat diet selectively impairs endothelium- dependent 
relaxation. The 4-week treatment of the WD rats with tocomin (40 mg/kg/day sc) 
significantly improved sensitivity to ACh in the aorta from WD-fed, but not SD-fed, 
rats. Tocomin treatment did not affect the endothelium-independent relaxation to SNP 
in any group. 
 
In the presence of inhibitors of SKCa (apamin) and IKCa (TRAM- 34), ACh-induced 
relaxation is mediated by NO. The sensitivity to ACh was significantly decreased in the 
WD rat aorta compared to the SD aorta (Table 5.8; Figure 5.8C). Following 4-week 
treatment with tocomin, there was no change in ACh-induced relaxation in aortae from 
rats fed the SD, but the sensitivity to ACh was significantly increased in the WD rat 
aorta by the tocomin treatment. Tocomin treatment had no effect on the endothelium-
independ-ent relaxant responses to SNP in any group (Table 5.4; Figure 5.8D). This 
suggests that tocomin treatment improves endothelial release of NO from the WD rat 
aorta rather than influencing sensitivity to either endogenous or exogenous NO. 
 
In the presence of the eNOS inhibitor L-NAME alone and in combination with the sGC 
inhibitor ODQ, the maximum relaxation to ACh was significantly decreased in SD rat 
aortae (Table 5.4; Figure 5.8D), indicating the predominant contribution of NO to 
endothelium-dependent relaxation in this large artery. ACh-induced relaxation in the 
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presence of L-NAME, with or without ODQ, was not different in the aortae from WD 
rats compared to SD rats (Table 5.4; Figure 5.9A), and tocomin did not affect responses 
in either groups. These results suggest that in both the SD and WD rat aortae eNOS 
derived NO is the main cause of endothelium-dependent relaxation and 4-week 
treatment of WD rats with tocomin does not improve ACh sensitivity through an 
eNOS/sGC-independent mechanism. The presence of TRAM-34 and apamin, in 
addition to L-NAME and ODQ, did not further attenuate responses to ACh in any group 
(Table 5.4; Figure 5.9C) indicating an absence of contribution of calcium-activated 
potassium (KCa) channels to endothelium- dependent relaxation in this large artery. 
 
L-NAME did not significantly affect responses to SNP (Figure 5.8F), but addition of 
ODQ did significantly reduce the sensitivity and maximum response to SNP in aortae 
from both SD and WD rats (Table 5.4; Figure 5.9B). Interestingly, in the presence of 
L-NAME and ODQ, SNP-induced relaxation was significantly greater in aortae from 
WD compared to SD rats (Table 5.4; Figure 5.9D). Tocomin did not affect responses 
to SNP under any of the tested conditions.
















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Table 5.4: The effect of 4-week tocomin treatment on ACh-induced endothelium-
dependent and SNP-induced endothelium-independent relaxation of rat aortae 
fed a standard diet (SD) or high fat western diet (WD). 
 
 

  ACh 
 n pEC50 (M) Rmax (%) pEC50 (M) Rmax (%)

      
Control XW 7.24±0.10 91±3 8.30-±0.17 95±3
Tram + apamin XW 7.24±0.15 85±5 7.99±0.26 99±2
L-NNA ^ 6.47±0.27 24±5* 8.36±0.21 99±2
L-NNA + ODQ  ` 6.82±0.23 8±3* 6.63±0.38* 46±12*
L-NNA + ODQ + tram + apamin [ 6.23±0.58 8±4* 5.85±0.29* 37±10*

     
Control _ 6.85±0.12# 83±2 8.35±0.10 98±3
Tram + apamin _ 6.77±0.16# 84±2 7.62±0.21 100±3
L-NNA ^ 6.70±0.16 26±8* 8.22±0.24 102±2
L-NNA + ODQ  ^ 6.30±0.11 17±2* 6.60±0.25* 67±4*
L-NNA + ODQ + tram + apamin _ 6.12±0.11 13±1* 6.00±0.24* 64±6*
		     
Control _ 7.27±0.11 89±3 8.30±0.13 92±5
Tram + apamin _ 7.19±0.10 86±5 7.95±0.26 95±4
L-NNA ] 6.70±0.22 11±4* 8.40±0.26 98±3
L-NNA + ODQ  ` 6.97±0.34 12±6* 6.19±0.64* 35±14*$
L-NNA + ODQ + tram + apamin _ 6.41±0.27 8±3* 4.70±0.9* 38±10*$
		     
Control XW 7.44±0.12$ 89±2 8.35±0.10 98±3
Tram + apamin ` 7.27±0.10$ 87±3 7.96±0.24 98±1
L-NNA ` 6.16±0.27 30±4* 8.30±0.13 101±4
L-NNA + ODQ  ` 6.33±0.23 18±2* 6.45±0.33* 50±12*
L-NNA + ODQ + tram + apamin ` 6.50±0.22 7±2* 6.21±0.37* 63±9*

Q*(/*'*$"/5-:%*''&3&/550$0/530-
V*(/*'*$"/5-:%*''&3&/5500'4".&53&"5.&/5(3061
U*(/*'*$"/5-:%*''&3&/5500'4".&53&"5.&/5(3061
&46-54"3&4)08/"4.&"/±D
80E8":A1dWDW\D*%",4.6-5*1-&$0.1"3*40/5&45D


"#-&*--6453"5&45)&1\W"/%."97"-6&4'03)*/"035*$3*/(4'30.45"/%"3%%*&5MNA
8&45&3/%*&5MN"/%50$0.*/53&"5&%Ma50$0.*/Ja50$0.*/N(30614D)&&''&$50'
7"3*064$)&.*$"-*/)*#*5034*44)08/D/c/0D0'&91&3*.&/54D

 135 

Figure 5.8 Cumulative concentration–response curves to ACh and SNP in endothelium-intact 
aortae isolated from standard diet (SD), western diet (WD), and tocomin treated (SD + 
tocomin/WD + tocomin) rats in control (A&B), or in the presence of Tram + apamin (C&D), 
and L-NAME (E&F). *pEC50 Significantly different to SD. 
#pEC50 Significantly different to 
WD. Data is expressed as mean±SEM. p<0.05. Sidak’s multiple comparison test. n=4-10. See 
Table 5.4 for values and statistical comparison. 
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Figure 5.9 Cumulative concentration–response curves to ACh and SNP in endothelium-intact 
aortae isolated from SD, WD, and tocomin-treated (SD + tocomin/WD + tocomin) rats in the 
presence of L-NAME + ODQ (A&B) and L-NAME + ODQ + Tram + apamin (C&D). *Rmax 
significantly different to SD. Data is expressed as mean±SEM. p<0.05. Sidak’s multiple 
comparison test. n=4-8. See Table 5.4 for values and statistical comparison. 
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The effect of a high fat WD on the expression of superoxide producing enzyme Nox2 
was significantly increased in aortae from WD in comparison to the SD rats (Figure 
5.10). Tocomin treatment did not affect Nox2 in aortae from SD rats but significantly 
reduced its expression in aortae from WD rats. The total expression of the NO 
producing enzyme eNOS was significantly lower in aortae from WD in comparison to 
SD rats (Figure 5.11A). In addition, in WD rat, aortae expression of calmodulin (CaM) 
was decreased, and caveolin-1 was increased in comparison to SD rats. The WD also 
decreased the proportion of Akt that was phosphorylated (Figure 5.11D). Treatment 
with tocomin reversed the diet-induced changes in eNOS, caveolin-1, CaM, and the 
phosphorylation of Akt (Figure 5.11D). 
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Figure 5.10 Protein expression of NADPH oxidase (Nox-2) from isolated aortae from SD, WD 
and tocomin treated (SD+tocomin/WD+tocomin) rats. Representative blots are shown for each 
corresponding graph. *Significantly different to SD. #Significantly different to WD. Results are 
shown as means ±SEM. p <0.05. 2-way ANOVA Dunnet’s Results are shown as means ± SEM. 
p<0.05. Two-way ANOVA Dunnett’s multiple test. n = 6 experiments.  
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Figure 5.11 Protein expression of total eNOS (a), calmodulin-1 (B), caveolin-1 (c), and 
pAkt/Akt (D) from isolated aortae from SD, WD, and tocomin treated (SD + tocomin/WD + 
tocomin) rats. Representative blots are shown for each corresponding graph. *Significantly 
different to SD. #Significantly different to WD. Results are shown as means ± SEM. p<0.05. 
Two-way ANOVA Dunnett’s multiple comparisons test. n = 6 experiments.   
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There is ample of literature that demonstrates the contribution of oxidative stress to the 
impairment of endothelium-dependent relaxation in the vasculature. This study has 
demonstrated that the tocotrienol rich tocomin acutely reduces the levels of oxidative 
stress and improves endothelium-dependent relaxation in aortae from type 1 diabetic 
and western diet fed rats.  
 
This study demonstrates that during diabetes, an impairment of endothelium-dependent 
relaxation that is associated with an increased expression of the NADPH oxidase Nox2 
subunit in the aorta and an increase in the vascular generation of O2
-
. The increase in 
vascular oxidative stress was accompanied by an impairment of NO mediated ACh-
induced relaxation. A decreased expression of eNOS is likely to contribute to the 
impaired NO-mediated relaxation. Diabetes did not affect calmodulin and cav-1 
expression, it also did not affect the ratio of phosphorylated Akt to Akt in the aortae. 
Tocotrienol rich tocomin was able to improve NO mediated relaxation in the diabetic 
rat aortae by increasing NO bioavailability, most likely due to an antioxidant action, a 
property of tocomin that we previously demonstrated in isolated vascular tissue 
(Chapters 3 and 4). 
  
The results of this study also demonstrate that rats fed a high-fat, “western” diet exhibit 
an impairment of endothelium-dependent relaxation that is also associated with an 
increased expression of the NADPH oxidase Nox2 subunit in the aorta and an increase 
in basal levels of superoxide. The increase in vascular oxidative stress was accompanied 
by a decrease in basal NO release in the WD rat aorta and an impairment of the 
contribution of NO to ACh-induced relaxation. A decreased expression of eNOS, 
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calmodulin, and phosphorylated Akt and an increase in caveolin-1 are likely to 
contribute to the impaired NO-mediated relaxation.  
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Type 1 diabetes caused a significant increase in BGL and HbA1c levels and a 
significant decrease in bodyweight. However, treating diabetic rats with tocomin did 
not affect the blood glucose or HbA1c levels nor did it increase bodyweight.  
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There was a significant increase in O2
-
 generation in arteries from diabetic rats, but not 
in the sham rat aortae. This was accompanied with an increase in Nox2 expression, 
once again only in the diabetic rat aortae. Four week tocomin treatment was able to 
significantly attenuate O2
-  
generation and reduce Nox 2 expression in the diabetic rat 
aortae. The results from this study are consistent with the findings of Chapters 3 and 4 
that demonstrated tocomin acutely reduced O2
-
 production in isolated aortae from 
diabetic rats and in the presence of oxidative stress. A possible mechanism through 
which tocomin treatment decreases Nox2 expression in the diabetic rat aortae could be 
through decreasing PKC activation. PKC is a family of proteins that have many 
functions that regulate cell growth, PKC are also a positive regulator of Nox2 activity 
by activating the enzyme (Seshiah et al., 2002). PKC-induced Nox2 activation is known 
to be involved in the pathophysiology of CAD and atherosclerosis (Inoguchi et al., 
2000). A study conducted by Clement et al., (1997) demonstrated that the treatment of 
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rat aortic smooth muscle cells with α-tocopherol could inhibit PKC activation. This 
could subsequently lead to decreased Nox2 activation and expression therefore 
decreasing oxidative stress. This α-tocopherol-induced inhibition of PKC activation 
was believed not to be connected to the antioxidant function of α-tocopherol indicating 
that α-tocopherol induced PKC inhibition is achieved by inhibition at a cellular level 
rather than a direct antioxidant effect of α-tocopherol (Carew et al., 1987, Esterbauer et 
al., 1992). We hypothesize that the tocomin-induced decrease in Nox2 expression that 
has been observed in this study could be explained by a similar mechanism, i.e; tocomin 
that is rich in tocotrienols, inhibits lipid peroxidation through its antioxidant function. 
Inhibition of lipid peroxidation leads to decrease activity of the DAG kinase enzyme 
that is a stimulator of PKC. By reducing DAG kinase dependent PKC activation 
tocomin has a direct effect on decreasing PKC activation and subsequent Nox2 
activation and expression. This phenomenon has been demonstrated by Lee et al., 
(1996) that demonstrated vitamin E (α-tocopherol) and its ability to prevent 
hyperglycemia-induced activation of the DAG-PKC pathway in vascular smooth 
muscle cell via an decrease in DAG kinase activity. As tocomin shares structural 
similarity and functionality as α-tocopherol, tocomin may also be acting through a 
similar mechanism. Confirmation of this possibility however would require further 
investigation. 
 
Diabetes also caused a significant impairment of endothelium-dependent relaxation as 
was observed in the Chapter 4.  Four-week treatment of the diabetic rats with tocomin 
significantly improved vascular relaxation. Neither diabetes nor tocomin treatment had 
any effect on responses to SNP in aortae from diabetic. Thus tocomin, which we have 
previously reported to acutely enhance endothelium-dependent relaxation in diabetic 
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and isolated vascular tissue exposed to oxidative stress (Chapters 3 and 4), is also able 
to improve endothelial function when administered in vivo.  
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Following investigation of the effect of diabetes and tocomin treatment on 
endothelium-dependent relaxation we wanted to investigate whether the NO-mediated 
component of that response was influenced by diabetes and/or by tocomin treatment by 
examining responses to ACh in the presence of TRAM-34 plus apamin to eliminate the 
EDH-type component of relaxation. In the presence of SKCa and IKCa channel blockers 
TRAM-34 and apamin, the ACh-induced relaxation was significantly impaired in 
aortae in the diabetic rats compared to sham rats indicating that diabetes impaired NO-
mediated relaxation. This has been demonstrated previously (Joshi and Woodman, 
2012, Leo et al., 2012). NO mediated relaxation was significantly improved in the 
diabetic rat indicating that 4-week tocomin improves NO bioavailability.  
 
The expression of eNOS was significantly reduced during diabetes. However, the 
expression of CaM, caveolin-1, pAkt and Akt was not affected by diabetes or 4-week 
tocomin treatment indicating that pAkt/Akt-or CaM induced eNOS activation and cav-
1-induced eNOS inhibition play no role in the endothelial dysfunction that was seen in 
this study. The effect of diabetes on eNOS uncoupling has been previously 
demonstrated (Leo et al., 2011a) and whether tocomin improves eNOS coupling in the 
diabetic rat aortae requires further investigation. Treatment with tocomin significantly 
increased NO-mediated relaxation in diabetic aortae but had no effect on relaxation of 
sham vessels. Tocomin treatment caused several effects that might have contributed to 
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the increased NO activity in the diabetic aortae. First, the decrease in Nox2 would 
contribute to the decrease in vascular superoxide generation reducing the inactivation 
of NO and formation of ONOO−. Furthermore, tocomin treatment increased expression 
of eNOS in comparison to the sham rats. 
 
Tocomin treatment did not affect the response to SNP under any conditions. The ability 
of tocomin to enhance responses only to endogenous NO supports the importance of 
the treatment on improvement of the endogenous generation of NO through the 
increased expression of eNOS. 
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To investigate how diabetes affects EDH-type relaxation and whether tocomin 
improves endothelium-dependent relaxation through an improvement in EDH-type 
relaxation we observed ACh-induced endothelium-dependent relaxation in the presence 
of eNOS inhibitor L-NNA alone, L-NNA plus ODQ and L-NNA. In the presence of L-
NNA alone endothelium-dependent was significantly reduced in both sham and 
diabetic rat aortae. However interestingly, in the presence of L-NNA alone the 
maximum response was significantly larger (Figure 5.2E) in the diabetic aortae in 
comparison to the sham rat aortae. This indicates that EDH-type relaxation helps 
preserve endothelium-dependent relaxation in the diabetic aortae. Neither diabetes nor 
tocomin treatment had any effect to the responses to SNP in the presence of L-NNA. 
 
In the presence of L-NNA plus ODQ and all of the inhibitors in combination both 
endothelium-dependent and independent relaxation was significantly reduced 
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demonstrating that NO dependent sGC activation is necessary for relaxation in the 
aortae. Responses to SNP in the presence of L-NNA and ODQ were not affected by 
diabetes nor tocomin treatment. 
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The high-fat WD did not cause any increase in blood glucose levels or HbA1c at the 
end of the study, but the WD group had a significantly higher body weight and 
epididymal fat mass at the end of the feeding period (Table 5.3) similar to observations 
previously made when using the same diet (Kosari et al., 2012). Epididymal fat pad 
mass provides an established indication of obesity (Mathai et al., 2008). 

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The WD caused a significant increase in the superoxide generated by the aortae and 
this correlated with an increase in the expression of the NADPH oxidase subunit Nox2. 
Others have reported that diets high in fats and sugars cause oxidative stress in the 
cardiovascular system (Chapter 4) (Malakul et al., 2008, Roberts et al., 2005). Our 
observation that there was an increased expression of Nox2 that might contribute to the 
generation of vascular oxidative stress is similar to a previous report that a high-fat, 
high-sucrose diet increased vascular Nox2, but not Nox4, expression in mice (Qin et 
al., 2014). Four week treatment of the WD rats with tocomin significantly reduced 
Nox2 expression similarly to the tocomin treated diabetic rats.  The mechanism for 
decreased Nox2 expression observed in the tocomin treated WD rat aortae could be 
similar to the diabetic rat aortae where tocomin acts at a cellular level to reduce PKC 
activated Nox2 O2
-
 production that subsequently reduces oxidative stress in the 
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vasculature thus improving NO bioavailability and endothelial dysfunction. However, 
this possibility requires further investigation. 
 The WD-induced increase in oxidative stress was accompanied by a decreased 
contractile response to the NOS inhibitor L-NAME and an impaired response to the 
endothelium-dependent relaxant ACh without any effect on the NO donor SNP. These 
observations are indicative of a selective impairment of endothelial function in the rat 
aortae as has been previously reported (Jenkins et al., 2016, Wang et al., 2016), when 
there is an increase in oxidative stress including in response to consumption of a high-
fat diet (Kshirsagar et al., 2015, Roberts et al., 2005).  
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Treating WD rats with tocomin did not affect the blood glucose or HbA1c levels nor 
did it decrease bodyweight or epididymal fat mass. However, there was a significant 
decrease of superoxide generation in arteries from WD, but not SD, fed rats and a 
decrease in the Nox2 expression, once again only in the WD fed rat aortae. Tocomin 
treatment did not affect responses to ACh or SNP in aortae from SD fed rats but did 
increase the sensitivity to ACh in the WD fed rat aortae. Thus tocomin, which we have 
previously reported to acutely enhance endothelium-dependent relaxation in isolated 
vascular tissue exposed to oxidative stress (Chapter 3), is also able to improve 
endothelial function when administered in vitro.  
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We next investigated whether the NO-mediated component of the endothelium-
dependent relaxation was influenced by the WD and/or by tocomin treatment by 
examining responses to ACh in the presence of the KCa channel blockers TRAM-34 
plus apamin to eliminate the EDH-type component of relaxation. In the presence of 
TRAM-34 and apamin, the ACh-induced relaxation was significantly impaired in 
aortae from WD rats compared to SD rats indicating that the high-fat diet impaired NO-
mediated relaxation. This impairment of responses to stimulated release of NO was 
consistent with the observation that the basal release of NO was also impaired in WD 
vessels, demonstrated by a decreased contractile response to NOS inhibition. A number 
of factors may have contributed to the WD-induced impairment of NO release. The 
expression of eNOS was significantly reduced by consumption of the high-fat diet. 
Further, the expression of caveolin-1, which inactivates eNOS, was increased, whereas 
calmodulin and pAkt expression was decreased. Calmodulin and pAkt both act to 
promote eNOS activity (Fleming, 2010, Takahashi and Mendelsohn, 2003). eNOS 
activity may also be influenced by the phosphorylation of Ser1179/1177 and Thr495, 
among other key sites (Siragusa and Fleming, 2016), but eNOS phosphorylation was 
not investigated in this study. The changes in modulatory protein expression are similar 
to changes observed under other circumstances of increased oxidative stress, such as 
diabetes (Leo et al., 2011a, Leo et al., 2010a). It is also well established that oxidative 
stress may also cause uncoupling of eNOS to promote synthesis of superoxide rather 
than NO (Siragusa and Fleming, 2016). We have previously reported that diabetes 
causes eNOS uncoupling (Leo et al., 2011a) and, while we did not explore whether a 
high-fat diet has a similar effect in this study, obese Zucker rats are reported to have an 
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elevated level of uncoupled eNOS (Munoz et al., 2015). Treatment with tocomin 
significantly increased NO-mediated relaxation in WD aortae but had no effect on 
relaxation of SD vessels. Tocomin treatment caused several effects that might have 
contributed to the increased NO activity in the WD aortae. First, the decrease in Nox2 
would contribute to the decrease in vascular superoxide generation reducing the 
inactivation of NO and formation of ONOO−.  
 
Furthermore, tocomin treatment increased expression of eNOS and calmodulin and 
increased phosphorylation of Akt to return levels in WD rats to be similar to those seen 
in SD rats. There was also a decrease in caveolin-1. Together, these actions are 
consistent with an increased capacity to synthesize NO reflected as both an improved 
basal release of NO, demonstrated by the contractile response to a NOS inhibitor, and 
enhanced ACh-induced relaxation reflecting stimulated NO release. An interesting 
observation was that SNP, an endothelium- independent NO donor, caused a 
significantly greater relaxation in WD versus SD aortae when NOS and sGC were 
inhibited. This is a surprising observation and there appear to be no previous reports of 
studies where responses to a NO donor were examined under similar conditions. The 
data suggest that WD may increase the activity of sGC or impair the inhibitory capacity 
of ODQ. Further investigation would be required to investigate these possibilities. 
Tocomin treatment did not affect the response to SNP under any conditions. The ability 
of tocomin to enhance responses only to endogenous NO supports the importance of 
the treatment on improvement of the endogenous generation of NO through the 
increased expression of eNOS, calmodulin, and pAkt and the decreased expression of 
caveolin-1. 
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To investigate whether the non-NO, EDH-type component of the endothelium-
dependent relaxation was influenced by the WD and/or by tocomin treatment, we 
examined responses to ACh in the presence of the NOS inhibitor L-NAME and the sGC 
inhibitor ODQ. In this large artery from SD-fed rats, only a small response to ACh 
remained in the presence of L-NAME, and the addition of ODQ virtually abolished the 
remnant relaxation indicating that normally there was little if any role for EDH-type 
relaxation. Responses in aortae from WD rats were the same as in SD rats, and tocomin 
treatment did not change responses in any group indicating that there was no influence 
of the treatment on EDH- type relaxation. We have previously found that an antioxidant 
can improve NO but not EDH-type relaxation even in small arteries where non-NO 
mediators make a more marked contribution to relaxation than in the large artery used 
in this study (Takahashi and Mendelsohn, 2003). The small relaxation remaining in the 
presence of L-NAME, ODQ, TRAM, and apamin is most likely mediated by 
prostacyclin. 
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There are many animal and human studies that demonstrate the link between ROS and 
the development of cardiovascular disease (Ritchie et al., 2017) including in diseases 
associated with diabetes and obesity (Roberts et al., 2005, Stump et al., 2005). There 
has also been extensive research on the effect of antioxidants including vitamin E 
(predominantly α-tocopherol) in the prevention and treatment of cardiovascular disease, 
but despite many positive results in animal studies, they have not translated the same 
results in humans or have had mixed outcomes (Saremi and Arora, 2010). There is 
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growing evidence that tocotrienols possess more potent antioxidant activity in 
comparison to tocopherols (Serbinova et al., 1991). Further, we demonstrated in 
Chapter 3 that the combination of tocotrienols with α-tocopherol is more effective at 
preserving endothelial function in the presence of oxidative stress than either α-
tocopherol alone or tocotrienols alone in combination (Chapter 3). 
 
The outcome of the present study, where a tocotrienol-rich extract that includes some 
tocopherol preserves endothelial function in the presence of diabetes and obesity-
induced oxidative stress, suggests further investigation of tocomin as a potential 
therapeutic agent is warranted. We have demonstrated that the in vivo treatment of 
diabetic and rats fed a high-fat “western” diet with the tocotrienol-rich extract of palm 
oil; tocomin, increases NO activity to improve endothelium-dependent relaxation in 
aortae from. Tocomin did not affect diabetes induced weight-loss and diet-induced 
weight gain or increase in epididymal fat but did attenuate the vascular oxidative stress. 
Our previous study demonstrated that tocomin, which contains a high proportion of 
tocotrienols (48%) with some α-tocopherol (11%), is able to acutely reduce oxidative 
stress to improve endothelium-dependent relaxation in vitro (Chapters 3 and 4). An 
additional beneficial action in this study to reduce vascular oxidative stress was a 
decreased expression of the vascular NADPH oxidase subunit Nox2 in both diabetic 
and WD rat aortae. Increased Nox2 expression is known to impact vascular function. 
This was demonstrated by Violi et al., (2009)   where people with heredity Nox2 
deficiency had enhanced endothelium-dependent relaxation. Another study conducted 
by Wang et al., (2016) demonstrated the antioxidant geraniol improves endothelium-
dependent relaxation and reduces Nox2 expression in the aortae of high fat diet fed 
mice by down regulating Nox2 expression.  Our results suggest that the antioxidant 
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activity of tocomin at scavenging O2
-  
and reducing oxidative stress in the vasculature 
has a down stream effect on Nox2 activity that is possibly due to tocomin decreasing 
PKC- induced Nox2 activation at a cellular level, leading to a decrease in Nox2 
activation and subsequent expression in the diabetic and obese aortae. However, this 
would require further investigation. 
 
 A further positive outcome of tocomin treatment in the obese rats was an increased 
expression of eNOS in the diabetic and WD aortae where in the WD aortae tocomin 
increased eNOS activity by promoting proteins calmodulin and pAkt. Further, there 
was also a decreased expression of the inhibitory protein caveolin-1. Interestingly 
neither diabetes or tocomin did not affect phosphorylated Akt, Akt, calmodulin or 
caveolin-1 expression. The beneficial actions of tocomin in this model of diabetes and 
diet-induced model of obesity suggest that it may have potential to be used as a 
therapeutic agent to prevent vascular disease in diabetes and obesity.  
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General Discussion & 
 
Conclusion 
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There is a substantial body of literature that demonstrates the contribution of oxidative 
stress to the impairment of endothelium-dependent relaxation in the vasculature. This 
thesis has demonstrated that diabetes and obesity causes endothelial dysfunction in the 
aorta from diabetic and obese rats resulting from increased oxidative stress in the 
vasculature. We have also demonstrated that the tocotrienol rich tocomin is up to 100 
times more potent than α-tocopherol at improving endothelial function acutely in the 
presence of oxidative stress and chronic animal models of diabetes and obesity. This 
thesis has demonstrated that α-tocopherol is a necessary component of tocomin and 
tocotrienols are not as effective as an antioxidant in the absence of α-tocopherol. This 
thesis also demonstrated that 4 week treatment of diabetic and obese rats with tocomin 
(40 mg/kg/day s.c.) reduces levels of oxidative stress and improves endothelium-
dependent relaxation.  
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The first study (Aims 1&2) investigated the effect of acutely exposing rat aortae to α-
tocopherol, tocotrienol isomers, various combinations of tocotrienol isomers, 
tocotrienol rich tocomin and a mixture containing the same components as tocomin in 
the rat aortae of pyrogallol/NADPH-induced oxidative stress. We also studied the O2
-
 
scavenging capacity of the above-mentioned molecules in a tissue free system using 
hypoxanthine and xanthine oxidase as a O2
-
 generator. The study demonstrated that that 
 154 
α-tocopherol, tocomin, tocotrienol isomers individually and in combination were able 
to scavenge superoxide generated from hypoxanthine/xanthine oxidase (Hypothesis 1). 
However, tocomin was able to scavenge superoxide at a concentration 100 times lower 
than that of α-tocopherol. These findings are consistent with findings from Serbinova, 
1991 which was one of the first studies that demonstrated α-tocotrienol to be 40-60 
times more potent as an antioxidant in comparison to α-tocopherol (Serbinova et al. 
1991).  
 
It has been suggested that tocotrienols may have superior antioxidant activity to 
tocopherols (Peh et al., 2016, Singh et al., 2013b), and we did find that to be true when 
superoxide is generated by hypoxanthine/xanthine oxidase in vitro (Chapter 3). It was 
therefore surprising when observing the effect of the same molecules on endothelium-
dependent relaxation in the presence of pyrogallol in isolated rat aortae α, δ and γ-
tocotrienols and various combinations in the absence of α-tocopherol were largely 
ineffective in improving NO mediated, endothelium-dependent relaxation in the 
presence of oxidative stress. However, tocotrienol rich tocomin, that has a minor 
component of α-tocopherol, was found to be the most effective compound tested. We 
also demonstrated that tocomin was up to 100 times more effective than α-tocopherol 
at improving endothelium dependent relaxation in the presence of pyrogallol. Also the 
efficacy of tocomin could be replicated by the presence of α-tocopherol with α, δ and 
γ-tocotrienols but not by the combined presence of the 3 tocotrienols alone. Thus the 
combination of tocotrienol isomers and tocopherol may prove to be an effective 
approach to the preservation of endothelial function where there is disease-induced 
oxidative stress such as in diabetes and hypertension. 
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This study also demonstrated that the tocotrienol isomers were less effective at 
scavenging superoxide radicals produced by vascular tissue in the presence of NADPH 
in comparison to those generated by hypoxanthine/xanthine oxidase. α-Tocopherol was 
less effective than the tocotrienol isomers at similar concentrations when superoxide 
was generated by hypoxanthine/xanthine oxidase but more effective against superoxide 
generated by vascular tissue. Tocomin was effective in both assays at 100 fold lower 
concentrations than α-tocopherol. Surprisingly tocomin was the most effective 
compound at improving endothelium-dependent relaxation and this effect could be 
replicated by a mixture of α-tocopherol and α, δ and γ-tocotrienols in all of the assays, 
suggesting that the tocotrienol isomers provide more effective vasoprotection when 
acting together in combination with α-tocopherol. This indicates that α-tocopherol 
possesses non antioxidant properties, which are beyond the scope of this thesis, but has 
been demonstrated in other studies (Kannappan et al., 2012, Ahsan et al., 2014). 
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After demonstrating the antioxidant activity of α-tocopherol and tocomin and their 
ability to improve endothelium-dependent relaxation in pyrogallol induced oxidative 
stress, the next study (Aim 3) compared the effect of diabetes and a high-fat diet rats 
western diet on endothelium-dependent relaxation in isolated aortae and whether acute 
exposure of α-tocopherol and tocomin can improve vascular relaxation. 
 
Diabetic rats had increased BGL and HbA1c levels in contrast to the high-fat western 
diet rats that in the absence of high BG and HbA1c levels developed obesity that was 
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seen as a significant increase in epididymal fat in comparison to the sham rats. O2
- 
production was significantly increased in both the diabetic and WD rat aortae that was 
associated with increased Nox2 expression and acute treatment of the aortae with 
tocomin was able to attenuate O2
- 
production in both diabetic and WD rat aortae. The 
acute exposure of aortae to α-tocopherol and tocomin was able to significantly improve 
endothelium-dependent relaxation in both diabetic and WD rats which was the 
hypothesis of the study (Hypothesis 3). Similarly to Chapter, 3 tocomin was up to 100 
times more potent in improving endothelium dependent relaxation in both diabetic and 
western-diet fed rat aortae. Endothelium-dependent relaxation in the WD aortae is 
almost entirely mediated through eNOS derived NO however the possible mechanism 
through which acute exposure of the WD aorta to tocomin improves endothelium-
dependent relaxation is through a non-eNOS source of NO or a greater contribution of 
EDHF-type relaxation which was seen as an enhanced maximum relaxation response 
of the WD rat aorate in the presence of L-NAME plus tocomin in comparison to L-
NAME alone. 
 
This study also demonstrated the different mechanisms of endothelial dysfunction in 
the diabetic and WD rat aortae in comparison to the sham and SD aortae respectively. 
Apart from increased Nox2 expression that was consistent with increased O2
- 
production in the diabetic and WD aortae, both diabetic and WD aortae also had 
decreased eNOS expression. However, during diabetes decreased eNOS expression is 
not due to decreased pAkt/Akt-induced eNOS activation or altered CaM/cav-1 
expression the expression of these proteins was not affected during diabetes. Rather 
these results suggest that in advanced diabetes (10 weeks), the potential up-regulation 
of other O2
- producing pathways e.g. polyol pathway and mitochondrial activity may 
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cause uncoupling of eNOS thus further exacerbating endothelial dysfunction. In 
contrast in the WD aorta, decreased eNOS activity is due to decreased Akt-induced 
eNOS activation that was demonstrated by a decreased pAkt/Akt ratio, a decrease in 
the eNOS stimulatory protein CaM expression and an increase in the eNOS inhibitory 
cav-1 expression.  
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Having demonstrated the ability of tocotrienol rich tocomin to attenuate oxidative stress 
and improve vascular function in the presence of pyrogallol-induced oxidative stress 
and diabetic and obese rat aortae in vitro the aim of the final study was to investigate 
whether the treatment of diabetic and high-fat fed rats with tocomin can improve 
endothelial function in the aortae and improve the expression of eNOS and decrease 
the expression of the O2
- producing enzyme Nox2 (Aims 4&5). 
 
We demonstrated that 4-week treatment with the tocotrienol-rich extract of palm oil, 
tocomin (40 mg/kg/day s.c.), increases NO activity to improve endothelium-dependent 
relaxation in aortae from diabetic rats and rats fed a high-fat “western” diet (Hypothesis 
4). Tocomin did not affect the diet-induced weight gain or increase in epididymal fat 
but did attenuate the vascular oxidative stress. Our previous study demonstrated that 
tocomin, which contains a high proportion of tocotrienols (48%) with some α-
tocopherol (11%), is able to acutely reduce oxidative stress to improve endothelium-
dependent relaxation in vitro (Chapter 3). An additional beneficial action in this study 
to reduce vascular oxidative stress was a decreased expression of the vascular NADPH 
oxidase subunit Nox2 which is perhaps due to tocomin acting at a cellular level 
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decreasing PKC-induced Nox2 activation, however this requires further investigation. 
A further positive outcome of tocomin treatment in the diabetic and obese rats was an 
increased expression of eNOS (Hypothesis 5) and its positive regulatory proteins 
calmodulin and pAkt/Akt. This study also revealed that in the WD aortae, eNOS 
expression is promoted by the proteins calmodulin and pAkt, whereas in the diabetic 
aortae endothelial function may potentially be improved due to an increase in eNOS 
coupling which was seen as a signifiacant improvement in eNOS expression. Further, 
there was also a decreased expression of the inhibitory protein caveolin-1. The 
beneficial actions of tocomin observed in these diet-induced model of diabetes and 
obesity suggest that it may have potential to be used as a therapeutic agent to prevent 
vascular disease in diabetes and obesity. 
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This thesis has extended upon the clear connection between type 1 diabetes and obesity 
and its ability its cause oxidative stress and subsequent endothelial dysfunction. The 
ability of tocotrienol rich tocomin to alleviate oxidative stress and improve endothelial 
dysfunction has also been made in this thesis. Therefore, based on the findings from 
this thesis, studies to further investigate the function of tocotrienols might include; 
 
1.  Investigating the expression of the eNOS protein as monomer/dimer and its 
level of phosphorylation at Thr495 and S1177 to further assess the effect of 
diabetes, a high- western diet and tocomin treatment on eNOS state of activation.  
 
2.  Investigating the effect of tocomin on endothelial dysfunction and oxidative 
stress in the same animal models of diabetes and obesity in the microvasculature 
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(eg: cerebral and mesenteric arteries) as an assessment in resistance rather than 
conductance vessels. 
 
3. Investigating the effect of tocomin on endothelial dysfunction and oxidative 
stress in a type 2 diabetes animal model such as the Zucker rat in the macro- 
(e.g. aorta) and micro-vasculature (e.g. mesentery artery). Of particular interest 
is how obesity and type 2 diabetes affects eNOS phosphorylation 
(Ser1179/1177 and Thr495) and eNOS coupling and the effect of tocomin on 
eNOS phosphorylation and eNOS coupling.  
 
4. The effect of type 2 diabetes on inflammatory markers of obesity (e.g. C-
reactive protein, TNF-α and IL-6) and insulin levels and whether tocomin can 
decrease the expression of any of these markers or affect insulin levels. Of 
interest will also be the effect of type 2 diabetes on lipid adiponectin levels and 
whether tocomin can affect adiponectin levels. 
 
5. Other areas of possible investigation would be the effect of obesity and type 2 
diabetes and its effect on pancreatic β-cell function and expression. Also 
studying fasting insulin levels to determine the presence of insulin resistance 
and investigate whether tocomin treatment has any effect on pancreatic β-cell 
function. 
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There is a significant body of evidence gathered from both animal and human studies 
that ROS play a fundamental role in CVD (Griendling and Fitzgerald, 2003) including 
in disease associated with diabetes and obesity (Furukawa et al., 2004). It is logical then 
that there has been intensive investigation of antioxidants in the prevention and 
treatment of cardiovascular disease, but despite many positive results in animal studies, 
the outcomes of large clinical trials have been predominantly disappointing (Schmidt 
et al., 2015). These include extremely high concentrations of tocopherol required to 
achieve any physiologically beneficial outcome and tocopherol becoming a prooxidant 
at high concentrations.  Studies examining the potential benefits of vitamin E have 
predominantly focused on α-tocopherol, one of eight naturally occurring isoforms of 
that vitamin, while there has been relatively little investigation of the potential capacity 
of tocotrienols as therapeutic agents (Peh et al., 2016). There is growing evidence that 
tocotrienols do not simply mimic the biological actions of tocopherols. For example, 
tocotrienols are reported to more effectively accumulate in cells compared to 
tocopherols, and this has been suggested to promote their efficacy as antioxidants (Saito 
et al., 2004). Further, we have demonstrated that the combination of tocotrienols with 
α-tocopherol is better able to preserve endothelial function in the presence of oxidative 
stress than either tocopherol or tocotrienols alone (Chapter 3). This could possibly be 
due to tocopherols enhancing the antioxidant activity of tocotrienols or the presence of 
α-tocopherol is necessary for the potent antioxidant activity of tocotrienols due to the 
high biological affinity of α-tocopherol to the α-TTP. 
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The outcome of the first study, where a tocotrienol-rich (48%) extract that includes 
some α-tocopherol (11%) preserved endothelial function in the presence of pyrogallol-
induced oxidative stress, suggests further investigation of tocomin as a potential 
therapeutic agent is warranted. We further demonstrated that the tocotrienol-rich extract 
of palm oil, tocomin, acutely improves endothelium-dependent relaxation and increases 
NO activity to improve endothelium-dependent relaxation in aortae from diabetic and 
obese rats fed a high-fat “western” diet (Chapter 4). An additional beneficial action in 
this study to reduce vascular oxidative stress was a decreased expression of the vascular 
NADPH oxidase subunit Nox2 in both diabetic and WD rat aortae. This could possibly 
be due to reduced oxidative stress in the aortae resulting from the antioxidant affect of 
tocomin having a downstream effect on Nox2 expression. A further positive outcome 
of tocomin treatment in the diabetic and obese rats was an increased expression of 
eNOS in the diabetic and obese rat aortae which could possibly due to due the decreased 
O2
- 
production in the vasculature increasing the bioavailability of eNOS cofactors such 
as BH4 from being reduced thus maintaining eNOS integrity. Also decreased O2
- 
production may also prevent the uncoupling of eNOS due to a decrease in oxidative 
stress, however this requires further investigation. In the WD aortae eNOS activity 
promoting proteins calmodulin and pAkt expression was improved. Further, there was 
also a decreased expression of the inhibitory protein caveolin-1. Interestingly, neither 
diabetes nor tocomin affected the proportion of phosphorylated Akt to Akt and the 
expression of calmodulin and caveolin-1.  
 
The beneficial actions of tocomin in these models of diabetes and diet-induced of 
obesity suggest that it may have potential to be used as a therapeutic agent to prevent 
vascular disease in diabetes and obesity. This thesis has made a significant contribution 
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to the field of endothelial dysfunction and the pharmacology of vitamin E which has 
resulted in a better understanding of the effects of tocotrienols on endothelial 
dysfunction in animal models of diabetes and obesity. This was necessary to study to 
determine whether these compounds may be able to create new adjunct therapy for 
diabetes and obesity induced cardiovascular disease 
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